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The emergence of circulating tumour cells (CTCs) readily available in the blood, renewed hope of 
developing a tool that may serve as a surrogate biomarker for the identification of metastatic 
disease in cancer patients, in the form of a ‘liquid biopsy’ (i.e. peripheral blood sample instead of 
cancer tissue). Examination of CTCs has been attempted for a number of years and been limited by 
several factors including biological heterogeneity and the small number of CTCs present.  Despite 
these limitations, there is increased evidence of the clinical utility of CTCs as diagnostic, prognostic 
and predictive markers in cancer patients.  
In this study, I evaluated the possibility of detecting and distinguishing prostate CTCs from blood 
cells using the ImageStreamX, a novel device that uses multispectral imaging flow cytometry.  In 
order to conduct this evaluation, PC3 prostate cancer cells were used to mimic CTCs in blood. To 
accurately define the sensitivity of imaging flow cytometry, immunological methods for CTC 
quantitation using the Epithelial Cell Adhesion Molecule (EpCAM), CD45 and Zonula Occludens Tight 
Junctions (ZO-1 TJ) antibodies were examined. Additionally, I have utilised the unique features of the 
ImageStreamX and examined its ability to distinguish CTCs from blood cells based on morphological 
and/or physical properties.  
The immunostaining methods appeared to produce false negative identification of PC3 cells. 
However, when live PC3 cells pre-stained with a nucleic acid stain (DRAQ5) were analysed using 
solely physical and morphological parameters such as cell size, the results were a far more robust 
enumeration of the CTC population, thus increasing markedly the detection sensitivity. The live cell 
analysis approach was then validated using blood samples collected from metastatic castrate-
resistant prostate cancer (CRPC) patients with an informed consent and ethical approval. CTC 
enumeration in these samples using the live cell analysis approach confirmed findings about the 
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1.1.1 Definition and origin  
 
Cancer is a collection of diseases in which a cell loses its normal reproduction function and begins 
multiplying without control, forming a tumour. This change is normally brought about when DNA 
damage takes place within cells (Hollstein et al., 1991). Cells have numerous mechanisms of 
detecting such damage and either repair it or induce programmed cellular death. This occurs either 
through autophagy, programmed necrosis or apoptosis (Ouyang et al., 2012). However, for a cell to 
become cancerous, six biological capabilities are thought to be required for such transformation. 
These capabilities comprise of cells maintaining proliferative signalling, being able to evade growth 
suppressors, resisting programmed cellular death, enabling immortality through continuous 
replication, the induction of angiogenesis and the activation of local invasion and metastasis. These 
changes are referred to as the six principal hallmarks of cancer (Hanahan and Weinberg, 2000). In 
the last decade, research advances have helped in recognising two new hallmarks, these include the 
process of reprogramming the energy metabolism as well as the ability to evade immune 
destruction (Hanahan and Weinberg, 2011).  
However, a recent study suggested that only a third of the variation in risk leading to cancer 
development in tissues is accredited to environmental factors or inheritance. It was proposed that 
the rest were simply due to an accumulation of random mutations in stem cells; in other words, 
“bad luck” (Tomasetti and Vogelstein, 2015). Conclusions made by that study were immediately met 
with heavy criticism for seemingly downplaying the essential role of an unhealthy life style in cancer 
development (Couzin-Frankel, 2015).  
23 
 
There are many types of cancer and they are usually named after the organs in which they are 
present or the tissue from which they originate. Tumours occur in two forms, benign and malignant. 
Benign tumours are formed in one location, self-limited and are normally encapsulated. They are 
localised to a particular region or organ and do not spread to other locations in the body. They are 
also known to generally have a better prognosis than malignant tumours. In comparison, malignant 
tumours very often invade surrounding tissues, while cancerous cells originating from these tumours 
are known to be able to travel in blood or in the lymphatic system to invade distant tissues, forming 
secondary tumours. This malignant nature of cancer is the single most challenging factor in the 





1.1.2 Cancer incidence worldwide 
 
In 2012, there were approximately 14 million new cases of cancer worldwide and more than 8 
million cancer-related deaths, with the highest number of deaths occurring in lung cancer patients, 
resulting in 1.59 million deaths (Figure  1.1). These numbers are on the rise and are expected to rise 
by nearly 70% over the next 20 years. This increase is thought to be occurring as a result of various 
factors such as the emergence of sensitive diagnostic methods. Vast industrialisation and carcinogen 
exposure in developing countries might also have played a role in the rising numbers of cancer 
incidence and cancer-related deaths. Moreover, there are gender specific biases for certain types of 
cancer. For instance, the main cancers occurring amongst females are breast, stomach, cervix, lung 
and colorectum cancer. Whereas most cases of cancer in males are related to lung, stomach, liver 
and colorectum (de Martel et al., 2012).  
Figure  1.1: Cancer incidence rates worldwide.  
 
The figure above shows the worldwide incidence rates of several cancers, such as lung, breast, colorectum and prostate 
cancers. The figure has been created using data set provided by CRUK (CRUK, 2012). 
 











Number of cases (millions) 
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Cancer has also been found to be associated with the levels of human development index (HDI) in a 
particular region as demonstrated in Figure  1.2. Cancer numbers in low HDI countries were found to 
be much lower than those in high HDI regions. Breast cancer for instance was found to be prevalent 
in regions with very high HDI, but not as much with medium HDI countries, where it is replaced by 
higher incidence rate of Lung cancer. Lung cancer itself was in low numbers in low HDI countries 
compared to the rest, an effect that could have resulted from various environmental factors, such as 
the low industrialisation of low HDI regions (CRUK, 2012).   
Figure  1.2: Distribution of different cancer types in males and females based on HDI. 
 
The figure above shows the distribution of the different types of cancer between both genders and how the number of 




1.1.3 Principal risk factors 
 
There are various risk factors associated with cancer and these differ from one cancer type to 
another. The fact remains however that age, tobacco use, alcohol intake, having an unhealthy diet 
and the lack of physical activity are the main environmental risk factors for most cancers worldwide 
(WHO, 2014). Table  1.1 on the following page shows the risk factors for different types of cancer. As 
can be seen, age is one factor that tops the list for most of the cancer types mentioned and the age-
related risk in cancer is in fact attributed to the number of cellular divisions.  
As mentioned earlier, a study by Tomasetti and Vogelstein  revealed that about two thirds of cancer 
cases occur due to random mutations rather than due to risk factors associated with lifestyle 
differences of individuals (Tomasetti and Vogelstein, 2015). The study compared the number of 
lifetime stem cells divisions in a range of tissues with the life time cancer risk. As a result, it was 
found that random mutations were the main cause of cancer. Since its publication, the study 
received wide criticism, mainly from the International Agency for Research on Cancer (IARC), which 
argued that an unhealthy lifestyle remains a huge contributor to cancer incidence and that according 
to our current knowledge, nearly half of all existing cancer cases can be prevented in the first place.  
In addition to age, other risk factors that are seen to be frequently associated with increased risk of 
cancer occurrence involve tobacco smoking and alcohol consumption. While some risk factors seem 
to be generally associated with several cancer types, others are more associated with certain types 
of cancer than others, such as exposure to radon gas and its link to lung cancer, or the increased risk 




Table  1.1: Common cancers and their risk factors 
 
The table above mentions some of the most common types of cancer for both males and females and outlines the major 
risk factors for each cancer type (CRUK, 2014a). 
  
Cancer type Risk factor 
Lung 
• Smoking 
• Air pollution  
• Exposure to radon gas 
• Exposure to chemicals  
• Family history 
• Lowered immunity  
Breast 
• Age 
• Family history  
• Alcohol 
• Smoking 
• Sex hormones  
• Ethnicity  
Skin 
• Age 
• Family history 
• Sun exposure  
• Skin conditions  
• Radiation exposure  
Prostate 
• Age 
• Ethnicity  
• Family history  
• Obesity  
• Height  
• Insulin like growth factor (IGF-1)  
• Vasectomy  
• Inflammation of the prostate 
Ovarian 
• Age 
• Family History (BRCA mutation) 
• History of breast cancer 
• Smoking  
• Infertility  
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1.1.4 The Nature of Malignancy  
 
Metastasis is the process in which cancerous cells detach from the primary tumour and travel to 
another anatomically distant location in the body forming a secondary tumour. Cancer cells can 
penetrate blood vessels and travel though the bloodstream or can invade lymphatic vessels and 
travel through lymph to various sites in the body (Klein, 2008). The invasive nature of cancerous cells 
is brought about by a number of biochemical and phenotypical factors that ultimately affect cell to 
cell adhesion, migration, cell polarity and cell motility as well as the upregulation of certain 
proteolytic enzymes, leading to metastasis (Leber and Efferth, 2009).  
The process in which epithelial cells convert their phenotype into mesenchymal-like phenotype is 
referred to as the Epithelial Mesenchymal Transition (EMT) (Pecorino, 2012). The EMT is of a huge 
importance in the overall metastasis process and will be explained in detail on page 37 in this 
chapter. 
The propensity of tumour cells to invade and metastasise as cancerous cells is what makes cancer as 
a life-threatening disease and makes its treatment clinically challenging (Jiang et al., 2009). The 
process of invasion and metastasis is yet to be fully understood as it varies from one cancer to 
another. For instance, breast cancer very often metastasises to the lymph nodes, bones, lungs, liver 
and brain, forming secondary tumours there. While in the case of colon cancer, tumour cells were 





1.1.5 Metastasis stages 
 
The invasion-metastasis cascade is a series of events which brings about the formation of secondary 
tumours through the process of metastasis (Valastyan and Weinberg). The crucial steps that 
cancerous cells undertake during this cascade include invasion, intravasation, transport, 
extravasation and metastatic colonisation. Cancer cells often interact with normal cells in 
surrounding tissues and it is this interaction that can determine whether or not a cancerous cell will 
metastasise. In other words, metastasis is not only dependent on the cancerous cell being able to 
invade and travel in the body but also on the microenvironment where it resides (Pecorino, 2012). 
The metastasis process is outlined in the figure below and subsequently explained in details.  
Figure  1.3: The different stages of tumour metastasis 
 
The figure above shows the different stages of metastasis. These include migration, intravasation, transport, 





The details involved in each stage of tumour metastasis are mentioned below. While the molecular 
events associated with each stage, such as mutations that occur in cadherin and catenin, are 
discussed later in this chapter.  
1.1.5.1 Detachment and migration  
The process usually begins with the migration of cancer cells to subsequently begin local invasion of 
the nearby blood vessel tissue and is then followed by dissemination into the bloodstream or the 
lymphatic system. It is worth pointing out, however, that cancer invasion through blood circulation is 
considerably more frequent than that which takes place at the lymphatic lumina (Gupta and 
Massagué).  
1.1.5.2 Intravasation  
The intravasation process itself, appears to be influenced by a combination of molecular changes 
and the structural features of the blood vessels where the tumour resides, giving rise to cancer cells’ 
invasion ability. This invasion is usually initiated by cancer cells migrating to a close blood vessel, 
which can either be found within the tumour itself or in close proximity (Reymond et al., 2013). 
Migration then takes place through the endothelial cells junctions or, in some cases, via transcellular 
movement through endothelial cells.  
1.1.5.3 Transport 
The process in which cancer cells are transported within blood is yet to be fully understood. 
However, as cancer cells are found to be relatively large in diameter with a range of 20-30µm, it is 
thought the vast majority of these cells get trapped within minutes after the intravasation process is 
complete. This is likely to happen at various capillary beds, where the luminal diameter is around 
8µm is length. This relatively short circulation process could also explain how metastasis of cancer 
cells goes unalarmed very often (Valastyan and Weinberg). Another theory suggested that cancer 
cells are capable of specific attachment to particular tissues in the body. It is thought that tumour 
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cells have a fixed preference for a certain type of tissue which leads to their attachment within that 
region. An example of this was investigated in breast tumour cells expressing Metadherin, a highly 
expressed protein in breast cancers. These cells were found to have a prearranged preference of 
metastasising to the lungs (Brown and Ruoslahti).  
1.1.5.4 Extravasation  
The arrival and subsequent attachment of cancer cells at a distant organ may trigger the formation 
of an intraluminal growth, such that would continuously increase in size until it ruptures walls of 
nearby vessels. This allows the tumour cells to come in immediate contact with the tissue 
parenchyma. Alternatively, tumour cells may directly invade the new tissue via extravasation, a 
process that can be looked at as a contrary form to that of intravasation. This happens when these 
cells penetrate the endothelial cells layer as well as the pericyte layer, both of which separate vessel 
lumina and the stromal microenvironment (Al-Mehdi et al., 2000).  
Migrated cancer cells often find it difficult to adapt to the new environment where they metastasise 
to, this is because the new microenvironment might be different from that of the primary tumour 
(Valastyan and Weinberg). In order for these cells to colonise within the new region, a “metastatic 
niche” must be created first (Psaila and Lyden, 2009). This is achieved when cancerous cells in the 
primary tumour release organ-specific fibronectin, up-regulating systemic signals that eventually 
alter the target microenvironment by making them more compatible sites for cancer cells prior to 
their arrival. 
1.1.5.5 Metastatic colonisation and formation of secondary tumour 
The metastatic colonisation leading to the growth of a new tumour, which concludes the metastasis 
process, is heavily dependent on two important factors, the identity of the primary tumour cells and 
the organ site at which the new tumour will grow (Valastyan and Weinberg). It should be noted that 
invasion-metastasis cascade is an extremely inefficient process, as many cancer cells fail in 
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completing the metastatic colonisation process. A study estimated that less than 0.01% of the cancer 
cells which have entered the blood circulation eventually result in the formation of macroscopic 
metastases (Chambers et al., 2002). The vast majority of cancer cells seem to suffer from attrition 






1.1.6 Metastasis theories 
 
There are several theories that describe how the process of metastasis occurs and try to explain the 
actions of cancerous cells as they migrate from one location to another, forming secondary tumours. 
One of these theories is the “Seed and Soil” theory (Qian and Teh, 2012). The theory was originally 
proposed in 1889 by Stephen Paget, an English surgeon. He proposed that the metastatic property 
of cancerous cells was not random, but rather due to some cancerous cells (the “seed”) having a 
unique attraction to environments that provide enhanced settings within specific organs (the “soil”) 
for them to grow (Ribatti et al., 2006). As previously mentioned, when tumour cells enter the blood 
circulation, they are disseminated wildly across the body. However, developed metastases can only 
be detected at the “soil” sites (Fidler, 2003).  
This theory was backed by studies investigating organ selectivity to particular tumours, confirming 
enhanced survival rate of tumour cells in particular tissues but not in others. For example, 
melanoma cancer cells tested in mouse models showed capability of these cells to thrive in the in 
situ lungs as well as in implants of pulmonary and even ovarian tissues. The same could not be said 
about implanted renal tissues, where neoplastic lesions failed to develop (Hart and Fidler, 1980).  
The past century saw discoveries of novel molecules that play key part with specific metastasis of a 
certain cancer with an organ. In addition, pathways leading to the occurrence of organ-specific 
metastasis have also been highlighted. All of which builds a strong identity to the “Seed and Soil” 
hypothesis (Fokas et al., 2007). Another theory suggested that tumour cells fusion with macrophages 
or other types of cells derived from the bone marrow would lead to metastasis (Pawelek and 
Chakraborty, 2008). Furthermore, metastases formation was also linked with cancer-transformed 
genes originating from the primary tumour and integrated in their identical form, with the help of a 




1.1.7 Molecular mutations involved in metastasis 
 
Cancer metastasis is believed to be largely influenced by cells adhesion molecules (CAM). Such 
molecules include cadherins, catenins, actin and integrin. Some molecular events are associated with 
these molecules and may contribute towards cells becoming cancerous. A perfect example of this 
would be the Wnt signalling pathway and its role in cancer. Molecular studies have confirmed that 
that mutations occurring in this pathway might be responsible for approximately 90% of the cases of 
colorectal cancer (Sansom et al., 2004). Some of the essential CAM molecules and molecular events 
involved in tumorigenesis and metastasis are mentioned in this section:  
1.1.7.1 Cadherin 
Cadherins, which are transmembrane calcium-dependent glycol-proteins, play a big role in 
determining the metastatic property of a cancer cell (Takeichi, 1993). Cadherins mediate cell 
adhesion via coordination with catenins (through the cytoskeleton). Research in this area (Cavallaro 
et al., 2002) underlined that in vitro observations – carried out on a variety of tumour cell-lines – 
suggest a strong link between a “switch” in cadherins expression and tumour progression and 
metastasis. Furthermore, a change in cadherins’ expression has been associated with loss of 
epithelial morphology in the prostate, playing a key role in driving the invasiveness and metastasis of 
prostate cancer. Poor prostate cancer prognosis was also found to be linked with the loss of E-
cadherin; however, further studies are required to study the link between cadherin switching and 
other cancer types (Tomita et al., 2000).  
1.1.7.2 Catenin  
Catenins are cytoplasmic proteins which bind to transcription factors and induce gene expression. 
Along with E-cadherin, they play a major role in mediating epithelial cell adhesion as well as 
intracellular signalling. There is a lot of evidence to suggest that mutation and/or loss of catenin 
expression very often drives forward tumour invasion and metastasis (Joo et al., 2002). It is of great 
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importance to understand the cadherin-catenin interaction as this might be the key to designing 
novel therapeutic approaches (Ramburan and Govender, 2002).  
Additionally, the accumulation of β–catenin as a result of mutations is found to be present in more 
than 90% of all colorectal cancer patients (Giles et al., 2003). These mutations have an activating role 
on the canonical Wnt signalling pathway, which is a signal transduction pathway comprising of 
proteins that utilise cell surface receptors to transmit signals into cells. This activating effect is 
brought about by the loss of the Adenomatous Polyposis Coli (Apc) gene, which is a tumour-
suppressor gene, leading to the stabilisation and accumulation of β–catenin in the nucleus, 
subsequently leading to the formation of tumour cells (Sansom et al., 2004). The loss of Apc itself 
also has a disturbing effect on the differentiation and proliferation of cells and is found to be linked 
with altering intestinal pathology and causing morbidity (Sansom et al., 2004, Logan and Nusse, 
2004).  
1.1.7.3 Integrin  
The role of integrins is another significant factor that can determine the progression of cancer. 
Integrins form a family of heterodimeric cell surface receptors that is capable of detecting changes 
within cells as well as connecting the actin cytoskeleton to the extracellular matrix. Changes 
detected by integrins occur as a result of the extracellular matrix undergoing phenotypical 
degradation or deformation, as a result of a mechanical force (Seguin et al., 2015). Upon detection 
of such changes, integrins then activate a series of cellular responses that form a connection 
between the inside and the outside of the cell. These signals ultimately control cell survival, 
proliferation, migration, adhesion and differentiation (Desgrosellier and Cheresh, 2010).  
Integrins comprise of a combination of alpha and beta subunits, forming at least 25 different 
receptors. Studies have shown that many of these integrins play a key role in tumour progression 
and invasiveness. One study investigated the effect of prostate cancer on bone microenvironment 
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and found that integrin-mediated interaction of prostate cancer cells was key in the development of 
bone metastasis (Keller and Brown, 2004).  
Figure  1.4: Graphical representation of heterodimeric integrins  
 
The figure above shows a graphical representation of the extracellular, transmembrane and cytoplasmic domains of 
heterodimeric integrins (Kuphal et al., 2005).  
 
Integrins’ role as invasiveness and metastasis regulators in prostate cancer was also confirmed by 
McCabe et al who demonstrated how integrin αVβ3 was mediating attachment to the bone 
microenvironment and, consequently, secondary tumour growth (McCabe et al., 2007). Additionally, 
integrins also play a vital role in tumour progression through increasing cellular matrix rigorousness, 
leading to increased microRNA expression, which in turn encourages tumour progression through 
integrin activation of β–catenin and MYC (Mouw et al., 2014). 
1.1.7.4 Actin 
Actin is a globular protein that is found in abundance in the majority of eukaryotic cells and 
contributes more to protein-to-protein interactions than any other existing protein. Moreover, the 
actin cytoskeleton is also responsible for the machinery which leads to cell migration (Lodish H, 
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2000, Dominguez and Holmes, 2011). It is for these reasons that actin can be an influencing factor in 
determining the metastatic ability of cancerous cells as suggested in a study by Jiang et al (Jiang et 
al., 2009). Besides cellular motility, the actin cytoskeleton’s proteins are also responsible for 
regulating cellular polarity, survival and the growth of normal cells as well as cancerous cells and 
their invasive ability (Stevenson et al., 2012).  
Myosins (Myo), which are a diversely large family comprising of molecular motors, play a key role in 
cellular migration and motility by influencing actin organisation. The modulation of the expression of 
some myosin isoforms was found to have an upregulating effect on cells, driving them towards a 
more migratory phenotype (i.e. becoming metastatic) (Pulukuri et al., 2005).  
Figure  1.5: Graphical representation of the actin motor proteins 
 
Actin motor proteins, such as Myo10, Myo9b and Myo1b and Myo18 (shown above), were linked with highly metastatic 
forms of prostate cancer as elevated expression levels of these proteins were observed in highly metastatic prostate 
cancer cell-lines, such as the PC3 cell-line (Makowska et al.). The figure shows how the knockdown of genes encoding for 
these proteins results in changes to cancer cells’ morphology, migration and actin organisation.  
 
 
1.1.7.5 Epithelial-mesenchymal transition (EMT) 
It is fair to say that for a tumour to obtain the ability to invade surrounding tissues, the EMT 
mechanism – which includes the conversion of connected epithelial cells into mobile mesenchymal 
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cells – is of high importance (Pecorino, 2012). Despite its common occurrence during early 
embryogenesis, this transition shares many similarities with metastasis. For instance, EMT is known 
to be characterised by a loss of cell polarity as well as the upregulation of mesenchymal proteins 
(e.g. N-Cadherin) and the downregulation of epithelial markers (e.g. E-Cadherin). This was recently 
investigated in thorough details with relation to ovarian cancer (Davidson et al., 2015). The results 
showed frequent expression of the proteins analysed in cancer cells, including E-Cadherin and P-
Cadherin.  EMT occurs when signals from a tumour stroma – such as growth factors (e.g. HGF) – 
induce EMT in nearby tumour cells, triggering the activation of transcription factors such as Twist. 
These transcription factors in turn regulate sets of genes needed to activate EMT.  
Figure  1.6: EMT contribution to tumour progression and metastasis 
 
 
The EMT plays a key role in the cancer advancement and spread by initiating the metastasis process as well as enabling 
cancerous cells to withstand cancer treatment (Kiesslich, 2013). 
 
In the context of metastatic invasion, EMT’s mechanisms may lead to the formation of circulating 
tumour cells that play a role in the creation of metastases in a distant body organ. EMT gives cells an 
enhanced migratory ability, tendency to invade as well as an elevated resistance capability to 
apoptosis, and its role does not end there (Kalluri and Weinberg). It is also found to hold the key to 




In 2008, a study revealed that the EMT also provides tumour cells with mammary stem cells’ 
properties. Such properties include self-renewal and the ability to successfully colonise elsewhere in 
the body (Mani et al., 2008). EMT was used to generate mesenchymal-like cells while flow cytometry 
analysis revealed that most of these cells expressed a CD44high/CD24low pattern. This particular 
configuration of these two cell surface markers is directly associated with both, breast cancer stem 
cells and normal mammary epithelial stem cells.   
At least four closely connected regulatory networks were found to be powering EMT. The activation 
of any of these networks would exert a relatively strong effect on the rest, leading to occurrence of 
EMT (Craene and Berx, 2013). Other studies also deduced that EMT plays a key role in converting 
normal epithelial cells to cancer stem cells. These in turn will acquire properties of normal stem cells 
that include self-renewal, invasiveness and colonisation ability. Such properties would indeed help 
these cells invade surrounding tissue and eventually reach the blood circulation, at which point they 
will be referred to as circulating tumour cells (Jolly et al., 2015).  
Furthermore, cancer cells that become motile as a result of EMT usually come in two shapes and 
associated behaviour, mesenchymal and amoeboid (Huang et al., 2014). These cells are allowed to 
adopt functional behaviours that vary with phenotypical choices, external signals and genetic 
changes such as the ability to switch between the two mesenchymal and amoeboid shapes. An 
example of ovarian and prostate cancer cells that acquire and express numerous epithelial and 
mesenchymal markers highlights the link between the EMT phenotype and the increased 
aggressiveness of tumours (Strauss et al., 2009, Ruscetti et al., 2015).  
In comparison to cancer cells, normal cells are unable to undergo EMT and detach from their 
extracellular matrix due to anoikis. Anoikis is the mechanism in which cells are programmed to die if 
they were to detach from the extracellular matrix, preventing the colonisation of these cells to 
distant organs (Gilmore, 2005). Anoikis is resisted in cancer cells mainly due to two factors involving 
integrins and the tumour microenvironment. Mutations that occur in cancer cell’s integrins have 
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several effects on these cells, including the ability to grow in different niches and the capacity to 
upregulate key enzymes involved in growth factor receptor signalling. The tumour 
microenvironment on the other hand aids in anoikis resistance via a number of ways, such as the 





1.1.8 Cancer Types and Statistics  
 
As previously mentioned, certain types of cancers are more prevalent than others in certain regions 
and are also distributed differently, based on gender, age group and other factors. The figure below 
gives an account to the distribution of different cancer types based on gender in the UK. While the 
table on the following page provides figures of cancer incidence and deaths in the UK  
Figure  1.7: Gender distribution of the most common cancers in the UK 
 
The figure above shows the 20 most common cancers in the UK and the number of cases for each type between males 





Table  1.2: Cancer incidence and death rates in the UK in 2011 and 2012 
 
The table above shows cancer incidence and death rates in the UK in 2011 and 2012 as well as the survival rate and 
percentages between 2010 and 2011 (CRUK, 2014b). 
 
Cancer survival in the UK has seen a tremendous improvement with recent statistical studies 
showing that in 2010-2011, about half of the adult cancer patients in England and Wales were 
predicted to survive 10 years or more with almost 46% of these being males and the rest being 
females (CRUK, 2014b).  
Cancer 
Statistics Males Females Persons Country Year 
Number of new 
cases per year 167,487 164,000 331,487 
UK 2011 Incidence rate 
per 100,000 
population 
426.5 376.2 396.2 
Number of 
deaths per year 85,068 76,755 161,823 
UK 2012 Mortality rate 
per 100,000 
population  
198.7 146.6 168.6 
One year 
survival rate 66.7% 74.1% 70.4% 
England and 








45.8% 53.7% 49.8% 
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Figure  1.8: Age standardised survival for selected cancers in England and Wales 
 
The figure above shows age standardised one-, five- and ten-year survival for selected cancers in adults (aged between 
15-99) in England and Wales (CRUK, 2014b). 
 
As shown in Figure  1.8, survival varies greatly from one cancer type to another. The range extends 
from an excellent 98% ten-year age-standardised net survival for patients suffering from testicular 
cancer to a mere 1% for those with pancreatic cancer. Generally, cancer occurring in the testes, skin, 
prostate and in the blood, is usually associated with a very high survival rate (more than 80%). In 
contrast, survival rate for pancreatic, lung, brain and stomach cancers are at the lowest end of the 
range (less than 20%).  
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1.2 Prostate Cancer 
 
1.2.1 Background and Epidemiology  
 
The Prostate gland is situated underneath the bladder and grows bigger as a male grows older. It is 
found to be surrounding the urethra and functions to produce semen. Some of the common illnesses 
that occur at this gland include prostate enlargement, prostatitis and prostate cancer (CRUK, 2014c).  
Prostate cancer is an adenocarcinoma cancer that develops mostly in the epithelial glandular cells of 
the prostate in males (ACS, 2015). In the UK, prostate cancer is the most diagnosed cancer in men 
with more than 47,300 new cases every year (NHS, 2015a). It is found that one in six men, in the UK 
and the USA, will develop prostate cancer at some stage of their life time. Most cases, however, 
develop in elderly men and the tumour grows slowly as patients very often die with the cancer 
rather than as a result of it. Anatomically, prostate cancer is a type of cancer that is characterized by 
the development of a tumour in walnut-sized structure in the male reproductive system (Fall et al., 
2009). It is known to be multifocal, as each tumour is present in a different location within the 




Figure  1.9: Most common cancers in males in the UK in 2011 
 
The figure above shows the most common cancers in males in the UK in 2011. Prostate cancer is the most common type 
with approximately 25% of the total number of cases (CRUK, 2014a). This figure was recreated using data from the 
original CRUK chart to create a clearer representation of cancer types’ percentages.  
  













The first case of prostate cancer was diagnosed in The London Hospital in 1853. Although the 
surgeon who first identified it histologically described it as a rare illness, prostate cancer incidence 
rate had been increasing since then (Denmeade and Isaacs, 2002). It was not clearly distinguished 
and was even regarded as another type of urinary obstruction until the early 1900s. Observation of 
prostate cancer incidence showed that a sharp increase in correlation with age, even more so than 
any other cancer type (Greenlee et al., 2001). Furthermore, an association with Western lifestyle has 
been suggested and backed by lower incidence rate in Asian populations in comparison to their 
Western counterpart. Those who migrated to Western countries also showed an increase in prostate 
cancer incidence rate, suggesting a possible environmental and/or dietary factor (Anand et al., 
2008).  
Figure  1.10: Average number of prostate cancer cases per year vs Age at diagnosis 
 
The figure above shows the average number of new cases of prostate cancer per annum and the age-specific incidence 




The risk of prostate cancer is at a high with men above the age of 50 and that risk increases with age 
thereafter (Burford et al., 2009). The average age for a male to be diagnosed with prostate cancer is 
65-69 and figures have also shown that family history is another major risk factor for the disease. 
Approximately 5-10% of all prostate cancers diagnosed are found to be linked with hereditary 
genetic mutations; Brunner et al demonstrated how family history is directly involved in increased 
risk of developing prostate cancer (Bruner et al., 2003).  













The table above shows the effect of prostate cancer family history on the lifetime risk of developing prostate cancer 
(Bruner et al., 2003).  
 
Additionally, In 1941 Charles Brenton Huggins, who was an American physician specialising in 
prostate cancer, found that the metastatic form of prostate cancer responds well to androgen-
ablation therapy (Huggins and Hodges, 2002). Huggins’ discovery led to a whole new approach in 
combatting the disease and, even today, androgen ablation remains the most commonly suitable 
prostate cancer treatment (Denmeade and Isaacs, 2002). 
Family history Lifetime risk (%) 
No history 8 
Father with prostate cancer at ≥60 
years 12 
One brother affected ≥60 years 15 
Father affected before 60 years 20 
One brother affected before 60 years 25 
Two male relatives with prostate 
cancer 30 
Three or more affected male relatives 35-45 
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1.2.3 Prostate cancer symptoms  
It is very uncommon for prostate cancer to show any symptoms until the tumour is effectively large 
enough to create pressure on the urethra that the patient can feel (NHS, 2015b). Such pressure on 
the urethra can have various implications, such as feeling the need to rush to the toilet and urinate 
more frequently than usual, a difficulty in starting to urinate (urinary hesitancy), weak flow of urine, 
taking a long time to urinate and even when finished, the patient might get the feeling that their 
bladder has not been fully emptied. 
Although such symptoms do not always mean the patient has developed prostate cancer, it remains 
of great importance that the patient should visit a doctor and get checked when one or many of 
these symptoms are experienced. Other symptoms can be experienced and may indicate that the 
cancer had spread to other organs in the body. Such include testicular pain, loss of appetite 
accompanied with unexplained weight loss as well as bone and back pain. In addition, gross 
haematuria had also been observed in prostate cancer patients. A study revealed that its aetiology 
could depend on the primary treatment of the cancer (Gofrit et al., 2013). It suggested that if radical 
surgery is not the primary treatment for a prostate cancer patient then haematuria is mostly caused 






1.2.4.1 Prostate-specific antigen  
Prostate-specific antigen (PSA) is a glycoprotein synthesised as a proenzyme by the secretory cells 
lining the prostate glands. It is then secreted into the lumen where the propeptide is removed to 
convert it from proPSA to active PSA. The deactivation of PSA then occurs via the action of 
proteolysis to generate inactive PSA. Small amounts of inactive PSA then enter the blood circulation 
and travels in the blood in an unbound form as free PSA (Adhyam and Gupta, 2012). In healthy 
individuals, the levels of free PSA are higher than that of prostate cancer patients. Prostate cancer is 
instead associated with higher levels of complexed PSA (Bjork et al., 1996).  
PSA is widely used as a prostate cancer biomarker with elevation indicating a high chance of 
developing the disease. Serum PSA measurement is possibly the most commonly used prostate 
cancer clinical test. It has contributed to an immense improvement in cancer detection in patients 
over the past 20 years (Hernández and Thompson, 2004).  










The table above shows the correlation between the PSA levels in the blood and the risk of developing prostate cancer 
(Heidenreich et al., 2014b). As can be observed, the higher the PSA levels in the blood, the higher the risk of developing 
prostate cancer. 
Annual PSA screenings have been generally advised, especially for elderly men (Polascik et al., 1999) 
and men with PSA levels of >4 ng/mL who would then undergo prostate biopsy following a repeat 
 
PSA Level (ng/mL) 
 
Risk of prostate cancer (%) 
0 – 0.5  6.6 
0.6 – 1 10.1 
1.1 – 2  17.0  
2.1 – 3 23.9 
3.1 – 4 26.9 
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abnormal PSA test (Erol et al., 2014). In spite of its satisfactory sensitivity, PSA screening reliability 
remains limited due to its inadequate specificity (Thompson et al., 2004). Recent studies had shown 
that PSA screening might not be very beneficial and, in some cases, men with a PSA level lower than 
4ng/mL developed prostate cancer while other men with higher PSA levels did not (Lilja et al., 2008, 
Etzioni, 2013, Hayes and Barry, 2014). It is worth mentioning that PSA levels can fluctuate and are 
influenced by a range of factors which are not necessarily related to prostate cancer. Such factors 
include prostatitis and benign prostatic hyperplasia. In addition to these factors, PSA elevation also 
occurs when the prostate is manipulated in instances of ejaculation, urinary retention and prostate 
biopsy. As a result, patients undertaking PSA testing, must refrain from having a sexual intercourse 





1.2.4.2 Gleason score 
Knowing the stage of cancer in a patient is very important in determining the treatment. One way of 
doing that is by looking at how differentiated the cells are following a biopsy. If the cells are well 
differentiated then the cancer is at a least advanced stage than if the cells were poorly 
differentiated. Observing cells’ differentiation is carried out using a microscope and the cells are 
then given a ‘Gleason score’. The score range is from 3 to 5, with 3 being well differentiated and 5 
being poorly differentiated. A doctor would look at many samples from a patient and then takes the 
two most common grades and adds them. If the two most common grades for a patient are 3 and 4 
then the Gleason score for that patient is 7. The Gleason score can give an idea of the cancer’s 
differentiation, but it cannot be relied upon to make clear-cut decisions about cancer progression 
and treatment (CRUK, 2014c).  
Figure  1.11: Gleason's Pattern Scale 
 
The figure above describes the Gleason grading system, showing its usefulness in predicting cancer risk through 
classifying how differentiated cancerous cells are (Middlesexhospital.org, 2016).  
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Treatment for prostate cancer differs from one patient to another, vitally depending on the severity 
of the disease and how far the cancer has spread. For example, patients with stage I prostate cancer 
(e.g. T1, N0, M0, Gleason score of 6 or less, PSA less than 10) may be treated in one or more of the 
following ways: 
1.2.5.1 Radical prostatectomy 
This method is used to remove the patient’s entire prostate as well as the tumour that lies within it. 
It represents an ideal treatment solution for men with localised prostate cancer and might even be 
considered for prostate tumours that have invaded adjacent tissues – depending on how far these 
tumours have spread.  The operation requires the patient to be physically fit as complications might 
occur in vulnerable individuals during or even after the treatment. Radical prostatectomy might not 
be suitable for patients who are over 70 or suffering from heart problems. It is also advisable to 
avoid this treatment for patients who are overweight (Heidenreich et al., 2014b). 
1.2.5.2 External-beam radiation therapy (EBRT) and Brachytherapy 
Both of these are radiotherapy approaches that are used to treat early stage prostate cancer. 
Accurate calculations are carried out to locate the right angle for aiming the radiation beams straight 
at the tumour, in a process known as the ‘simulation’. Brachytherapy, however, is very similar to the 
interstitial radiation therapy in using relatively small radioactive pellets, placed directly into the 
prostate. Imaging techniques, such as CT scans or MRI, might be used to provide guidance in 
implanting these pellets (Babaian et al., 2008). 
1.2.5.3 Transurethral resection of the prostate (TURP)  
TURP is an approach which aims at relieving the symptoms of prostate cancer rather than curing it 
and it has been used in early stage prostate cancer as well as the cancer’s advanced stages. The 
inner part of the prostate is removed, while the skin itself is not damaged as an instrument called 
the resectoscope is used. The resectoscope is inserted through the tip of the penis and into the 
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urethra until it reaches the enlarged prostate. Once in range, an electric voltage is used to heat the 
wire and vaporise the tissue. Sometimes a laser is used to burn through the tumour tissue in the 
prostate using the same method (Rassweiler et al., 2006). 
1.2.5.4 Interstitial implantation of radioisotopes  
The use of interstitial radioisotopes implanted adjacent to or directly into the tumour provides an 
efficient tool to deliver radioactive doses to the tumour without harming the surrounding normal 
tissue. This method could be used as a temporary or as a permanent solution to early stage prostate 
cancer and the delivery method varies from needles to catheters. This kind of implantation may also 
include administrating an unsealed radioactive source that the body is able to metabolise over a 
period of time (Janetschek, 2008). 
1.2.5.5 Watchful waiting  
Watchful waiting or active surveillance might be ideal following treatment and is carried out to 
observe the development of prostate cancer that is not accompanied by any symptoms or causing 
any immediate health problems. Furthermore, as it is often the case, most prostate tumours are 
slow growing and potentially might not require treatment during the patient’s lifespan, watchful 
waiting might be an optimal strategy to deal with this type of tumours. Should an unexpected rapid 
growth of the tumour take place, then immediate treatment options will be considered to manage 
the tumour (Loeb et al., 2013). Watchful waiting in cases of prostate cancer includes digital rectal 
examination, regular PSA testing, transrectal needle biopsies and transrectal ultrasound (NCI, 2014).  
 
On the other hand, patients with a more advanced stage of prostate cancer (e.g. T4, N1, M1, 
Gleason >8, PSA >20) may require more aggressive approaches, such as: 
1.2.5.6 Chemotherapy  
Until 2004, the treatment for patients with advanced prostate cancer was limited to the use of 
androgen depravation therapy (ADT) in an attempt to slow down the progression of the disease. The 
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recording of two positive cases at phase III trials of docetaxel presented a huge step forward in the 
treatment of advanced prostate cancer (Petrylak et al., 2004, Tannock  et al., 2004). In addition to 
docetaxel, research advances have paved way for more chemotherapeutic drugs, such as TAX 327 
and SWOG 99-16, to be used in the treatment of prostate cancer. However, with the side effects of 
chemotherapy, more attention is now given to the detection and treatment of prostate cancer 
before it becomes castration-resistant as patients with early treatment were found to be healthier 
than those treated with castration-resistant forms of the cancer (Davda et al., 2016).  
1.2.5.7 Immunotherapy  
Advanced and recurrent forms of prostate cancers are often treated with immunotherapeutic 
techniques such as Provenge®. Such systems rely on the enhancement of the body’s own immune 
system to target cancerous cells (Thara et al., 2011). This stimulation of the immune system is 
focused mainly on the immune checkpoint inhibitors and presents oncologists with a less toxic 
approach when compared with chemotherapy and a more efficient and optimisable way in which 
the immune system can be stimulated (Gulley and Madan, 2016). An example of an 
immunotherapeutic vaccine is sipuleucel-T, targeting the prostatic acid phosphatase. The method 
relies on the use of the patient’s immune cells that have been previously extracted from circulation 
and processed ex vivo, before being injected back into the patient’s circulation (Kantoff  et al., 2010).   
1.2.5.8 Hormone therapy  
Home therapy alone does not cure prostate cancer; instead it aims to slow down its progression by 
preventing testosterone from reaching the prostate (Heidenreich et al., 2014a). This is achieved via a 
variety of ways, including the use of implants to inhibit the production of testosterone by the 
testicles, orchidectomy (surgical removal of one of the testicles or both) or through drugs that inhibit 
the production of testosterone (Nguyen and Pastuszak, 2016, Heidenreich et al., 2014a). Despite 
evidence supporting the role of hormone therapy in relieving prostate cancer symptoms in advanced 
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stage patients, some argued it may also lead to the deterioration in the quality of life in these 




1.3 Circulating tumour cells  
 
1.3.1 Background and History 
Circulating tumour cells (CTCs) are cells which shed from the primary tumour in which they originate 
and migrate away from that site, travelling in blood or lymph circulation and attaching to another 
distant location forming a secondary tumour (Millner et al., 2013). The link between CTCs and 
metastasis was first examined by Thomas Ashworth, an Australian physician, in 1869 (Krebs et al., 
2010). He reported microscopic observations of cancer cells in a sample of blood from a patient with 
metastatic cancer. He then went on to compare the morphology these cancerous cells with ones 
from different cancer lesions in that patient and stated that “if they (CTCs) came from an existing 
cancer structure, they must have passed through the greater part of the circulatory system to have 
arrived at the internal saphena vein of the sound leg” (Ashworth, 1869).  
His findings have paved way for thousands of studies in the years that followed, which focused on 
using these cells as possible biomarkers for detecting metastasis. However, despite all the work that 
has been carried out in the past 140 years, the CellSearch® remains the only method to have 
undergone rigorous testing and succeeded in becoming an FDA-approved method for detecting CTCs 
in the US (Miller et al., 2010). However, even in the case of CellSearch®, the system requires specific 
high end equipment to perform the test and is limited a few types of cancers, clearly indicating that 
more work in the CTC-detection field remains a necessity.  
Although metastasis in malignant tumours is believed to be a result of CTCs entering blood 
circulation and migrating to distant sites where they form secondary tumours, full confirmation of 
this has been challenged by their rarity (one CTC per 100 million blood cells) in peripheral circulation. 
Enumeration and identification of CTCs in the blood can provide us with a much greater 
understanding of the biology of cancer metastasis as well as help us find novel therapeutic targets 
for cancer treatment (Paterlini-Brechot and Benali, 2007). CTCs can also be used to monitor the 
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effectiveness of treatment and identify cancers that have relapsed. Early metastasis detection might 
be a very vital tool that CTCs can aid in, but their use is not limited there. Successful cancer 
treatment can lead to complete remission of the tumour, however, in some cases cancer relapses 
occur. It is of great importance to be able to detect CTCs before and after a patient is treated in 
order to evaluate the success of the treatment. As a result, CTCs might indeed be crucial as a 
biomarker in a point-of-care test that would evaluate a patient’s health status and assist in making 
accurate therapeutic decisions (Franken et al., 2012).  
Because of their low numbers in the blood, most CTC detection techniques rely heavily on 
enrichment methods to separate CTCs from the rest of the sample to help detect and identify them 
(Millner et al., 2013). CTC enrichment techniques aim at condensing the number of CTCs within a 
sample and separate them from unwanted hematopoietic cells. This is usually carried out by 
separating cells based on their size, density, migratory properties and protein expression.  
It is also believed that many CTCs evade the immune system and detection via their interaction with 
platelets in blood circulation after the intravasation process is complete (Lou et al., 2015). Platelets 
may play a role in protecting CTCs from host cells attacks, shear stress inflicted upon migrating cells 
as well as apoptosis. Additionally, CTC surface-coating with platelets may provide the perfect barrier 
to prevent the accurate labelling of these cells with epithelial-specific immunological markers 
(Storkus and Dawson, 1991, Nierodzik et al., 1995, Lou et al., 2015).  
CTCs rarity also makes detecting them both expensive and time consuming (Heitzer et al., 2013, 
Nagrath et al., 2007a). These difficulties along with their unique molecular characteristics makes 
isolating CTCs from blood very difficult and therefore limits their use as potential biomarkers for 
cancer research and therapy development (Hou et al., 2013). Additionally, many CTC diagnostic 
techniques do not take into account different heterogeneous phenotypes of CTCs. Not to mention 
their incapability of capturing functionally viable CTCs, which may aid in predicting the site at which 
metastasis would take place and thus tailoring personalised treatment (Millner et al., 2013).  
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1.3.2 CTCs in prostate cancer  
 
CTCs have previously been linked with metastasis in the prostate and their enumeration was found 
to be potentially useful as a prognostic molecular marker for prostate cancer (Thalgott et al., 2013). 
Most studies, have focused solely on certain patient groups (such as ones that have recently been 
treated) and may need to cover a wide range of patients. However, advanced methods have 
improved the detection of CTCs in early stages of prostate cancer (Danila et al., 2011, Friedlander 
and Fong, 2014). Aside from informing physicians of the metastatic properties of a cancer within a 
patient, CTCs can also provide a molecular profile of the tumour to help predict the patient’s 
sensitivity or resistance to treatment.  
Knowing the molecular profile of the tumour plays a big part in developing a personalised treatment 
for cancer patients, thus increasing their chances of survival. The focus is now on developing a very 
sensitive assay that is capable of detecting even the smallest amounts of CTCs in the blood as their 
rarity makes detecting them even more valuable than using other diagnostic techniques, such as the 
PSA test. This is also confirmed by a study which stated that CTCs’ enumeration in castrate-resistant 
prostate cancer (CRPC) was indeed a very useful prognostic method which can aid in redirecting and 
optimising therapy (Goldkorn et al., 2014).   
Prostate cancer is directly associated with metastases in the bone and lymph and this is thought to 
be a hugely contributing factor in morbidity-associated deaths through skeletal related events such 
as spinal cord compression (Saylor et al., 2011). Numerous studies have confirmed the presence of 
CTCs in CRPC; perhaps the most notable one was the CellSearch® assay study which enrolled 276 
patients with progressive CRPC (de Bono et al., 2008). The study carried out tests before treatment 
and on a monthly basis afterwards. Patients were said to have an unfavourable CTC count if 5 or 
more CTCs were detected in 7.5mL of their blood or a favourable count if less than 5 CTCs were 
observed. Categorising patients in this way was previously used in similar studies that looked at CTC 
detection in breast cancer (Miyamoto et al., 2014). 
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Numerous studies have been conducted to investigate the possibility of molecular characterization 
of CTCs in prostate cancer. In 2009, a study by Attard et al concluded that CTCs obtained from 
prostate cancer patients showed chromosomal translocation which resulted in TMPRSS2-EGR gene 
fusion in about 30-70% of the therapy-naive cases examined (Attard et al., 2009). The study used 
real time-polymerase chain reaction (RT-PCR) as well as fluorescence in situ hybridization (FISH) to 
confirm the 100% concordance in EGR gene status between primary tumour biopsies and CTCs.  
Another study reported the fusion of the same gene in RNAs extracted from CTCs in metastatic 
prostate cancer patients (Stott et al., 2010b). The study made use of PSA to stain cells believed to be 
CTCs in men with the localised and metastatic forms of the tumour. 8 out 19 patients with the 
localised tumour that were yet to receive treatment tested positive for CTCs with a range of 38 to 
222 CTCs per millilitre of blood. Whereas 23 patients out of 36 tested, who had the malignant form 
of the disease, showed CTCs presence at a range of 14 to 5000 per millilitre of blood. TMPRSS2-EGR 
fusion was detectable in 45% of the patients with malignant prostate tumours. 
Whether it is to be used for early metastasis detection or for disease management, the use of CTCs 
as biomarkers in prostate cancer still requires more work. Limitations have been identified in 
methods mentioned earlier and other ones that used imaging modalities and bones biopsies. New 
CTC detection methods showed great sensitivity and improved isolation methods of CTCs that target 
cells’ surface receptors or cells that are undergoing EMT (Miyamoto et al., 2014). However, 
extensive validation remains a requirement before any of these techniques can be approved for 
clinical use.   
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1.3.3 Methods of CTCs detection 
 
In prostate cancer, CTCs can be found and identified as possible biomarkers for the different stages 
of the disease with a variety of methods, including CellSearch® System, CAM Assay, CTC-chip 
microchip, Epispot assay, Ikoniscope® imaging system and others (Thalgott et al., 2013). Macroscale 
CTCs isolation or enrichment are used in CTCs detection and include: 
• Density gradient centrifugation 
• Red blood cell (RBC) lysis, to extract mononuclear cells  
• Physical filtration, using commercial filter pores (Isolation by size of epithelial tumour cells 
(ISET)) 
• Immunomagnetic separation  
 
Figure  1.12: The different approaches of CTC enrichment 
 
Above is an illustration of the approaches used in CTC enrichment and identification which include kinetic (physical) and 




































CellSearch® system Blood/ 7.5 mL Positive marker: CK Negative marker: CD45 Nucleus: DAPI 
CTC-chip microchip Blood/0.9 mL Positive marker: CK Negative marker: CD45 Nucleus: DAPI 
EPISPOT assay Blood, bone marrow/10 mL 
Secretion of proteins:CK19, MUC1, Cath-D 
(breast); CK19 (colon); PSA (prostate); TG 
(thyroid) 
ACIS®Ariol® Automated scanning of 
chromogenic immunostainings Bone marrow/blood 
Positive markers: CK Negative control: MOPC-
21 Nucleus: hemalaun 
CAM Assay Blood, 3 mL Positive marker: CK 4,5,6,8, 10,13, and 18 Negative marker: CD45 
Ikoniscope® imaging system Blood/1 mL 
Positive markers: EpCAM, CK7/8 PSA 




1.3.3.1 CellSearch® System 
 
The CellSearch® technology is used to detect, identify and count CTCs in a blood sample. The data 
gathered by the CellSearch® system would then help physicians make informed decisions on 
choosing the best course of treatment for cancer patients (Armakolas et al., 2010). The system had 
previously been tried and tested in metastatic breast, prostate and colorectal cancer and the 
manufacturing company claims that the system can also give a good estimation of the progression-
free survival as well as the overall survival of patients. CellSearch® is often used in conjunction with 
other detection methods and tests to enhance the accuracy of the diagnosis.  
The system requires 7.5mL of blood for each analysis and is comprised of two vital steps. Initially it 
enriches epithelial cells via the selection of epithelial cell adhesion molecule (EpCAM) positive cells. 
This is done by mixing peripheral blood samples with iron particles coated with EpCAM to confer 
magnetic properties within all epithelial cells present. The identification of epithelial carcinoma cells 
then follows and is achieved via double staining with cytokeratin (CK) and CD45 antibodies while 
using DAPI to visualise the cells’ nuclei.  Anti-CK antibodies are used to identify epithelial cells 
whereas anti-CD45 antibodies would inform the user which cells are lymphocytes and should be 
disregarded from further analysis. Automated digital fluorescence microscopy is the final step where 
the CTCs population can be viewed and assessed (Barh, 2014). 
Studies have confirmed that using a combination of diagnostic methods (including CellSearch®) 
provides significantly more reliable prognostic information in comparison to using serum PSA alone, 
especially in cases of metastatic CRPC (Helo et al., 2009). The CellSearch® system is used in more 




1.3.3.2 CTC-chip microchip  
 
CTC-chip is a microfluidic device which allows for the isolation and enumeration CTCs from 
peripheral whole blood samples (Nadal et al., 2013). Originally developed by a team of investigators 
from the Massachusetts General Hospital, CTC-chip helps in the selective separation of viable CTCs 
via the interaction of the targeted CTCs with EpCAM-coated microposts. All of which is achieved 
under carefully controlled laminar flow conditions. The method had worked well when tested on 
patients with metastatic lung, prostate, pancreatic, breast and colon cancers with a success rate of 
99% of the cases (115 case out of 116) (Nagrath et al., 2007b).  
CTC-chip has a purity of about 50% and was able to detect a range of CTCs in the samples trialled, 
ranging from 5 CTC/mL of blood in some samples to 1281 CTC/mL in others. For prostate cancer 
patients, CTCs were isolated in all of the cases (7 patients in total) despite the patients being in the 
early stage of the disease. In addition, CTC-Chip was also tested to see its efficiency in monitoring 
patient’s response to anti-cancer treatment. The changes in CTCs numbers showed a reasonable 





1.3.3.3 Epithelial ImmunoSPOT (EPISPOT) Assay 
 
The EPISPOT assay has a vital advantage over other CTC detection methods in that it allows for the 
detection of viable epithelial secreting cells only. This detection is performed after CD45+ cell 
depletion and with the use of protein markers such as MUC1 and CK19 (Nadal et al., 2013). This is 
achieved as dying cells do not secrete the usual amounts of these proteins and thus the assay will 
not regard them as epithelial cancerous cells (Alix-Panabieres et al., 2005). Despite the correlation 
between the increased detection of CK19 mRNA transcripts in a blood sample and bad survival 
outcomes in early stage breast cancer patients with oestrogen receptor-negative tumour (Ignatiadis 
et al., 2007), further research and validation are required to prove that EPISPOT is in fact a reliable 
tool for CTCs detection. The assay general steps are explained in Figure  1.13 below. 
Figure  1.13: EPISPOT assay 
 
The figure above briefly describes the key events taking place during the EPISPOT assay. Initially, the membranes of the 
EPISPOT plates are coated with a specific antibody as shown in day 1. During the next two days, cells are seeded in each 
well and cultured for 48 hours. The immunocapture of the released proteins takes place at this stage during the 
incubation period and is achieved via the immobilised antibody at the bottom of the well. After washing the plates to 
remove the cells, the presence of the released protein is revealed using a fluorochrome-conjugated antibody. Finally, on 
the 4th day, the fluorescent immunospots are counted; one immunospot represents one protein-releasing viable cell 
(Alix-Panabières et al., 2008).    
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1.3.3.4 Other methods 
 
Other CTCs detection methods vary in the approach taken to isolate and enumerate CTCs but most 
systems use enrichment methods that rely on the biological and physical properties of cells captured 
as shown in Figure  1.14 below (Miyamoto et al., 2014).  
Figure  1.14: CTC detection approaches 
 
Above is an illustration showing variation of methods used in the detection of CTCs. Some methods rely on the use of 
biological properties such as cell surface antigens. By doing so, these antigens are targeted with immunofluorescent 
antibodies to identify and isolate them in what is known as positive or negative selection. Some biological methods rely 
on the depletion of cells and detecting cellular viability. Other techniques involve the use of advanced imaging 
technique for direct analysis. Whereas another approach is to examine the physical properties of cells, such as the 
electric charges or cellular density (Miyamoto et al., 2014). 
 
Automated Cellular Imaging System (ACIS®) and Ariol® system are also used for the enumeration of 
CTCs. Ariol® is an automated system that is used for image capture and analysis and is capable of 
combining multiple fluorescent and brightfield images of the same cell at the same time. The system 
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had previously been tested in cases of metastatic breast cancer (Deng et al., 2008) and was found to 
have higher sensitivity, accuracy and reproducibility than the CellSearch® system mentioned earlier.  
Another method of detection is the Ikoniscope® Imaging System which relies on the use of 
Ikoniscope® robotic microscope. The company describes its product as self-handling and can do 
automated scanning, eliminating in the process many of the factors that cause human error in 
testing. The company also claims that the device can provide real-time image capture and analysis of 
up to 2 million cells on a single slide. Spiking experiments involving samples taken from prostate, 
colorectal and ovarian cancer patients were carried out and analysed with Ikoniscope® microscope 
(Ntouroupi et al., 2008). Results showed that less than one epithelial cell per one millilitre of blood 
can be detected. However, despite being unable to detect CTCs in only 2 out of the 25 colorectal 
cancer patients tested on, the method was deemed relatively simple, rapid and useful for clear-cut 
identification of CTCs for possible cancer screening and monitoring purposes.  
Other antibody-based capture assays for CTCs detection include Magsweeper (EpCAM-based), 
GILUPI cell collector, Adna Test and IsoFlux. Physical characteristic-based assays include ISET®, Dean 
Flow Fractionation and Dielectrophoretic field-flow fractionation. There are also other CAM assays, 




1.4 Imaging flow cytometry  
 
 
1.4.1 History and background  
 
In 1968, Wolfgang Gödhe from the University of Münster in Germany developed the first 
fluorescence-based flow cytometry device, the ICP 11. The technology used by the ICP11, was 
named pulse cytophotometry and was then changed to flow cytometry 10 years later 
(BeckmanCoulter, 2015). The term rapidly became popular and many devices soon emerged such as 
Cytofluorograph, PAS 8000, ICP 22, Epics and the first Fluorescence-Activated Cell Sorter (FACS).  
In the past 10 years, imaging flow cytometry emerged as a powerful tool used for cell capture and 
analysis. There were few challenges, however, that have been long associated with the imaging of 
cells in flow. Such include acquiring sufficient fluorescence sensitivity, the production of high spatial 
resolution imagery, combining fluorescence imagery with other imaging modes and the ability to 
image all of the cells in flow (Basiji et al., 2007).  
Advanced imaging flow cytometers (such as Amnis ImageStreamX) combine the powers of 
microscopy and flow cytometry to help scientists detect, capture images and analyse thousands of 
heterogeneous cells in flow in seconds. The cell capture and analysis is done in real time and graphs 
can be produced to compare cell parameters, staining intensity and other criteria (Barteneva et al., 
2012). Imaging flow cytometers are commercially available nowadays from Amnis Incorporated 
(Merck Millipore) and are involved in a wide range of research involving the detection and analysis 
of tumour cells in different cancer types as well as various cell-lines in other diseases (van Beers et 
al., 2014, Hui et al., 2014). Imaging flow cytometry methods also aid in the detection of changes 
within cells themselves. Such changes include DNA damage and nuclear alterations.  
When compared with normal flow cytometry, the imaging aspect of this technology allows for the 
detection of chromosomal signalling, antigen localization and other events that take place within the 
68 
 
cell as demonstrated by Grimwade et al in the study that explored the use of an imaging flow 
cytometer in the diagnostic assessment of acute leukaemia (Grimwade et al., 2017). The technique 
showed a major advantage in its ability to visualise certain cells of interest as well as the localising 
the cellular compartment in which an antigen is expressed. Full comparison between standard and 
imaging flow cytometry is summarised in the table below.  
Table  1.6: Standard flow cytometry vs imaging flow cytometry 
 
Above is a comparison between imaging flow cytometry and standard flow cytometry (Grimwade et al., 2017) 
 
Another study utilised the use of this technology in studying the biology and different pathologies of 
erythrocytes (Samsel and McCoy Jr, 2015). It praised how easily the process of enucleation in 
mammalian erythrocyte maturation was detected but warned that the use of such technique has its 
limits too. For example, cells are required to be in suspension in order for them to be examined 




Visualise cell morphology No Yes 
Analyse differences in cell size and shape No Yes 
Immunophenotype cells based on antigen expression detected 
with fluorescent antibodies Yes Yes 
Assess multiple fluorescent parameters simultaneously  Yes Yes 
Determine cellular location of antigen expression, i.e. 
cytoplasmic versus nuclear No Yes 
Determine the pattern of antigen expression, i.e. diffuse versus 
punctate  No Yes 
Ability to perform all tests required in leukaemia diagnosis in 
one analysis, as defined by WHO Classification , i.e. morphology, 
phenotype and chromosomal analysis 
No Yes 
Multiparametric analysis of small volume (<100µl) or low cell 
number  Limited Yes 
Return any residual sample after you have finished acquiring Yes Yes 
Automated data analysis software available  Yes Yes 
Ability to use software to create “masks” to calculate similarity 
or co-localisation of expression No Yes 
High throughput analysis, i.e. >100 cells per second  Yes Yes 
In Vitro Diagnosis (IVD) compliant  Yes Pending 
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rather than having them on a slide or adhered to a plate. There is also the concern that adherent 
cells might be damaged when they are trypsinised and removed prior to being analysed; such 
damage may come in the shape of affecting cell surface receptors.  
Imaging flow cytometry also showed a great potential in the analysis of primary megakaryocytes 
isolated from murine bone marrow in order to study the decreased platelet production by these 
cells following bone marrow injury, which could ultimately lead to thrombocytopenia (Niswander et 
al., 2014a). All in all, both studies as well as many others concluded that the use of such technology 
would indeed provide us with a highly sophisticated insight in a less time-consuming manner than 






The ImageStreamX is one of the commercially available imaging flow cytometers that combines 
microscopy with flow cytometry. Enhanced with the powerful analysis software IDEAS®, the 
ImageStreamX is capable of producing 60,000 images of 10,000 cells in approximately 30 seconds. 
IDEAS® is useful in the analysis of captured images of cells as it compares cellular morphology, 
fluorescent signal strength, signal locations and other cellular features. The software provides 40 
quantitative features per image, allowing for approximately 250 features to be analysed per cell 
(Basiji et al., 2007). The results based on these features are displayed on scatterplots or histograms, 
giving an accurate count of each population gated in each analysis. 
The instrument’s mother company, Millipore, recently released the Amnis ImageStreamX Mark II 
with multiple magnification powers (20×, 40× and 60× objective), twin excitation lasers – with a 
maximum of 12 channels for image acquisition – and the Extended Depth of Field (EDF) feature using 
multilayer stacking to allow the capture of whole cells in flow (Headland et al., 2014).  
Even prior to the injection of these new features, numerous works had been published with the help 
of the imaging tools provided by the ImageStreamX. Such publications include the study of primary 
megakaryocytes and their involvement in thrombocytopenia (Niswander et al., 2014b), an 
investigation into the possibility of using extracellular matrix domain formation as an indicator of 
chondrocyte dedifferentiation and hypertrophy (Wu et al., 2014) as well as research into CTCs 
detection and metastasis (Lopez-Riquelme et al., 2013).  
Furthermore, a recent study explored how the use of the ImageStreamX can benefit scientists in the 
detection and characterisation of CTCs in different types of cancer (Dent et al., 2016). It utilised the 
cancer cells’ expression of a range of biomarkers such as EpCAM and CK. CTCs were detected in 
patients with oesophageal, hepatocellular, thyroid and ovarian cancers. The authors showed that 
the method they developed may be piloted for other cancer types and has the advantage in reduced 
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cell damage when handling cancer cells with cell recoveries greater than 50%. The relatively fast 
speed at which the test was performed was highlighted, as well as the lack of reliance on a single 
expression of a biomarker by cancer cells.  
Unenriched samples could also be analysed, but in comparison with enriched samples, they would 
be vastly time consuming. A 5mL unenriched sample would require about 15 hours to be fully 
analysed for the presence of CTCs, whereas it would take 1 hour 40 minutes to analyse an enriched 
sample. Additionally, the recovery of cells was also compared between enriched and unenriched 
samples. Enrichment led to CTC losses which accounted for about 38.1%, and there were also losses 
of about 6.7% which occurred during image collection. However, unlike CellSearch® which positively 
selects cells that are EpCAM positive only, cell recovery was increased with the use of EasySep® 
magnetic separation kit. This is because many cancerous cells undergo EMT and as a result, they are 
likely to lose EpCAM expression or have it changed during the cell cycle (Hyun et al., 2016).  
CTCs detection using the ImageStreamX system was recently tested against the CellSearch® system in 
pancreatic cancer (Lopez-Riquelme et al., 2013). The study used PANC-1 pancreatic cancer cells in 
cells spiking experiment with healthy peripheral blood cells. It was claimed that the enumeration of 
these cells was lower using the ImageStreamX platform than it was using CellSearch®. Despite using 
the same biomarkers for CTC detection in both systems, the enrichment methods used – which as 
previously explained, accounts for a considerable cell loss – differed for each system, rendering the 
results of that study questionable.  
Our research group recently explored the benefits of using the ImageStreamX system and how it 
surpassed older methods used (Parris et al., 2015b). We demonstrated that the detection of γ‐H2AX 
DNA damage foci can be further enhanced when using the new ImageStreamX Mark II featuring the 
multi-magnification of 20×, 40×, and 60× as well the EDF focus stacking module. This was achieved 
by imaging and quantifying γ‐H2AX foci in human cells with normal and defective DNA double-stand 
break repair capacity.  
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Our study showed that using the new 60× magnification and EDF helped to accurately detect 40-50% 
more foci in cell nuclei. Thus, the use of these new features may be utilised in diagnostic tests 
developed to predict the response of cancer patients to clinical radiotherapy or for the detection of 
CTCs. This work comes as a follow up to what has been previously published by our group about the 
use of imaging flow cytometry as a novel and robust technique for the estimation and quantification 







The aim of my study is develop and validate a reliable diagnostic method that is capable of 
identifying CTCs in blood samples using Amnis ImageStreamX Mark II. Initially, PC3 prostate cancer 
cells were used (mimicking the role of CTCs) in samples containing peripheral blood lymphocytes 
(PBLs). A comparison between a number of immunological and physical methods will be conducted 
to deduce the most specific and sensitive approach for the identification of CTCs.  
The attainment of a precise CTC detection method will be followed by a validation test using clinical 
samples obtained from different metastatic CRPC patients. Defining the sensitivity of the test will 
give a clue as to how effective it can be in the early detection of CTCs in prostate cancer patients, 
determining the metastatic properties of prostate tumours and, possibly, utilising its use as point-of-
care system in monitoring cancer patients before and after treatment.  
In this research, I will be thoroughly investigating a number of biomarkers and their staining 
intensity and localisation such as the Epithelial Cell Adhesion Molecule (EpCAM), Zonula Occludens-1 
Tight Junctions (ZO-1 TJ) protein antibody and the leukocyte-specific marker, CD45 antibody. 
Moreover, the physical characteristics of CTCs and leukocytes will be examined using a range of 








Chapter 2  




 Materials and methods 2.
 
 
2.1 Cell Maintenance  
 
2.1.1 Cell culture 
  
PC3 cells derived from a primary epithelial prostate cancer were used and regularly maintained in 
Hams F-12 medium containing 10% foetal calf serum, 100 units/mL penicillin–streptomycin (Biosera, 
Sussex, UK) and 2 mM L-glutamine. Cells were grown in T75 flasks at a temperature of 37°C and a 
humidified atmosphere of 5% CO2 in air. PC3 cells were sub-cultured in a Heraeus Class II Laminar 
Flow hood for no more than 10 times and not beyond 60 passages.   
Peripheral blood lymphocytes (PBL) were obtained from various healthy individuals with full ethical 
approval and with informed consent and kept in liquid nitrogen until use. When required for an 
experiment, vials containing PBL were thawed in a water bath at 37°C, washed with RPMI-1640 
medium (Biosera, Sussex, UK) containing 10% foetal calf serum, 100 units/mL penicillin–
streptomycin and 2mM L-glutamine, and then grown in PB-MAX (Thermo Scientific™, Leicestershire, 
UK) medium in T25 flasks for approximately two days prior to use. PBL are also maintained at a 
temperature of 37° C and a CO2 level of 5%. GMO0893 cells were maintained in RPMI-1640 medium 
containing 10% foetal calf serum, 100 units/mL penicillin–streptomycin and 2 mM L-glutamine and 
sub-cultured in a similar way to PC3 cells. 
The PC3 cell-line (human prostate cancer cells) is used to mimic the role of CTCs in blood with similar 
characteristics to prostatic small cell carcinoma (Tai et al., 2011), whereas the PBLs – which were 
taken from different healthy individuals – and the GMO0893 cell-line played the role of blood cells in 
the body. The sources for the three types of cells used are mentioned in Table  2.1.   
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Table  2.1: List of cell-lines used 
Cell-line Supplier Medium Growth conditions 
PC3 





Incubation at 37°C in a 
humidified atmosphere of 
5% CO2 in air 
GMO0893 Coriell Institute, New Jersey, USA RPMI 1640 
Incubation at 37°C in a 
humidified atmosphere of 
5% CO2 in air 
PBL Multiple donors  PB-MAX 
Incubation at 37°C in a 
humidified atmosphere of 
5% CO2 in air 
 
Above is a table listing the cell-lines used, their suppliers, their media and growth conditions.   
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2.1.2 Cell trypsinisation  
 
The PC3 cells were grown as monolayers in T75 cell culture flasks (Tai et al., 2011), the Hams F12 
medium the cells grew in was initially removed using a glass Pasteur pipette. Cells were then washed 
with 10mL of phosphate-buffered saline (PBS) (Scientific Laboratory Supplies Ltd., Loughborough, 
UK). The PBS was then aspirated and 1.5 mL of Trypsin-EDTA (SLS) was added to each flask and 
incubated at 37°C for 5 minutes.  
Flasks were then examined under the microscope to ensure that most cells have detached from the 
flask. The cells were then resuspended in 10mL of Hams F12 medium and either transferred into 




2.1.3 Cell Counting  
 
Prior to using any cell-line for culture or in an experiment, cells in each flask were counted using one 
of two methods, a glass haemocytometer or the Cell Countess device (Invitrogen, Life Technologies, 
Paisley, UK). To count the cells, Trypsin was first used to detach them from the flask if they were 
adherent as previously explained. After recovering the cells in 10mL growth medium, a 10µl sample 
was taken from the cell suspension and added to another 10µl of Trypan Blue dye in an Eppendorf 
tube. This was performed to distinguish between live and dead cells when counting. Trypan blue is 
an extensively used dye for staining and identifying dead cells. The dye is negatively charged and 
would only interact with cells with damaged membranes, Figure  2.1 below demonstrates the steps 
taken to count cells using Trypan Blue and a Cell Countess (Tran et al., 2011).  
Figure  2.1: Counting cells using a Cell Countess 
 
The figure shows the steps of staining dead cells with Trypan Blue and how the number of viable cells is counted using a 
Cell Countess device (Invitrogen, Life Technologies, Paisley, UK). The graphics in steps A and C are taken from the 
Nanoentek website (Nanoentek, 2015).  
 
According to the manufacturer’s instructions, the Cell Countess is limited to a certain cell 
concentration to ensure accurate counting, with a minimum of 1×104 cells/mL and a maximum of 
1×107 cells/mL. In cases of low cell numbers, cells were reseeded in 20mL of medium and back into 
their T75 flasks and returned in the incubator where they are left to grow and while being 
periodically observed. In rare occasions, cell numbers were found to exceed the range beyond which 
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the Countess accuracy would no longer be reliable. For these experiments, a Neubauer 
haemocytometer was used and the samples were stained with the Trypan Blue dye and then loaded 




2.1.4 Cell Freezing  
 
Cells were used over a restricted range of 10 passages, thus frozen cell stocks were produced for 
future use. To freeze cells for future use in experiments, a freezing solution was made comprising of 
10% DiMethyl Sulfoxide (Sigma-Aldrich), 10% foetal calf serum and 80% medium containing 
penicillin/streptomycin and L-glutamine.  
As described before, cells were grown in T75 flasks until they reach a confluency of about 90%. They 
were then trypsinised (in the case of adherent PC3 cells) and recovered with 10mL of growth 
medium and moved into a 15mL falcon tube (Sarstedt). After centrifugation for 5 minutes at 1500 
rotation per minute (rpm), the medium was aspirated and 1mL of the freezing solution was added to 
cells. These were then transferred into cryo-vials (Sarstedt) and placed in a cell freezing container 
(Nalgene, Sigma-Aldrich). These containers were used to ensure that the samples stored reached at 
least -80°C temperature before storing them in liquid nitrogen dewars.  
Freezing containers comprise a foam insert that is soaked in isopropanol, a solution which allows for 
a slow freezing rate of cells at about 1°C/minute. The freezing containers were then left in the      -




2.1.5 Mycoplasma PCR for PC3 cell-line 
 
The Mycosensor PCR Assay Kit (Agilent Technologies™) was used to verify the existence of 
mycoplasma in the PC3 cell-line. The primer mix is capable of detecting mycoplasma infections in cell 
cultures in a procedure that lasts 3 and half hours using 100µl of cell culture supernatant (Agilent, 
2016). The test showed no presence of mycoplasma in the PC3 cell-line that was used.  
One hundred microliters of the Hams F-12 medium in which PC3 cells were growing was used to 
determine the presence of mycoplasma in the culture. This amount was then transferred into an 
Eppendorf tube and heated to 95°C for 5 minutes using a heat block. The medium was then 
centrifuged for about 30 seconds at a speed of 14k rpm at room temperature. 10µl of Strataclean 
(non-flammable slurry of proprietary hydroxylated silica particles) was added to the sample and 
mixed by gentle agitation, ensuring that resin had combined with the medium. Centrifugation 
followed for 1 minute at a speed of 13k rpm and then 5µl was transferred into a 0.25mL PCR tube 
containing 45µl of the required PCR mastermix. The mastermix consisted of 13.5µl nuclease free 
water, 25µl 2x reaction mix, 2µl primer mix and 4µl internal control template.  
The 0.25mL PCR tube containing PC3 medium was then placed into the thermal cycler with 10 µl of 
the final product being later used in a 1% agarose gel. Below is a table outlining the conditions used 
in the thermal cycler: 













Above is the table outlining the conditions used in the thermal cycler for the Mycoplasma PCR program. 
 
Steps Temperature Duration Cycles 
Denaturation 94°C 30 seconds 1 
Denaturation 94°C 30 seconds 35 
Annealing 55°C 1 minute 35 
Elongation 72°C 1 minute 35 
Extension 72°C 10 minutes 1 
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2.2 Immunocytochemistry and live cell analysis  
 
In this research, two types of experiments were conducted. A set of experiments used cells that 
were fixed before mixing them with another cell-line to reconstruct presence of CTCs in the blood. 
These cells were then stained with a number of biomarkers such as EpCAM, ZO1 TJ and CD45 
antibodies to detect CTCs based on the immunological staining of cells in the test samples. The other 
set of experiments used cells that were live in order to measure and compare the physical and 
morphological properties of these cells.  
To fix these cell-lines, PC3 cells were first washed with 10mL of PBS and detached from the flask by 
trypsinisation in 1.5mL in Trypsin-EDTA. They were then fixed in 1mL of 3.7% Paraformaldehyde 
(PFA) for approximately 5 minutes on ice. GMO0893 and PBL cells were washed with PBS and fixed 
in a similar way to PC3 cells but without adding Trypsin to these cells.  
Following fixation, cells they were then washed with PBS to rehydrate them. They were then 
centrifuged at 2000rpm for 3 minutes and blocked with 1mL block buffer containing 5% rabbit serum 
(or goat serum when using CD45 antibody) (Thermo Scientific, Leicestershire, UK) and 95% PBS and 
left to rotate on a spinning wheel (Bibby Scientific, Staffordshire, UK) for 1 hour at a speed of 20 rpm 
at room temperature. Cells were then washed with 1mL PBS and the primary antibody (diluted in 
blocking buffer) was added before incubating them at 4°C overnight. Table  2.3 on the following page 
outlines the antibodies used, their source and dilution.  
After 24 hours of incubation, the cells were then centrifuged at 2000rpm for 3 minutes before being 
washed with 1mL of PBS and incubated with 1µl of the secondary rabbit anti-mouse (or goat anti-
rabbit, in the case of CD45 antibody) IgG Alexafluor 488 conjugated antibody diluted at 1:1000 in 
blocking buffer (Invitrogen Scientific, Paisley, Scotland, UK) on the rotating wheel at a speed of 
25rpm for 1 hour at room temperature while covered from light. 100μl of Accumax (Global Cell 
Solutions Inc., Charlottesville, VA, USA) was added to samples and incubated at 4°C overnight. 1μl of 
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the nuclear stain DRAQ5 (Biostatus, Hitchin, Herts, UK.) was added to the samples and left to stand 
for 15 minutes prior to ImageStreamX image capture. 
 
Table  2.3: List of the three antibodies used 
Antibody Source Dilution  (in blocking buffer) 
EpCAM 
IgG mouse monoclonal 
antibody (ABCAM, 





IgG rabbit monoclonal 
antibody (ABCAM, 




IgG mouse monoclonal 
antibody (ABCAM, 
Cambridge, UK. Clone 
number: mAbcam 61357) 
1:200 
 
The table above shows the different antibodies used to detect PC3 cells, GMO0893 or PBL cells. The source and dilution 
of each antibody are also mentioned. 
 
Cells used in live cell analysis were prepared in a similar procedure to the one used in the 
immunostaining method with the exception of fixing, blocking and staining of cells with primary and 
secondary antibodies. Following the transfer of cells from flasks to Eppendorf tubes, they were 
resuspended in 100μl of Accumax and stored for approximately 20 minutes at 4°C. 1μl of the nuclear 
stain DRAQ5 was then added to the samples and were left to stand for 15 minutes prior to 




2.3 Sample acquisition and analysis using imaging flow cytometry  
 
2.3.1 ImageStreamX Mark II  
The ImageStreamX Mark II (Amnis Inc., Seattle, Washington), as previously described, is a flow 
cytometer with microscopic capabilities. It is capable of capturing thousands of images of cells in 
flow on twelve different channels simultaneously. The Mark II is an upgrade on the previous version 
and possesses unique features such as multi-magnifications (20×, 40× and 60×) as well as the 
extended depth of field (EDF™) technology. EDF™ makes use of Wavefront Coding technology which 
combines the use of specialised optics and a special imaging processing algorithms, allowing for all 
information about a captured cell to be grouped onto a single focal plane using focus stacking (Parris 
et al., 2015a). This allows for an in-depth imaging of cellular morphology without losing the 
sensitivity of fluorescence staining (Millipore, 2016).  
 
Figure  2.2: Utilising the use of EDF technology in the ImageStreamX 
 
The figure above shows two panels to compare the difference between normal cell imaging and EDF-enabled imaging. 
Both images are captured at 60×; however, Panel - B shows more detailed features (Parris et al., 2015a). 
 
The device is also capable of capturing images on different optical channels using a range of lasers, 
of which the 800nm will be used to capture brightfield (BF) images, the 488nm for Alexa Fluor (AF) 
Panel - A 
Panel - B 
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and 642nm for DRAQ5. Below is a table which describes the uses of these lasers and the 
fluorochromes used in this study.  
 
Table  2.4: List of fluorescent antibodies that can be used with the ImageStreamX 





























































Alexa Fluor 488 
Alexa Fluor 500 














PE-Texas Red (ECD) 




PE-Alexa Fluor 647 












Alexa Fluor 546 
Alexa Fluor 555 
DyLight 549 
Calcium Orange 
PE-Texas Red (ECD) 







Alexa Fluor 568 
Alexa Fluor 593 
Alexa Fluor 610 
DyLight 594 
Texas Red 
PE-Alexa Fluor 647 






PE-Alexa Fluor 750 
 
mCherry 
Alexa Fluor 568 
Alexa Fluor 594 









MitoTracker Deep Red 
APC-Cy7 







MitoTracker Deep Red 
Alexa Fluor 647 
Alexa Fluor 660 









The table above shows different fluorescent antibodies that can be used with the ImageStreamX (Millipore, 2016). The 






2.3.2 INSPIRE®  
 
Samples containing no less than 20µl were prepared for ImageStreamX analysis and cells were gently 
resuspended to break cell clumps before each run on the ImageStreamX. The option “Load” was used 
to load the sample into the machine while “Acquire” was used to examine the sample and capture 
single cells in real time using a premade INSPIRE® template.  
Figure  2.3: Sample acquisition using INSPIRE® 
 
The figure above shows the sample acquisition function buttons as currently used in the ImageStreamX Mark II. The 
‘Load’ button was used upon placement of the sample inside the machine to inform the device that the sample is ready 
to be examined. The ‘Return’ button on the other hand is used upon the completion of sample acquisition. Acquisition 
information that can be provided by the user includes the sample name, sequence number, number of cells required to 
be captured and the population of (gated) cells to collect images from. The remaining sample volume is demonstrated 
by the blue bar with the exact volume figure displayed directly underneath the bar. The acquire function button was 
used to begin the capture process and the creation of .rif files. 
The number of cells captured from one sample may differ to others. In some experiments there was 
a shortage of cells available for examination (e.g. when cells were lost in washes or when there were 
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not many cells to begin with). The 488 excitation laser power was set to 100mW, while the side 
scatter was set to 2mW as shown in Figure  2.4. 
Figure  2.4: INSPIRE® sample acquisition control features 
 
The figure above shows various INSPIRE® settings such as illumination, magnification and fluidics which can be modified 
prior to capturing cells from a sample. (A) The laser power is set to 100mW but can be changed depending on the 
intensity of staining. (B) The ImageStreamX Mark II also allows for a 60× objective which proved very useful, especially in 
the most diluted samples. In addition there is also the option of extended depth of field (EDF) which helps in projecting 
all structures and probes for an increased focus and better image clarity. (C) Fluidics control provided a balance between 
speed of cell capture and the sensitivity of the device. (D) The Focus and Centering was automatically controlled by the 
device, however, at times it required adjustment to obtain the optimal results. (E) The Startup and Shutdown functions 








Cell classifiers were then set to a minimum cell size of 50 and a maximum cell size of 900. This was 
set on Ch01 when collecting cell images from normal samples, on Ch02 for the capture of AF 488 
intensity from the AF compensation tube and on Ch05 for the DRAQ5 compensation tube. 
Furthermore, compensation settings must be applied before loading the compensation tubes. 
Figure  2.5: Captured images of cells using the ImageStreamX 
 
The INSPIRE® software was used to display and capture cells from the ImageStreamX. Images of cells are displayed on six 
different channels as shown above. Channel 1 (Ch01) represents brightfield images of cells captured, channel 2 (Ch02) 
displays primary antibody staining of these cells, while channel 5 (Ch05) shows the nuclear staining with DRAQ5 
antibody. The toolbar above the six channels shows a range modification tools including ones that could be utilised to 
adjust properties of images captured, such as brightness and contract.  
 
The option Acquire was then used to capture images of the cells, the process usually takes no more 
than 3 minutes. A raw image file (.Rif) was saved onto the computer and then used for analysis via 
the IDEAS® analysis software. When data collection from one sample was complete, the sample was 
returned via the option “Return” before loading the next sample.  
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Figure  2.6: Distribution of cells based on a variety of features using INSPIRE® 
 
Different graphs are created by the capture software, INSPIRE®, to select the regions from where images of cells will be 
captured, with each white dot in these graphs representing an object (e.g. cell, cluster of cells, debris). The graphs also 
show real-time numbers of cells (displayed as white dots) and in which region they fall with regards to each feature 
displayed (e.g. area, intensity of antibody on channel 2, etc.). Selected regions such as the one displayed in blue (Single 
cells) allow for selective capture of cells within these gates only. 
 
Once work with the machine is complete, the option “Shutdown” was then used to sterilise the 
ImageStreamX prior to shutting it down. This includes physically emptying the waste tank and filling 




2.3.3 Image Compensation  
 
In every experiment in which two different fluorescent labels were used (such as EpCAM [488nn] 
and DRAQ5 [648nm]), image compensation was carried out. This was done to measure the intensity 
of fluorescence, relying only on a single source of illumination and the reason behind that is to 
eliminate the fluorescence leaked into adjacent channels.  
Image compensation is performed with a single source of illumination (the 488nm laser). A 
compensation matrix was generated using the Wizard tool in the image capture software INSPIRE®. 
The process is made easier than the older models in which the two different compensation files 
were used in the analysis software IDEAS® to generate a coefficients table where light captured from 
images was placed on the corresponding channel (e.g. Ch05 for DRAQ5) on a pixel by pixel basis. 
These coefficients represent the leakage of a certain fluorochrome into adjacent channels and would 
require to be normalized to 1.   
Figure  2.7: A typical ImageStreamX compensation matrix table 
 
The figure above shows an example of a compensation matrix table created by the analysis software IDEAS® prior to 
analysing the sample. Values shown in this table represent coefficient figures of leakage into adjacent channels. The 
coefficient of leakage decreases as it becomes distant from the principal channel indicated with a 1 value. The values 
used in this research were adjusted to have a margin of error that is less than 0.001.  
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Image compensation helps in representing the true intensity of certain fluorescent lights for each 
image and will therefore lead to an accurate data capture and analysis. The method which generates 
a compensation matrix using IDEAS® has been previously explained by our research group (Parris et 
al., 2015a). 





(A) Shows examples of uncompensated images of PC3 cells captured in this research using the ImageStreamX. Channel 2 
shows EpCAM staining, while fluorochrome leaks can be seen on adjacent channels (e.g. Ch03). Using the Image 
Compensation tool in the IDEAS® allows for the correction of this leakage. Figure (B) shows the exact same PC3 cells 










The IDEAS® software is used to analyse samples captured with the ImageStreamX, forming data 
analysis files (.Daf). The software firstly views all of the captured objects (cells, debris, etc.) and 
allows the user to gate a section of them (based on manual examination of these objects) and tag 
them as single viable cells, the analysis can then proceed using only single cells. It is worth 
mentioning that the INSPIRE® capture software allows for single cells to be isolated and exclusively 
collected; however, careful examination of collected cells is important, this is done to exclude small 
clusters of cells that might have been accidentally included in the original capture. The next step is to 
narrow the analysis only to focused cells which have a clear cell structure and morphology.  
Figure  2.9: Identification of single cells using IDEAS® 
 
The Y-axis shows the distribution of the cells in terms of their aspect ratio while the X-axis shows their distribution in 
terms of size. Each one of the blue dots represents one captured object (e.g. cell, debris, cell clusters). The “_M01” at the 
end of the axis’ name refers to the channel it applies to. The software automatically generates statistics about the 
captured data such as the number of cells, mean and more and these statistics are displayed in a table below the graph. 




Figure  2.10: Identification of focused cells using IDEAS® 
 
A graph was then created from the single cells that were gated to identify the clearly focused cells and exclude any 
blurred cells from further analysis. On the X-axis, a gradient of cells based on image focus is used, while the Y-axis 
represented the normalised frequency. Following examination, a line gate was created (in green) separating single 
focused cells from blurred unclear cells. The table below the graph is automatically generated by the analysis software 
after a number of cells in that graph are gated. This is done to show the number and percentage of cells included in that 
range. 
Choosing from the focused cells only, the software was used to create a gradient based on the 
intensity of EpCAM staining in the PC3 cells (Figure  2.11Figure  2.10). When the graph was created in 
the IDEAS® software, different sections of it were examined to decide points at which cells would be 
classified as positively stained. When created, statistics regarding percentages of each section of the 
graph as well as cell numbers can be obtained. This gives us precise numbers in terms of how well 
the cells stained for each dilution of the antibody used.  
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Figure  2.11: Identification of positively stained cells using IDEAS® 
 
The histogram above was used to identify focused EpCAM-positive and negative cells. The figure shows normalised 
frequency on the Y-axis against antibody staining intensity (captured on channel 2) on the X-axis. A region-selecting tool 
was used to obtain a cell count for cells that were stained with EpCAM. These were determined after examining various 
regions and then gating them with the line tool. 
 
Figure  2.12 compared the intensity of the primary antibody staining on the X-axis against the 
intensity of DRAQ5 staining on the Y-axis. This graph gave a better representation of each cell within 
the EpCAM positive and negative regions and I was able to view each cell’s morphology, primary 




Figure  2.12: The use of scatterplots to identify EpCAM positive and negative PC3 cells 
 
A scatterplot created to help in identifying and gating focused EpCAM positive and negative PC3 cells, each dot 
represents a captured cell. After manual examination of various cells, the population of cells that was EpCAM positive 
was gated and separated from the population that was EpCAM negative as can be seen in the red and purple boxes in 
the figure above.    
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2.4 Lymphocyte separation  
 
The isolation of peripheral blood lymphocytes from whole blood was achieved using lymphocyte 
separation medium (LSM®) (SLS, Nottingham) in a method explained by the solution manufacturer. 
The LSM was mixed thoroughly by inverting it few times. 3mL of LSM was then transferred to a 15mL 
tube. 2mL of defibrinated blood was then diluted by mixing it with 2mL of RPMI medium (1:1). It was 
then layered carefully in a way that the blood was positioned right above the 3mL separation 
medium at room temperature, creating a sharp blood-LSM interface.  
Centrifugation of the tube then took place at 400 x g at room temperature for 15-30 minutes. This 
was done in order to deposit erythrocytes and polymorphonuclear leukocytes to the bottom of the 
tube, while drawing mononuclear lymphocytes to a level above the LSM. The top layer, containing 
clear plasma, was then aspirated to within 2-3mm above the lymphocytes layer, which itself was 
then transferred to a new tube along with approximately half of the LSM layer below it.  
An equal volume of buffered balanced salt solution was added to the tube and centrifuged at room 
temperature for 10 minutes at a speed of 200 x g. This speed was chosen to deposit the cells to the 
bottom of the tube without causing cellular damage. The cells were then washed with buffered 
balanced salt solution and resuspended in PB-MAX to be used immediately or frozen in liquid 
nitrogen in a method previously explained. The reason for washing cells is to remove LSM from the 
sample, as well as reducing the percentage of platelets (MPBiomedicals, 2016).      
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2.5 Proof of principle (mixing) experiment   
 
To test the sensitivity of the CTC identification method used and to evaluate which analysis feature 
would be most suitable to distinguish CTCs from other blood cells, a series of serial dilution 
experiments were conducted. PC3 cells were diluted and mixed with PBLs as shown in the table 
below before being examined using the ImageStreamX. This was also done to compare cell retrieval 
numbers when immunological approaches were used to when the live cell analysis approach is 
undertaken.  
Table  2.5: Serial dilution of PC3 cells to test CTC detection sensitivity 
Tube number Total PC3 cells  spiked in 1mL 
Total number of PBLs in 
1mL 
1 3,000,000 3,000,000 
2 300,000 3,000,000 
3 30,000 3,000,000 
4 3000 3,000,000 
5 300 3,000,000 
6 30 3,000,000 
 
An outline is given above of how samples were spiked with different dilutions of PC3 cells to test the sensitivity of the 
ImageStreamX using immunological and physical approaches. 
 
The spiking step was carried out after both cell-lines were counted using the Countess and 
calculations were made of the volume required for each sample. Care was taken when mixing both 
cell-lines and very often dilutions were made instead of relying on using pipettes to deliver minute 
volumes for test tubes 4, 5 and 6, ensuring the number of cells in these tubes were very accurate. 
The proof of principal experiment was also carried out using fixed cells in a three days experiment 
and live cell analysis within one day to test which approach provided better PC3 cell retention.  
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2.6 Clinical sample preparation  
 
Whole blood samples were collected from two metastatic castrate-resistant prostate cancer (CRPC) 
patients with informed consent and NHS ethical approval. The samples were initially collected in 
EDTA tubes and inverted several times. 7mL of red blood cell (RBC) lysis buffer was added to each 
sample in a falcon tube and inverted several times prior to 10 minutes incubation on ice. The 
samples were then centrifuged for 10 minutes at a speed of 2500rpm at room temperature. The 
supernatant was removed from each sample and an additional 3mL of RBC lysis buffer was used to 
resuspend the cells pellet.  
The samples were then centrifuged again at 2500rpm for 10 minutes at room temperature to create 
RBC-free pellets of cells. Following the centrifugation of samples, the supernatant in each sample 
was carefully aspirated and the cells were then immediately used for live cell analysis or fixed with 
3.7% PFA, blocked with a blocking buffer and stained with primary and secondary antibodies as 







Chapter 3  
Identification of PC3 cells 





 Identification of PC3 cells using the Epithelial Cell 3.
Adhesion Molecule  
 
3.1 Introduction  
 
Epithelial cell adhesion molecule (EpCAM) is a glycoprotein expressed in epithelia and in the majority 
of carcinomas, prompting interest in utilising its use as a possible biomarker for cancer detection 
(Litvinov et al., 1994). In a study that investigated 3360 cases of primary colon, lung, prostate and 
stomach tumours, EpCAM was found to be overexpressed in 94.1% of them (Went et al., 2006). The 
epithelial tissue lines all external and internal surfaces in multicellular organisms, providing a well-
governed barrier of molecular exchange with the extracellular milieu. Epithelial tissue is made up of 
two main types; simple epithelium and stratified epithelium and features an abundance of cell 
adhesion molecules (CAMs) (Schnell et al., 2013).  
Figure  3.1: The variety of CAMs present on epithelial cells 
 
The variety of CAMs that exist in epithelial tissue and play a vital role in upholding epithelial cellular adhesion. 
Mutations in these CAMs may also give rise to diseases like cancer (Schnell et al., 2013).  
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Many diseases affect the intergrity of the epithelial layers. These include pathogenic infections, 
autoimmune diseases and cancer. EpCAM is a cell adhesion protein and was indentified as a tumour 
antigen in the 1970s when functional screens were carried out to identify possible tumour-specific 
cell surface antigens that can be used as cancer biomarkers (Herlyn et al., 1979).  
 
Figure  3.2: An example of EpCAM staining of MCF-7 cells 
 
The figure above shows a modified diagram by Gadalla et al of anti-EpCAM antibody staining (green) in dividing MCF-7 
cells. The blue stain represents nuclear staining with DAPI (Gadalla et al., 2013).  
 
The EpCAM antibody has a molecular mass of approximately 40 kDa with variable levels of 
expression. However, there is a usually lower expression in normal epithelia in comparison to 
carcinoma cells (Trzpis et al., 2007). With regards to prostate cancer, EpCAM is found to be 
expressed at high levels in most of its metastatic cell-lines and in metastatic forms of prostate cancer 
compared to non-metastatic primary cell-lines and tissue samples. Interestingly, the EpCAM marker 
may be a useful indicator of chemotherapeutic efficacy and expression of EpCAM is found to be 






1. The identification of PC3 cells by exploiting the EpCAM epithelial marker using 
immunocytochemical techniques 
2. Determination of the efficacy of EpCAM staining for the identification of PC3 cells within a 
mixture of PBL cells 
3. Determination of the sensitivity of EpCAM identification of PC3 cells by spiking PBL samples 
with dilutions of PC3 cells 
4. Determination of the specificity of CTC identification using EpCAM antibody 






3.3.1 EpCAM antibody optimisation  
 
Prior to using EpCAM for the identification of PC3 epithelial cells, it was serially diluted in an 
extensive series of optimisation tests to determine the best dilution at which the majority of 
epithelial (PC3) cells were visibly stained. Three test tubes were used, each with a different dilution, 
as shown in the table below.  
Table  3.1: EpCAM staining optimisation for PC3 cells 
EpCAM dilution Percentage of stained cells Example of a stained cell 
Tube 1 (1/1) 95.8% 
 
Tube 2 (1/5) 60.4% 
 
Tube 3 (1/10) 20.1% 
 
 
The table above shows brightfield images of PC3 cells (Ch01), EpCAM staining of these cells (Ch02) and nuclear staining 
with DRAQ5 (Ch05). In tube 1, the dilution was kept the same as the recommended volume and 200µl of the prediluted 
EpCAM antibody was used. In tube 2, 40µl of the EpCAM antibody was diluted by adding it to 160µl of the blocking 
buffer. Whereas in tube 3, the dilution was doubled as only 20µl of EpCAM was added to 180µl blocking buffer. 
 
This data demonstrated that the clarity of EpCAM staining was optimal when the recommended 
prediluted antibody was used to stain the cells. There was visible staining in tube 2 (1/5 dilution), 
some cells were clearly stained but the vast majority showed lower EpCAM intensity in comparison 
to PC3 cells in Tube 1. Cells in tube 3 on the other hand showed little or no EpCAM staining (1/50 






optimal dilution was found to be the original in which the antibody is provided, with the amount of 
antibody added to each sample recommended to be no less than 200µl. The optimisation 
experiments and observations indicated that the 200µl of the prediluted EpCAM antibody was 




3.3.2 PC3 cells staining with EpCAM antibody 
 
Various optimisation strategies were conducted to confirm the optimal staining conditions for the 
labelling of PC3 cells with the EpCAM antibody.  Parameters that were examined were the antibody 
incubation time, fixation method and fixation time. Different batches of the EpCAM antibody were 
also examined to test the efficacy and specificity of each batch in labelling PC3 cells. The anti-EpCAM 
antibody batch that showed clear membrane staining in most PC3 cells captured was the HEA125 
EpCAM antibody (ABCAM, Cambridge).  





Samples shown in the figure above demonstrate different patterns of staining of PC3 cells with the EpCAM antibody. 
The first column, titled brightfield shows brightfield images of cells captured at 40× on Ch01. The second column shows 
EpCAM antibody staining in green on Ch02. DRAQ5 nuclear staining is displayed in red in the third column, titled Ch05. 
 
The majority of PC3 cells in all experiments showed an optimal level of staining. There was, however, 
a small percentage in each PC3 population in which the intensity of EpCAM staining was barely 
detectable or non-existent even when the optimised method was used. Examples of such cells are 
shown in Figure  3.3 on panels C, D and E. The intensity of staining was less than that of A and B and 
Ch01 Ch02 Ch05
Panel - A 
 
Panel - B 
 
Panel - C 
 
Panel - D 
 
Panel - E 
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in some cases, panel C for example, staining of the cytoplasm of cells was observed. The percentage 
of cells that showed weak but detectable staining was approximately 11% of the entire PC3 
population captured. There were also few PC3 cells (2.21%) that did not stain with EpCAM, such as 
the ones shown in panels D and E. 







The figure above shows the normalised frequency of PC3 cells (Y axis) against the intensity of EpCAM antibody in these 
cells (X axis). Cells on the left (marked in green) were cells that showed no staining at all or a very minute antibody 
intensity that would also be obtained without using any antibodies. The blue region in the middle categorises cells with 
higher intensity of EpCAM antibody, but not high enough to be classified as EpCAM-positive cells. Cells on the right 
(within the red region) were EpCAM-positive cells. The table below the graph displays the exact percentages of PC3 cells 
within these three regions. 
Region Population Percentage (%) 
 No staining 2.21 
 Some staining 11 
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Some of the PC3 cells that were partially stained or not stained at all presented a less intact 
structural morphology than cells with optimal staining. This observation prompted a hypothesis that 
perhaps alterations to the structural integrity of these cells were brought about by the numerous 
and rigorous steps required in sample preparation before cells are examined with the ImageStreamX. 
However, prolonged examination of several PC3 samples stained with EpCAM revealed many more 
cells that expressed no EpCAM staining, yet possessed morphology that was similar, if not better 
than that of EpCAM positive cells. This indicated that the poor morphology and cell structure in 
EpCAM-negative cells might not be the only reason behind the lack of staining and that this 
acquisition of false-negative PC3 cells might be linked to non-specific abnormalities observed in 
immunostaining experiments where biomarkers such as EpCAM antibody were used (Punnoose et 




3.3.3 GMO0893 staining with EpCAM antibody 
 
The use of GMO0893 lymphoblastoid cells in an immunological experiment involving the EpCAM 
antibody was done to test if this cell-line will show negative staining behaviour as expected of non-
epithelial cell-lines. The figure below shows examples of various types of EpCAM staining patterns 
observed in a GMO0893 sample.  
Figure  3.5: EpCAM staining of GMO0893 cells 
 
 
Samples shown in the figure above demonstrate different patterns of staining of GMO0893 cells with the EpCAM 
antibody. The first column, titled Ch01 shows brightfield images of cells captured at 40× on channel 1. The second 
column (Ch02) shows EpCAM antibody staining in green colour. DRAQ5 nuclear stain is displayed in red on the third 
column (Ch05). Panel A and B are examples of EpCAM-positive cells, while panel E is an example of a GMO0893 cells that 
was not stained with the antibody. Panels C and D show variable levels of weak staining with EpCAM. 
 
Approximately 30% of the cells in the sample were EpCAM positive, a strong indication that non-
specific staining with EpCAM is predominant in the GMO0893 cells. The structure of cells examined 
was generally in poor status compared to the two other cell-lines used. Nevertheless, only the 
staining for cells with robust shape and morphology was taken into account when the analysis of 
EpCAM non-specific staining was conducted.  
Perhaps the more interesting fact was the higher percentage of partially stained cells compared to 
other cell-lines. Approximately 39.1% of the cells displayed a weak level of EpCAM intensity, similar 
to that demonstrated in Figure  3.5 panel – C above.   
Ch01 Ch02 Ch05
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The figure above shows the normalised frequency of GMO0893 cells (Y axis) against the intensity of EpCAM antibody in 
these cells (X axis). Cells on the left (marked in green) were cells that showed no staining at all or a very minute antibody 
intensity that would even be obtained without using any antibodies. The blue region in the middle categorises cells with 
higher intensity of EpCAM antibody, but not high enough to be classified as EpCAM-positive cells. Cells on the right 
(within the red region) were EpCAM-positive cells. The table below the graph displays the exact percentages of 
GMO0893 cells within these three regions. 
The pattern of EpCAM staining in GMO0893 cells differs from that of PC3 cells in that it was not 
peripheral (restricted to the membrane) in any of the cells. This could be an indication that the 
staining observed in GMO0893 cells is not caused by antibody-antigen binding but rather by the loss 
of structure in these cells.  
Region Population Percentage (%) 
 No staining 30.6 
 Some staining 39.1 


















3.3.4 PBL staining with EpCAM antibody 
 
The failure of GMO0893 cells to maintain a prototypical and optimal morphology and structure 
prompted the need for an alternative substitute for these cells. Peripheral blood lymphocytes (PBLs) 
from historical stock of frozen cells from normal individuals (collected with ethical approval and 
informed consent) provided just that and were compared in every step of this research to GMO0893 
cells in their ability to limit nonspecific staining and maintain optimal morphology and structure. In 
this chapter they were stained with the same prediluted form of EpCAM used on PC3 and GMO0893 
cells and the results were as follows:  
Figure  3.7: EpCAM staining of PBL cells 
 
 
Examples shown in the figure above demonstrate different patterns of staining of PBL cells with the EpCAM antibody. 
The first column, titled Ch01 shows images of cells captured at 40×. The second column (Ch02) shows EpCAM antibody 
staining in green colour. DRAQ5 nuclear stain is displayed in red on the third column (Ch05). Panel A and B are examples 
of EpCAM-positive cells with variable levels and patterns of staining, while panels D and E are EpCAM-negative cells. 
Panel C is an example of a partially or weakly stained PBL cell. 
 
As can be seen in the figure above, the staining with EpCAM was apparent in a number of PBL cells 
(17.3%). However, the total percentage of cells that were partially stained or not stained at all 
represented 82.7% of the entire PBL population. A percentage that is higher than that of the 
GMO0893 cells that were partially or not stained (69.7%). However, the disadvantage in using PBL 
Ch01 Ch02 Ch05
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Panel - E 
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cells was that more than half (51%) of the PBL cells were partially stained such as shown in the 
example in Panel – C of Figure  3.7. 







The figure above demonstrates the distribution of PBL based on the intensity of EpCAM antibody in these cells. Cells on 
the left (marked in green) were cells that showed no staining at all or a very minute EpCAM intensity that would 
otherwise be observed even without using any antibodies. The blue region in the middle represents cells with higher 
intensity of EpCAM, but not high enough to be classified as EpCAM-positive cells. Cells on the right (within the red 
region) were EpCAM-positive cells. The table below the graph shows exact percentages of the cells within each one of 
the three regions mentioned. 
 
Region Population Percentage (%) 
 No staining 31.7 
 Some staining 51 
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Single focused cells, which were derived as described in the materials and methods chapter by using 
the gating and regions tools, were divided based on their level of EpCAM staining as shown in 
Figure  3.8. Cells with little or no staining can be found on the left of the graph (green region) while 
those with a visually detectable level of staining are positioned on the right of the intensity plot 




3.3.5 Mixing Experiment using EpCAM antibody  
 
Based on a comparison of results in the two previous sections of this chapter, examining staining 
behaviours of GMO0893 and PBL cells, it was unequivocal that PBL cells were to be used in mixing 
experiments which reconstruct the presence of CTCs in the blood of prostate cancer patients by 
spiking PBL samples with different dilutions of PC3 cells. The experiment aims at verifying the 
sensitivity of EpCAM marker in labelling and isolating PC3 cells using the ImageStreamX. All samples 
contained a constant number of PBL cells and varying dilutions of PC3 cells as explained in the proof 
of principal (mixing) experiment section of the materials and method chapter of this research. 
Examples of images captured of both cell-lines are given below:  
Figure  3.9: EpCAM staining of PC3 and PBL cells 
 
 
The figure above shows a gallery of images captured from a sample containing both PC3 and PBL cells. Ch01 column 
shows the brightfield images of cells captured, Ch02 column shows staining patterns with the EpCAM antibody in green, 
while the Ch05 column shows nuclear staining with the DRAQ5 antibody. Panels A and B show examples of PC3 cells that 
were EpCAM-positive, while Panels C and D shows examples of PBL cells that were EpCAM-negative. Panel E shows an 
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example of PC3 cells that was EpCAM-negative (false negative) and Panel F demonstrates how some PBL cells can be 
found to be EpCAM-positive (false positive). 
 
Images captured of both cell-lines revealed that the majority of PC3 cells (94.4%) were EpCAM-
positive and that the vast majority of PBL cells (89.13%) were EpCAM-negative as demonstrated in 
Figure  3.10 on the following page. Examination of EpCAM-positive PC3 cells revealed that some PC3 
cells had peripheral EpCAM staining confined to the membrane region of these cells (Figure  3.9, 
Panel – A), while others expressed high intensity of EpCAM staining on the membrane of the cells as 
well as the cytoplasm (Panel – B), an indication of an increased permeabalisiation of some of these 
PC3 cells. More importantly, however, a small percentage of the PC3 population (5.6%) was found to 
have weak or no EpCAM staining. Although this percentage may be relatively small, the number of 
PC3 false-negative cells that it represents (966 cells) is higher than can be ignored.  
On the other hand, careful examination of the PBL region also revealed that there was a small 
percentage of PBL cells that were stained with EpCAM as shown in panel F of the same figure. The 
staining patterns of PBL cells were different from PC3 cells in that there was no staining confinement 
to the periphery of these cells but rather high intensity patches distributed irregularly within the 
cells. Despite this clear difference in staining, EpCAM false-positive PBL cells were seen to overlap in 
parts of the intensity graph in Figure  3.10 with PC3 cells due to the high intensity of staining in these 
cells. Several repetitions of this experiment yielded varying numbers of false positive and negative 
PC3 and PBL cells, but all of them confirmed the persistence of EpCAM lack of specificity. 
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The figure above shows the distribution of PC3 and PBL cells from the same sample. The X axis shows the intensity of the 
EpCAM antibody staining, while the Y axis represents the normalised frequency for both cell-lines. Different staining 
intensities are categorised on three different sections and the overlapping region between the two cell-lines – where 
intensity of staining was similar – is highlighted in a purple. The table below the graph shows exact percentages for cells 




PC3 cells PBL cells 
Region Population Percentage (%) Region Population Percentage (%) 
 No staining 0.55  No staining 89.13 
 Partial staining 5.05  Partial staining 5.97 

































When EpCAM was used to measure cell retrieval of PC3 cells, the numbers were much lower than 
the original used. The percentage of cell retrieved might have varied, but the number of cells was in 
decline as the number of PC3 cells used decreased. The numbers presented in Table  3.2 do not give 
a precise account for the actual number of PC3 cells captured but of the cells that fall within the 
EpCAM positive region on the scatterplot as some of these cells were later identified as PBLs when 
individually examined. Additionally, there were PC3 cells that were not accounted for as they did not 
express a high EpCAM staining to be considered amongst the PC3 population. Furthermore, there 
were also cells that lost their structural integrity and had a relatively bad morphology and structure 
accompanied with a high EpCAM intensity; these were also counted as PC3 cells by the analysis 
software.  
Table  3.2: Retrieval numbers of EpCAM positive cells 
Total PC3 cells  
spiked into 1mL 
Approximate retrieval of 
EpCAM stained cells 
3,000,000 24.98%  
(749,540) 
300,000 0.66%  
(1973) 
30,000 2.27%  
(680) 
3000 15.97%  
(479) 
300 7%  
(21) 
30 16%  
(5) 
 
The table above shows the number of PC3 cells counted and spiked in each of the test tubes and the number of PC3 cells 
retrieved following examination with the ImageStreamX. The percentage of cells acquired fluctuated from one tube to 
another, but the number of cells was in constant decline. These numbers do not represent the actual number of PC3 
cells retained but the number of cells that lie within the PC3 region on the scatterplot based on their EpCAM intensity. 
Upon manual examination of some of these cells, it was found that some PBL cells were identified amongst cells 





In this study, imaging flow cytometry was used to investigate the identification of CTC cells by 
exploiting the EpCAM epithelial marker using immunocytochemical techniques. It also explored the 
specificity and sensitivity of PC3 identification using the EpCAM antibody. Staining localisation and 
general structural and morphological properties of cells were also observed. The method used was 
originally optimised to ensure that PC3 cells would stain with EpCAM, an epithelial-specific marker. 
PC3 cells were used to mimic CTCs in cancer patients, whereas GMO0893 cells and PBLs were used 
as blood cells. The use of GMO0893 cells was limited to simply testing if EpCAM would stain these 
cells and whether they can withstand the sample preparation steps, comprising of several washes. 
These cells displayed poor morphology upon examination and it was decided that they would not be 
further used to optimise a protocol to detect CTCs in blood using EpCAM. EpCAM was tested with 
each cell-line separately and a proof-of-principal experiment was then conducted where samples 
containing PBLs were spiked with dilutions of PC3 cells. The aim was test the efficacy of EpCAM in 
specifically targeting PC3 cells and distinguishing them from other cells in a given sample.  
A number of EpCAM dilutions were initially tested to establish the most efficient amount of the 
antibody required to stain PC3 cells. It was found that 200µl of the pre-diluted form in which the 
antibody was provided was sufficient to stain the majority of cells in a given sample. There was, 
however, the problem of having a percentage of the PC3 population that would stain inadequately 
or not stain at all. Increasing the amount of antibody used or its concentration did not help solve this 
issue, which remained persistent even when the experiment was repeated several times with a 
variety of fixation methods and timing as well as other protocol modifications that were applied.  
In the case of GMO0893 cells, EpCAM staining was prevalent throughout these cells with more than 
30% of them found to be EpCAM-positive. These cells are lymphoblastoid cells and are not expected 
to stain with an epithelial marker such as EpCAM. The fact that the majority of them did, may 
provide an insight of a vital weakness in the functionality of this antibody. In addition to failing in 
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obtaining specific staining, images of GMO0893 cells revealed poor morphology, which can be 
attributed to the prolonged protocol and its rigorous washing steps. Following careful observation of 
captured images, it became clear that the nonspecific staining of these cells can also be attributed to 
the loss of cellular integrity throughout the sample preparation steps. This was also evident for other 
antibody staining methods tested on this cell-line, which will be demonstrated in the next few 
chapters.  
When PBLs were used, an identical problem of nonspecific staining was recurring. More than 17% of 
a sample containing PBLs was positively stained for EpCAM, even though they should not have. 
However, unlike their GMO0893 counterparts, PBLs maintained a good morphology throughout the 
experiment. The EpCAM staining patterns observed differed from those obtained in the other two 
cell-lines. EpCAM staining did not cover the entire cell like it did with the GMO0893 cells, nor did it 
stain the periphery of these cells, as in the case of PC3 cells. EpCAM was observed in localised 
regions across PBLs in an irregular pattern. Despite the relatively small area these regions covered, 
the intensity of antibody staining in them was equivalent if not higher than that of some PC3 cells. As 
a result, many of these cells were falsely categorised as PC3 cells based on their EpCAM staining 
intensity when an EpCAM staining-intensity graph was created.  
The proof of principle (mixing) experiment was the core aim of this study, as it would examine 
whether or not this immunological method would provide accurate results in the identification of 
CTCs in real cancer patients. To implement it, samples containing identical amounts of PBLs were 
spiked with dilutions of PC3 cells. This was done to test if the assay developed can identify PC3 cells 
based upon their staining patterns and intensity of EpCAM antibody as well as validating the 
sensitivity of this test. Six Eppendorf tubes were used with the highest retrieval being 24.98% for the 
tube containing 3×106 PC3 cells. The percentage then fluctuated from one sample to another, with 
the most diluted sample having a retrieval percentage of approximately 16% (5 cells out of 30). 
However, cells that were retrieved based on their EpCAM staining were not easily confirmed as PC3 
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cells due to the relatively poor morphology and structure of cells which may have also incorrectly 
contributed to their positive staining. As described before, some PBLs showed similar EpCAM 
staining patterns to PC3 cells and were often found in overlapping regions together when histograms 
were created from the data captured. Low EpCAM staining in some epithelial cells has previously 
been reported as a weakness of this antibody in a number of studies (Punnoose et al., 2010, Millner 
et al., 2013).  
Another issue that needed to be addressed was the severe loss of PBL and PC3 cells during the 
sample preparation steps. The retrieval rate of cells in general was relatively low and can be 
explained by the excessively long procedure in which the cells were prepared prior to ImageStreamX 
examination. This poor recovery of cells was indeed a major setback as it meant that many PC3 cells 
that could have been detected by the device were lost before they could get to the image capture 
stage. This raised few doubts on whether the current assay is capable of preserving cell numbers and 
maintaining a good morphology for the cells.  
The use of EpCAM as a sole marker for PC3 cells also became unconvincing following a series of 
consistent incidents in which a number of PC3 cells showed no patterns of EpCAM staining. On the 
other hand, some GMO0893 and PBLs showed high levels of EpCAM intensity. Although the staining 
patterns are generally different from one cell-line to another when examined individually, the 
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PC3 cells 
 
4.1 Introduction  
  
In the previous chapter I investigated the use of the EpCAM epithelial marker for the identification of 
prostate epithelial (PC3) cells within a mixture of peripheral blood lymphocytes (PBLs). It was 
demonstrated that the EpCAM antibody was a promiscuous marker where non-epithelial cells were 
positively stained. This made the accurate enumeration of PC3 cells very challenging. As a result, the 
use of an antibody that was specific to haematopoietic cells was considered. The aim was to target 
GMO0893 and PBL cells and then to enumerate the CD45-negative cells (PC3 cells).  
The CD45 antigen (lymphocyte common antigen) is a glycoprotein found to be expressed exclusively 
in all hematopoietic cells with the exception of mature erythrocytes. It is also known as the human 
common leukocyte antigen and has a molecular weight of approximately 200kDA (Nakano et al., 
1990). Furthermore, CD45 plays vital roles in the immune system as the prototypic member of 
transmembrane receptor-like protein tyrosine phosphatases (RPTPs). Essentially, CD45 is required 
for the development process of T and B cells as well as the antigen-induced activation of these cells 
(Nam et al., 2005).   
T cell activation often takes place when a foreign antigen is presented as short peptides by an 
antigen presenting cell (APC) such as macrophages, dendritic cells, Langerhans cells and B- 
lymphocytes. T cells may also be activated by a process that can be achieved via other class I or class 
II major histocompatibility complexes (MHC) (Malissen and Schmitt-Verhulst, 1993). Recognition of 
these molecules by T cells follows, leading to the activation of the T cell receptor (TCR),  resulting in 
a cascade of events comprising of intracellular responses that consequently lead to T cells 
differentiation (Perlmutter et al., 1993). Besides TCR, a number of other T cell surface molecules 
were also found to be essential for T cell activation.  
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 Previous studies found that co-receptor molecules such as CD4 and CD8 were expressed on 
different T cell subsets. These molecules were found to have a key role in initiating or stabilizing the 
T cell-APC interaction. Furthermore, these studies also suggested that CD45 molecules expression on 
T cells is vital for an effective activation of T cells (Ledbetter et al., 1993, Altin and Sloan, 1997).  
CD45 has been previously used to distinguish PBL cells in various types of metastatic cancer cells 
from blood cells in patient samples (Figure  4.1).  
Figure  4.1: CD45 antibody staining of leukocytes 
 
The figure above shows two images of cells stained with CD45 antibody. Image A shows an example of white blood cells 
peripherally stained with CD45 antibody (Chen et al., 2016). Image B shows similar but clearer image of CD45 staining. 
However, the cells in (B) are Jurkat cells, an immortalised cell-line of human T lymphocyte cells (ABCAM, 2016).  
 
An example of that are enrichment methods utilising anti-CD45 monoclonal antibodies in 
combination with FISH to deplete haematopoietic WBCs from patient samples, leaving behind a 
more concentrated sample of CTCs (Ning et al., 2014). 
Additionally, FACS has also been used for the sensitive detection of CTCs via labelling leukocytes with 
anti-CD45 antibody. FACS is a flow cytometry technique that can sort or isolate a mixture of 
heterogeneous cells based on the fluorescent characteristics or the light scattering of cells. Using 
this method, CD45 negative cells (potential CTCs) were isolated and examined using immunostaining 




with advanced localised gastric cancer and found that this technique might be useful in detecting 
and isolating CTCs (Baran et al., 1998). Despite all the studies conducted about the biology and 
function of CD45, there are still many aspects of it that remain unclear. Studies of CD45 variations 
between different human individuals might hold the key to a better understanding of this molecule 
(Holmes, 2006).   
In this chapter, the CD45 antibody was used to stain lymphoblastoid cells and PBLs before testing its 
sensitivity in identifying PC3 cells via the negative selection of CD45 positive cells. Therefore  I 
attempted to distinguish PC3 cells from a population of Epstein Barr transformed B-lymphocyte cells 
as a proof principle of the utility of using CD45 immunostaining and imaging flow cytometry to 






• To identify PC3 cells by negative selection of cells stained with CD45 antibody through an 
immunocytochemical technique and imaging flow cytometry 
• To determine the efficacy of CD45 antibody staining in distinguishing PC3 cells spiked in a 
sample containing PBL cells  
• To determine the sensitivity of CD45 staining in the identification of CTCs through the 
staining of PBL cells spiked with PC3 cells 
• To determine the specificity of PC3 identification using CD45 antibody 
• To investigate the effects of the CD45 staining approach on the morphology and structure of 





4.3.1 CD45 antibody optimisation  
 
Prior to staining cells with the CD45 antibody, optimisation tests similar to those conducted for the 
use of EpCAM were undertaken. It was vital to determine the best dilution of the antibody required 
to specifically stain all the non-epithelial cells within the sample, subsequently minimising the use of 
reagents and the cost of procedure. As previously explained, these tests were aimed at using a 
number of antibody dilutions, mixed with blocking buffer and then observing the percentage of cells 
– in this study GMO0893 – that were visibly stained. GMO0893 cells are lymphoblastoid cells that 
were expected to stain with CD45 antibody and were initially used to optimise the dilution of this 
antibody prior using it on other cell-lines. The method of staining with CD45 antibody is similar to 
that of EpCAM antibody staining described in the materials and method chapter. 
Table  4.1: CD45 optimisation for GMO0893 cells 








The table above shows the dilutions of the CD45 antibody that were used to stain GMO0893 cells. The 2nd column 
displays the percentage of GMO0893 cells that were positively stained with CD45 out of the total number of cells 
collected in the sample. In the 3rd column, examples of stained cells are given, showing brightfield images of GMO0893 
cells on Ch01, Ch02 shows the intensity and pattern of the CD45 antibody staining while Ch05 shows DRAQ5 nuclear 
stain in red. 
 
The use of CD45 dilutions did not yield expected results as all dilutions used showed very similar 






cells stained remained lower than anticipated even when the empirically determined optimal 
dilution of the antibody was used (1/15). It is worth pointing out that the morphology of the 
GMO0893 cells was relatively poor in all samples and might be a contributing reason as to why many 




4.3.2 PC3 cells staining with CD45 antibody 
 
Classified as epithelial cells, PC3 cells were not expected to be stained with the CD45 antibody. 
However, they were subject to an experiment that would verify this and test whether non-specific 
staining would occur or not.  




Samples shown in the figure above demonstrate different patterns of staining of PC3 cells with the CD45 antibody. The 
first column, titled Ch01 shows brightfield images of cells captured at 40×. The second column (Ch02) shows CD45 
antibody staining in green. DRAQ5 nuclear staining is displayed in red in the third column titled Ch05.  
 
The morphology and structure of these cells was optimal for most of the cells captured, although 
some cells did show loss of structure which could have resulted in the high levels of CD45 non-
specific staining observed in some cells. Panels-A and B show examples of PC3 cells that showed no 
CD45 staining; these cells accounted for approximately 69.9% of the total population of PC3 cells in 
that sample.  Panels-C and D show examples of cells that might initially appear as CD45 negative; 
however, the presence of small but high-intensity patches of CD45 within these cells forces the 
software to classify them as CD45 positive cells. The total number of these cells accounted for 23.3% 
of the PC3 cells in that sample. Lastly, there were cells that expressed non-specific staining with the 
CD45 antibody at an elevated and clear intensity. An example of these cells is demonstrated in 
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Panel-E; these cells accounted for approximately 6.8% of the entire sample. Figure  4.3 below shows 
the distribution of these three intensities of CD45 staining. 







The figure above shows normalised frequency of PC3 cells (Y axis) against the intensity of CD45 antibody in these cells (X 
axis). Cells on the left (marked in green) were cells that showed no staining at all or a very minute CD45 intensity that 
would otherwise be observed even without using any antibodies. The blue region in the middle highlights cells with 
higher intensity of CD45, but not high enough to be classified as CD45 positive cells. Cells on the right (within the red 
region) were CD45 positive cells.  
Region Population Percentage (%) 
 No staining 69.9 
 Partial staining 23.3 
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4.3.3 GMO0893 staining with CD45 antibody 
 
GMO0893 cells are lymphoblastoid cells that are expected to be captured by the ImageStreamX as 
CD45 positive cells. This experiment was conducted to test the percentage of GMO0893 cells that 
would stain with the marker in what is essentially a similar experiment to the one testing the efficacy 
of different dilutions of CD45 in staining GMO0893 cells.  
Figure  4.4: CD45 staining of GMO0893 cells 
 
Samples shown in the figure above demonstrate different patterns of staining of GMO0893 cells with the CD45 
antibody. The first column, titled Ch01 shows brightfield images of GMO0893 cells captured at 40×. The second column 
shows CD45 antibody staining in green colour on Ch02. DRAQ5 nuclear stain is displayed in red on the third column on 
Ch05. Panels A and B are examples of CD45 positive cells, while panels D and E are cells that were not stained with the 
antibody. Panel C shows an example of a partially/weakly stained cell. 
 
Figure  4.4 above demonstrated that GMO0893 cells have similar staining patterns to the ones 
observed before in Figure  4.1 in the introduction of this chapter. There were, however, cells that 
showed higher CD45 staining intensity in their cytoplasm and the percentage of stained cells was 
found to be 39.9%, an increase on what was previously recorded for this cell-line with the same 
dilution of the antibody (35.1% positively stained GMO0893 cells), examples of such staining is 
shown in panels-A and B. It is worth noting that the morphology of these cells as well as the cell in 
panel-C, which was only partially stained, was not satisfactory like that of panel-E. A vast number of 
cells (46.3% of the entire GMO0893 population captured) did not show any forms of CD45 staining, 
examples of these cells are those shown in Panels-D and E. The remaining 13.8% of the cells in the 
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sample were partially stained (e.g. panel-C). These cells showed slight levels of staining with a lower 
intensity than the fully stained cells. They were also characterised with a morphology and structure 
that is less robust than that of the negatively stained cells. The distribution of these cells within the 
sample are demonstrated in the figure below, which shows the varying intensities of CD45 staining 
recorded for cells in this experiment.  






The figure above shows the distribution of GMO0893 cells based on the intensity of CD45 antibody in these cells. Cells 
on the left (marked in green) were cells that showed no staining at all or a very minute CD45 intensity that would 
otherwise be observed even without using any antibodies. The blue region in the middle highlights cells with higher 
intensity of CD45, but not high enough to be classified as CD45 positive cells. Cells on the right (within the red region) 
were CD45 positive cells.  
Region Population Percentage (%) 
 No staining 46.3 
 Some staining 13.8 
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4.3.4 PBL staining with CD45 antibody 
 
The procurement of less than 40% CD45 positive GMO0893 cells raised concerns as to whether this 
cell-line is to be used to examine the sensitivity of using the CD45 biomarker in identifying PC3 cells. 
PBL cells had previously produced improved morphology and better antibody specificity when 
EpCAM was used; therefore they were stained with the CD45 antibody separately to examine the 
patterns and percentage of positive staining and compare it to the GMO0893 cells. 
Images of PBL cells stained with the CD45 antibody are shown in Figure  4.6 below. 
Figure  4.6: CD45 staining of PBL cells 
 
 
Samples shown in the figure above demonstrate different patterns of staining of PBL cells with the CD45 antibody. The 
first column, titled Ch01 shows images of cells captured at 60×. The second column shows CD45 antibody staining in 
green colour on Ch02. DRAQ5 nuclear stain is displayed in red on the third column on Ch05. Panels-A and B are examples 
of CD45 positive cells, while panel C is an example of a cell that was partially/weakly stained with the antibody. Panels-D 
and E are examples of CD45 negative PBL cells. 
 
As can be observed in the figure above, the expected staining configuration of CD45 was acquired in 
many CD45 cells. In fact, 75.5% of the PBL cells were stained positive with CD45 antibody, a vast 
improvement on the 39.9% obtained with the GMO0893 cell-line. The levels of CD45 staining 
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intensity varied in PBL cells, with some (e.g. Panel C) showing weak or partial staining in their 
periphery. Some PBL cells showed no CD45 staining, and these accounted for approximately 10.3% 
of the entire sample. Despite acquiring a number of PBL cells with no CD45 staining present, the use 
of PBL cells was preferred to the GMO0893 cells when the sensitivity test was conducted.   







The figure above demonstrates the distribution of PBL based on the intensity of CD45 antibody in these cells. Cells on 
the left (marked in green) were cells that showed no staining at all or a very minute CD45 intensity of similar level to 
that of background staining. The blue region in the middle represents cells with higher intensity of CD45 antibody, but 
not high enough to be classified as CD45-positive cells. Cells on the right (within the red region) were CD45 positive cells. 
The table below the graph shows exact percentages of the cells within each one of the three regions mentioned. 
Region Population Percentage (%) 
 No staining 10.3 
 Some staining 14.2 














CD45 staining of PBL cells 
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4.3.5 Mixing experiment using CD45 antibody 
 
Samples containing PBL cells were spiked with dilutions of PC3 cells to test the sensitivity of CD45 
antibody in identifying non epithelial cells. Figure  4.8 below shows examples of positively and 
negatively stained PC3 and PBL cells, as well as cells false negative and positive cells for both 
populations of cells. 
Figure  4.8: CD45 staining of PC3 and PBL cells 
 
The figure above shows a gallery of images captured from a sample containing both PC3 and PBL cells. The Ch01 column 
shows the brightfield images of cells captured at 60×, Ch02 column shows staining patterns with the CD45 antibody in 
green, while the Ch05 column shows nuclear staining with the DRAQ5 antibody. Panels-A and B show examples of PC3 
cells that were CD45 negative, while Panels-C and D shows examples of PBL cells that were CD45 positive. Panel-E shows 
an example of PC3 cells that was CD45 positive (false positive staining) and Panel-F demonstrates a PBL cell that was 
CD45 negative (false negative cell). 
Ch01 Ch02 Ch05




Panel - B 
 
 
Panel - C 
 
Panel - D 
 
 
Panel - E 
 
Panel - F 
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As shown by images taken of both cell-lines in the sample, the majority (83.8%) of the PC3 cells 
showed weak or no CD45 staining as would be expected since CD45 is a haematopoietic marker. 
Examples of similar cells are shown in panels-A and B of the figure above. However, the rest of the 
PC3 cells were found to exhibit a high CD45 staining intensity. The PC3 cells that showed high 
staining intensity were found to have poorer morphology than those that did not. Comparison of 
brightfield images of panels-A and B with that of panel E in Figure  4.8 provides evidence that PC3 
cells with different staining intensity had contrasting morphologies.  
On the other hand, 62.27% of the PBL population in that sample were found to be stained positive 
for CD45 antibody (Panels C and D, Figure  4.8). The existence of false negative cells was present too 
with more than 30% of the PBL cells showing no CD45 staining (e.g. Panel F). There were also cells 
that were partially stained, accounting for approximately 6.83% of the entire PBL population. 
Distribution of staining characteristics of both cell-lines is presented in Figure  4.9 which also 
highlights the existence of an overlapping region (purple section) between the two cell-lines, in 
which the staining intensity is very similar, making it difficult to distinguish PC3 cells from PBL cells 
based on their CD45 staining intensity. 
Furthermore, it is worth noting that the CD45 staining observed in PC3 cells was different to that of 
the PBL cells. In some PC3 cells, CD45 highly stained regions were distributed randomly across these 
cells, forming fluorescent dots. The existence of several small areas with high CD45 intensities in 
some PC3 cells deceived the analysis software into categorising these cells in the same region as PBL 
cells on the CD45 intensity graph. Careful examination of several cells from both populations, 













The figure above shows the distribution of PC3 and PBL cells imaged from the same sample. The X axis shows the 
intensity of the CD45 staining, while the Y axis represents the normalised frequency. Different staining intensities are 
categorised on three different sections and the overlapping region between the two cell-lines – where intensity of 
staining was parallel – is coloured in purple. The table below the graph shows exact percentages for cells that were fully 
stained, partially stained and ones that did not stain for both cell-lines.  
  
PC3 cells PBL cells 
Region Population Percentage Region Population Percentage 
 No staining 22.3  No staining 30.9 
 Partial staining 61.5  Partial staining 6.83 
































The isolation of CD45 negative cells was done for samples serially diluted with PC3 cells. The 
numbers in the table below might be inaccurate due to the nonspecific CD45 staining observed, but 
they represent an improvement on the number of PC3 cells identified through the positive selection 
of EpCAM stained cells. 
 

















The table above shows the number of PC3 cells counted and spiked in each of the test tubes and the number of PC3 cells 
retrieved following examination with the ImageStreamX. The percentage of cells acquired fluctuated from one tube to 
another, but the number of cells was in constant decline. These numbers do not represent the actual number of PC3 
cells retained but the number of cells that lie within the PC3 region on the histogram based on their CD45 staining 
intensity. Upon manual examination of some of these cells, it was found that some PBL cells were identified amongst 
cells attributed to the PC3 population  
Total PC3 cells  
spiked into 1mL 
Approximate retrieval of 
CD45 negative cells 
3,000,000 5.8%  
(174,107) 
300,000 2.19%  
(6579) 
30,000 7.01%  
(2105) 
3000 1.8%  
(54) 
300 8.76%  
(26) 




4.4 Discussion  
 
Imaging flow cytometry was used in this study to investigate the possibility of using the CD45 
antibody to distinguish epithelial (PC3) cells from haematopoietic cell derivatives (In this case the B-
lymphoblastoid cell-line derived from a normal individual – GMO0893 as well as PBLs) by negative 
selection. The CD45 antibody was used to target the GMO0893 and PBL cells. GMO0893 and PBL 
cells were expected to be identified as CD45-positive, whereas PC3 cells – which are epithelial cells – 
were not expected to stain with this antibody. The specificity of the CD45 antibody was tested as 
follows 
1. By staining of GMO0893 cells,  
2. Staining PBLs, 
3. Spiking PC3 cells in samples containing PBL cells and staining these samples with the CD45 
antibody.  
The number of false positives and negatives would give a clear indication of how specific the 
antibody is. The sensitivity of the antibody was also tested by diluting the number of PC3 cells in PBL 
samples and identifying the CD45-negative cells. Initially, the dilution of the CD45 antibody was 
optimised so that most of the PBL and GMO0893 cells would be identified by 
the ImageStreamX as CD45-positive. The initial recommended dilution of 1/15 was used, as well as 
1/100 and 1/200. The percentage of CD45 positive GMO0893 cells for these three dilutions was 
similar, and the 1/200 dilution was used thereafter.   
Most of the sample containing PC3 cells showed no CD45 antibody staining (69.9%). However, with 
the more than 6% of the cells being CD45-positive, the non-specificity of the CD45 antibody was 
becoming apparent. This was further confirmed when a sample containing GMO0893 cells were also 
partially stained with the same antibody. This time, only 39.9% of the sample was CD45-positive at 
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an optimal level, and more than 46% of the cells showing no CD45 staining at all. PBL cells were used 
instead of GMO0893 cells for the proof of principal experiment as more PBL cells (75.1%) were 
found to be CD45 positive than GMO0893 cells (39.9%). Using PBL cells for the sensitivity test 
(spiking them with PC3 cells) was investigated to test the sensitivity of this approach in identifying 
PC3 cells through negative selection of stained cells.  
It is worth mentioning that a relatively poor morphology was observed for the cell-lines used and 
most of the cells’ structure did not appear intact for most cells. Perhaps this lack of a comprehensive 
cellular structure could have contributed to PC3 cells exhibiting nonspecific CD45 staining. Patterns 
of false positive PC3 cells and false negative PBL cells were evident throughout the results. The 
difference when the cell-lines are mixed is that more PC3 cells were stained positively with the 
antibody (6.2% separately and 16.2% when mixed) and less PBL cells were detected as CD45-positive 
than when spiked with PC3 cells (75.1% separately and 62.27% when spiked with PC3 cells). The 
overlapping region (in Figure  4.9) in which both, PC3 and PBL cells, showed similar staining 
intensities and patterns was relatively large, due to the prevalence of nonspecific CD45 staining. The 
presence of this overlap presented a huge disadvantage in distinguishing cells based their CD45 
staining intensity.  
Additionally, the inadequate morphology of both cell-lines – possibly caused by the numerous 
sample preparation steps, such as cells fixing – did not help in discriminating between both 
populations of cells. It remains possible that some PBL cells might have lost their cellular structure 
and expanded in size, making them closer in appearance to PC3 cells than the usual PBLs. This loss of 
structure may have also contributed to the absence of staining in some PBL cells. Despite the fact 
that many PC3 cells did not stain with the CD45 antibody and that the majority of PBL cells were 
observed to be fully stained, the isolation of PC3 cells based on CD45 staining might not be the most 
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 Identification of PC3 cells using Zonula Occludens-1 5.
Tight Junction Protein Antibody  
 
 
5.1 Introduction  
 
Following the approach previously taken in this research in which PC3 cells were targeted with an 
epithelial-specific marker, an alternative was also tested targeting PC3 cells in the form of Zonula 
Occludens-1 tight junction (ZO-1 TJ) protein antibody. This approach was investigated as a possible 
alternative due to the lack of specificity of EpCAM antibody. The interaction between adjacent 
epithelial cells and between epithelial cells and their extracellular matrix is mediated by special 
protein complexes that are also responsible for cells’ adhesion such as tight junctions (TJ). These 
junctions are located at the lateral membrane of epithelia and play a key role as barriers, regulating 
the diffusion of ions and molecules through the paracellular pathway (between cells) in accordance 
to their size and charge (Balda and Matter, 2016).  
TJ comprise of a very complex set of transmembrane proteins that are found to function as signalling 
centres controlling epithelial processes such as proliferation, polarisation and differentiation. The 
mechanisms in which TJ control such processes, however, remain poorly understood (Zihni et al., 
2014). There are at least 40 different proteins at the TJ, some of which are transmembrane ones that 
are divided into three domain proteins groups: Occludin, MarvelD2 and MarvelD3 (González-
Mariscal et al., 2003). Others proteins are intracellular plaque proteins which provide a structural 
support platform between transmembrane proteins and the actin skeleton. An example of such 
structure-supporting intracellular proteins is ZO-1, which additionally has a gene expression 
regulatory role that contributes to epithelial cellular proliferation through various signalling 
pathways (Balda et al., 2003).  
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ZO-1 was the first identified as a TJ-associated protein and has a molecular mass of about 220kDA. 
Some suggested a possible link between this protein and the development of cancer. For example, 
one study investigated the role of ZO-1 in the formation of gap junctions’ plaques as well as the 
creation of intracellular coupling (Hervé et al., 2014). Cancer is thought to be associated with cell-to-
cell communication malfunction as a multitude of tumours were observed to have gap junction 
defects (Cronier et al., 2009); potentially linking ZO-1 to cancer development and metastasis.   
Figure  5.1: The protein complexes that exist within the paracellular pathway 
 
The figure above shows the paracellular pathway between cells comprising of several protein complexes, such as TJ (in 
red outline). TJ consist of several transmembrane proteins such as caludins and occludin that interact directly with ZO 
proteins. ZO proteins are also found to be associated with several peripheral junctional proteins, creating a complex 
intracellular network (Bauer et al., 2010). More direct interactions occur between these proteins and actin filaments, 
highlighting their crucial function as crosslink mediators between TJ strands and the cytoskeleton (Fanning et al., 1998).   
 
Previous work in this area already presented clear links between TJ and cancer metastasis (Martin, 
2014), and some studies even demonstrated ZO-1 involvement in intracellular signalling and gene 
expression with one study particularly highlighting the urgent need for an intensive investigation of 
similar proteins (Bauer et al., 2010). There has also been strong evidence to suggest that the ZO-1 
protein is associated with several regulatory molecules such as growth factors, subsequently 
regulating the cell cycle. Moreover, while thorough work is still required to confirm it, it was 
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hypothesised that these proteins might also play a role in virus-induced cancers and hold the key to 
a better understanding of such diseases (Javier, 2008).  
Some studies have utilised the ZO-1 TJ antibody to label epithelial cells and distinguish them from 
other types of cells that do not possess TJ (Zahabi et al., 2012, Leung et al., 2012). These studies 
confirmed the high expression of ZO-1 in epithelial cells and gave an insight into its role in several 
cellular events such as membrane fusion and cell detachment. Others have used this marker to 
detect expression levels of ZO-1 in non-small cell lung cancer (NSCLC) (Ni et al., 2013b). The study by 
Ni et al concluded that high expression levels of ZO-1 can be interpreted as a good prognostic 
outcome in cases of NSCLC.  
Figure  5.2: ZO-1 TJ staining of epithelial cells 
 
The figure above shows an immunofluorescence image demonstrating ZO-1 TJ protein antibody staining of murine 
peripheral retinal pigmented epithelium cells. The green stain on the outer layer (pointed at) of cells indicate the 
localisation of TJ in these cells (Kokkinopoulos et al., 2011).  
 
In this study ZO-1 TJ antibody was used to stain the epithelial PC3 cells in a similar way to the EpCAM 
antibody. PC3 cells were cultured in flasks and required to be trypsinised before they were used in 
experiments. In order for Trypsin to achieve cell detachment, tight junctions between epithelial cells 
were processed and dissolved first (Vilen et al., 2012). Meaning that, unlike studies that examined TJ 
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staining patterns in conventional microscopy, flow cytometry staining of these junctions might be 
different and disrupting. ZO-1 TJ was also tested on control samples containing GMO0893 cells or 






• To identify PC3 cells by the positive selection of cells stained with ZO-1 TJ antibody through 
an immunocytochemical technique 
• To determine the efficacy of ZO-1 TJ antibody staining in distinguishing PC3 cells spiked in a 
sample containing PBL cells  
• To determine the specificity of ZO-1 TJ antibody staining in the possible identification of 
CTCs through the staining of PC3  
• To observe and categorise different ZO-1 TJ staining patterns for PC3, GMO0893 and PBL 
cells 
• To determine the sensitivity of ZO-1 TJ staining in the identification of PC3 cells by spiking 
PBL samples with dilutions of PC3 cells  
• To investigate the effects of the ZO-1 TJ staining method on the morphology, shape and 





5.3.1 ZO-1 TJ antibody optimisation  
 
Optimisation of the ZO-1 TJ antibody was conducted prior to using it for staining the three cell-lines 
(PC3, GMO0893 and PBL cells) in a very similar way to the way EpCAM and CD45 antibodies were 
optimised. The initial step was to establish which dilution of the antibody would adequately stain 
most of the PC3 cells. The dilution of the antibody recommended by the supplier was 1/50; however, 
additional titres of the antibody were also tested to determine the efficacy and specificity of staining 
as shown in the table below.  
Table  5.1: ZO-1 TJ optimisation for PC3 cells 












The table above shows the dilutions of the ZO-1 TJ antibody in the first column. The 2nd column contains the percentages 
of PC3 cells that were positively stained with ZO-1 TJ antibody out of the total number of cells collected in the sample. 
The 3rd column shows examples of stained cells, including brightfield images of PC3 cells on Ch01, the intensity of ZO-1 








The staining patterns for all dilutions were different than those observed when EpCAM and CD45 
antibodies were used. Instead of a continuous membrane staining like that of the EpCAM, the ZO-1 
TJ antibody was staining small separate sites within PC3 cells. Some of these sites were located 
within the cells while others were observed at the cell’s periphery.  
The ZO-1 TJ antibody, as explained previously in the introduction of this chapter, targets the tight 
junctions on the membrane of the epithelial cells. Hence why, it is vital to observe the various effects 
inflicted on these complexes by different reagents used in the optimisation process. For example, 
Trypsin-EDTA is used to dissociate the adherent PC3 cells from flasks in order to collect them for 
experimental use. This dissociation process is achieved by dissolving the CAM molecules (such as TJ) 
between the cells and the flask as well as those between cells themselves. Once dissolved, 
complexes such as TJ are expected to be seen displaced within the cell or even outside it. Which may 
explain the why ZO-1 TJ staining was observed in sites where these complexes reside within cells 
rather than at cell periphery. It might also provide evidence for the elevated levels of background 
staining intensity, when compared to staining using other markers, such as EpCAM.   
The 1/50 dilution demonstrated high intensity staining of PC3 cells that was, for a number of cells, 
far too excessive causing these cells to appear completely concealed by the antibody on Ch02. 
Reducing the concentration of the antibody certainly resulted in a clearer staining of cells, with the 
percentage of stained cells reaching elevated levels when the 1/500 dilution was used (94.7% ZO-1 
TJ-positive PC3 cells). As a result, the 1/500 dilution became the standard dilution of this antibody 
that was used for the immunostaining of PC3, GMO0893 and PBL cells. It was also used in the proof 
of principle experiment to test the sensitivity of this marker in identifying PC3 cells.   
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5.3.2 PC3 cells staining with ZO-1 TJ antibody 
 
As the only epithelial cell-line used in this research, PC3 cells were expected to be stained with the 
ZO-1 TJ antibody. The figure below shows different types of staining observed when a sample 
containing PC3 cells was stained with the ZO-1 TJ antibody.  
Figure  5.3: ZO-1 TJ staining of PC3 cells 
 
Samples shown in the figure above demonstrate different patterns of staining of PC3 cells with the ZO-1 TJ antibody. The 
first column, titled Ch01 shows brightfield images of cells captured at 40× magnification. The second column shows ZO-1 
TJ antibody staining in green on Ch02. DRAQ5 nuclear staining is displayed in red in the third column, titled Ch05.  
 
Figure  5.3 demonstrates how different cells showed different intensity levels of ZO-1 TJ staining. The 
vast majority (95.76%) of PC3 cells, however, showed high and clearly visible staining patterns such 
as the ones displayed by cells in panels-A and B. A very low number of PC3 cells (1.94%) showed a 
slight staining intensity, such as these shown in panels-C and D. The number PC3 cells that were not 
stained at all with the ZO-1 TJ antibody was also low (2.3%). Cells which showed a clearly visible ZO-1 
TJ staining, regardless of the localisation of that staining, were classified as ZO-1 TJ-positive cells. It is 
Ch01 Ch02 Ch05
Panel - A 
 
Panel - B 
 
Panel - C 
 
Panel - D 
 
Panel - E 
148 
 
worth mentioning that the percentage of PC3 cells that were ZO-1 TJ-positive was higher than that 
of the EpCAM-positive PC3 cells. The distribution of PC3 cells in this experiment, with regards to 
level of staining intensity of the ZO-1 TJ, is represented with the histogram in Figure  5.4 below. 






The figure above shows the normalised frequency of PC3 cells (Y axis) against the intensity of ZO-1 TJ antibody in these 
cells (X axis). Cells on the left (marked in green) were cells that showed no staining at all or a very minute antibody 
intensity that would even be obtained without using any antibodies. The blue region in the middle categorises cells with 
higher intensity of ZO-1 TJ antibody, but not high enough to be classified as ZO-1 TJ-positive cells. Cells on the right 
(within the red region) were ZO-1 TJ-positive cells. The table below the graph displays the exact percentages of PC3 cells 
within these three regions. 
  
Region Population Percentage (%) 
 No staining 2.3 
 Some staining 1.94 














ZO1 TJ antibody staining of PC3 cells 
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5.3.3 GMO0893 staining with ZO-1 TJ antibody 
 
As lymphoblastoid cells, GMO0893 cells were not expected to show ZO-1 TJ staining, mainly because 
these cells do not possess TJ like epithelial cells do. A sample containing GMO0893 cells was stained 
with ZO-1 TJ antibody to verify this and the results can be seen in Figure  5.5 below.  
Figure  5.5: ZO-1 TJ staining of GMO0893 cells 
 
Samples shown in the figure above demonstrate different patterns of staining of GMO0893 cells with the ZO-1 TJ 
antibody. The first column, titled Ch01 shows brightfield images of cells captured at 40×. The second column shows ZO-1 
TJ antibody staining in green colour on Ch02. DRAQ5 nuclear stain is displayed in red on the third column on Ch05. 
Panels-A and B are examples of ZO-1 TJ-negative cells, while panels D and E are GMO0893 cells that were stained with 
the antibody. Panel-C shows an example of a partially or weakly stained GMO0893 cell. 
 
Images of different GMO0893 cells displayed in the figure above show a relatively poor morphology 
compared to prior experiments. It was expected that these cells would not stain with an epithelial 
marker such as ZO-1 TJ antibody, but this was true for only 4% of the GMO0893 cells in that sample. 
Panels-A and B show examples of GMO0893 cells that were ZO-1 TJ-negative. Cells that showed 
partial ZO-1 TJ staining (e.g. Panel-C) accounted for 15.4% of the cells in that sample. The vast 
majority of cells in that sample were ZO-1 TJ positive (80.6%), panels-D and E are perfect examples 
of these cells. Obtaining a high number of false positive cells is quite unusual, especially when 
Ch01 Ch02 Ch05
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Panel - B 
 
Panel - C 
 
Panel - D 
 
Panel - E 
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considering the fact that these cells do not possess TJ to allow them to be stained with this antibody. 
Some of the patterns of ZO-1 TJ staining in these cells were similar to those observed in PC3 cells. 
GMO0893 cells were arranged in order of their staining intensity with ZO-1 TJ and are shown in a 
histogram in Figure  5.6 below.  








The figure above shows the distribution of GMO0893 cells based on the intensity of ZO-1 TJ antibody in these cells. Cells 
on the left (marked in green) were cells that showed no staining at all or a very minute ZO-1 TJ intensity that would 
otherwise be observed even without using any antibodies. The blue region in the middle represents cells with higher 
Region Population Percentage (%) 
 No staining 4 
 Some staining 15.4 














ZO1 TJ staining of GMO0893 cells 
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intensity of ZO-1 TJ antibody, but not high enough to be classified as ZO-1 TJ-positive cells. Cells on the right (within the 
red region) were ZO-1 TJ-positive cells. The table below the graph shows exact percentages of the cells within each one 
of the three regions mentioned.   
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5.3.4 PBL staining with ZO-1 TJ antibody 
 
Blood lymphocytes do not possess any TJ and are not expected to be stained with the ZO-1 TJ 
antibody. This experiment was conducted to confirm the level of ZO-1 TJ staining in PBL and 
compare it to that PC3 cells and GMO0893 cells. The results are shown by images in Figure  5.7 and 
the graph and table in Figure  5.8.  
 
Figure  5.7: ZO-1 TJ staining of PBL cells 
 
Examples shown in the figure above demonstrate different patterns of staining of PBL cells with the ZO-1 TJ antibody. 
The first column, titled Ch01 shows brightfield images of cells captured at 40×. The second column shows ZO-1 TJ 
antibody staining in green colour on Ch02. DRAQ5 nuclear stain is displayed in red on the third column in Ch05. Panel A 
and B are examples of ZO-1 TJ-positive cells, while panels D and E are ZO-1 TJ-negative cells. Panel C shows an example 
of a partially or weakly stained PBL cell. 
 
PBL expressed lower level of ZO-1 TJ staining compared to that of PC3 cells and the false-positive 
GMO0893 cells. In fact, only 0.71% of the PBL cells in the sample were ZO-1 TJ-positive (e.g. Panel A 
and B). 3.39% of the cells showed very weak/partial staining (Panel - C) while the rest (95.9%) did not 
stain at all, such as cells in panels-D and E. It is also worth noting that the ZO-1 TJ positive cells were 
larger than the ZO-1 TJ-negative ones and displayed poorer morphology, which may explain the non-
specific staining observed in these few cells. Overall, the morphology of most PBL was optimal and 
presented an improvement on what has been previously achieved with the GMO0893 cell-line. The 
Ch01 Ch02 Ch05
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staining patterns that were observed in the positive cells had lower intensity than their GMO0893 
counterparts. However, these staining patterns resembled some of the staining seen in the previous 
experiment were GMO0893 cells were used. The graph and table in Figure  5.8 below demonstrate 
the low number of false positive staining in PBL cells.  








The figure above demonstrates the distribution of PBL based on the intensity of ZO-1 TJ antibody in these cells. Cells on 
the left (marked in green) were cells that showed no staining at all or a very minute ZO-1 TJ intensity that would 
otherwise be observed even without using any antibodies. The blue region in the middle represents cells with higher 
Region Population Percentage (%) 
 No staining 95.9 
 Some staining 3.39 














ZO1 TJ staining of PBL cells 
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intensity of ZO-1 TJ antibody, but not high enough to be classified as ZO-1 TJ-positive cells. Cells on the right (within the 
red region) were ZO-1 TJ-positive cells. The table below the graph shows exact percentages of the cells within each one 
of the three regions mentioned.  
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5.3.5 Mixing experiment using ZO-1 TJ antibody 
 
Samples containing PBL cells were spiked with dilutions of PC3 cells as previously explained in the 
second chapter of this research. This was done to test the sensitivity of the ZO-1 TJ antibody in 
identifying PC3 cells found in a sample comprising of PBL cells. Figure  5.9 below shows examples of 
the cells found in that sample following careful observation.  








The figure above shows a gallery of images captured at 60× from a sample containing both PC3 and PBL cells. Ch01 
column shows the brightfield images of cells captured, Ch02 column shows staining patterns with the ZO-1 TJ antibody 
in green, while the Ch05 column shows nuclear staining with the DRAQ5 antibody. Panels-A and B show examples of PC3 
cells that were ZO-1 TJ-positive, while Panels-C and D shows examples of PBL cells that were ZO-1 TJ-negative. Panel-E 
shows an example of PC3 cells that was ZO-1-TJ-negative (false negative) and Panel-F demonstrates an example of a PBL 
cell that was ZO-1 TJ-positive (false positive). 
 
The PC3 cells showed similar forms of staining to the ones observed previously when ZO-1 TJ 
antibody was used. The displacement of TJ was present and clear around the cells, mostly near the 
membrane of these cells. The vast majority of PC3 cells were ZO-1 TJ-positive, accounting for 
96.12%. A small percentage of PC3 cells was partially stained (2.36%) while only 1.52% of the PC3 
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population was not stained at all. In comparison, the majority of PBL were ZO-1 TJ negative 
(53.25%), but this was a vastly lower percentage than the one previously obtained from a sample 
containing PBL cells only. 20.45% of the PBL population showed partial staining, while 26.3% of the 
PBLs were fully stained with the epithelial marker.  
This abnormal change in the percentage of ZO-1 TJ positive PBL cells when spiked with PC3s is 
perhaps attributed to the effect of PC3 cells spiked, as these cells possess dissolved TJ complexes 
within them and within the PBS solution in which they resided. The existence of dissolved TJ 
molecules in samples containing PC3 and PBL cells might be the main reason for obtaining this high 
false-positive percentage of PBL cells. PC3 cells on the other hand maintained a very low percentage 
of false-negative cells. However, the large overlapping region caused by the high number of false-
positive PBL cells made it difficult to distinguish between the two cell-lines based on ZO-1 TJ staining. 
This staining overlap is demonstrated in the Figure  5.10 on the next page. 
Additionally, Table  5.2 shows PC3 retention numbers for each of the samples in which PC3 cells were 
spiked. The table demonstrates the sensitivity of using ZO-1 TJ antibody staining in identifying and 














PC3 cells PBL cells 
Region Population Percentage (%) Region Population Percentage (%) 
 No staining 1.52  No staining 53.25 
 Partial staining 2.36  Partial staining 20.45 
























The figure above shows the distribution of PC3 and PBL cells within from the same sample. The X axis shows 
the intensity of the ZO1 TJ antibody staining, while the Y axis represents the normalised frequency for both 
cell-lines. Different staining intensities are categorised on three different sections and the overlapping region 
between the two cell lines – where intensity of staining was parallel – is highlighted in a dark red colour 
between the two populations of cells. The table below the graph shows exact percentages for cells that were 
fully stained (red section), partially stained (blue section) and ones that did not stain (green section) for both 
cell lines.  
 



















The table above shows the numbers of PC3 cells counted and spiked in each of the test tubes and the number of PC3 
cells retrieved following examination with the ImageStreamX. The percentage of PC3 cells acquired fluctuated from one 
dilution to another, but the number of cells was in constant decline. These numbers do not represent the actual number 
of PC3 cells retained but the number of cells that lie within the PC3 region on the scatterplot based on their ZO-1 TJ 
antibody intensity. Upon careful examination of some of these cells, it was found that some PBL cells were identified 
amongst these cells and attributed to the PC3 population. Other PC3 cells were simply burst cells that were identified as 
viable and ZO-1 TJ-positive PC3 cells.  
Total cells  
spiked in to 1mL 
Approximate retrieval 

















The ZO-1 TJ antibody staining was chosen as a final immunological method to be tested in identifying 
PC3 cells. With the failure of EpCAM and CD45 antibodies in establishing an accurate PC3 
identification method, the use of the ZO-1 TJ antibody was then considered to enhance PC3 
detection specificity and sensitivity using the ImageStreamX.  
Following a similar antibody optimisation protocols that were previously applied to the first two 
antibodies used, it was decided that a 1/500 dilution of the ZO-1 TJ antibody would sufficiently stain 
most the PC3 cells in the sample. Table  5.1 demonstrated how the sample stained with a 1/500 
dilution of the ZO-1 TJ antibody provided almost 95% ZO-1 TJ positive PC3 cells, compared to only 
81.4% in the sample where a 1/50 dilution of the antibody was used. It was apparent from early 
experiments that the existence of TJ within PC3 cells rather than on the membrane might have been 
due to the effect of Trypsin-EDTA used to dissociate PC3 cells from the flasks.  
The experiments that followed in this research focused on staining each cell-line individually with 
the antibody before spiking PC3 cells in samples containing PBL cells in what would be a 
reconstruction of the proof of principle experiment. Most of the PC3 cells – much like when the 
antibody dilution was optimised – were ZO-1 TJ-positive. In fact, only 2.3% of these cells did not 
show any ZO-1 TJ antibody staining. The GMO0893 cells on the other hand were characterised with a 
relatively poor morphology and the vast majority of them (80.6%) were found to be ZO-1 TJ-positive. 
In contrast, there was only a small percentage (0.71%) of ZO-1 TJ-positive cells when PBL cells were 
stained with the antibody. The results of these experiments meant, in theory at least, that mixing 
PC3 cells with PBL might be the most sensitive immunological tool obtained in this research in 
discriminating PC3 cells from PBLs.  
The mixing experiment delivered unforeseen results to what was originally anticipated, with 
approximately 26.3% of the PBL cells being ZO-1 TJ-positive. There was also a small population 
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(1.52%) of the PC3 cells that were observed to be false negative. The overlap between PC3 cells and 
PBL (as shown in Figure  5.9) meant that, just like its predecessors, the ZO-1 TJ antibody might not be 
the ideal tool to isolate PC3 cells using imaging flow cytometry.  
The morphology of the cells was perceived to be an improvement on what was previously obtained 
when the CD45 antibody was used. Although, few exceptions in which cells looked overly 
enlarged/expanded and had completely lost their structural integrity were also evident. The 
existence of TJ within cells could be due to the effect caused by Trypsin-EDTA which was used to 
dissociate PC3 cells from their flasks. Trypsin-EDTA helps in dislodging cells by dissolving the cell-to-
cell adhesion molecules, such as TJ, however, the presence of positively stained areas within PBL 
cells may be due to an increased permeabalisiation of these cells.  
Perhaps a better approach would be to avoid using Trypsin-EDTA in the sample preparation 
protocol; however, this may prove difficult as cultured PC3 cells must first be dissociated from their 
flasks before being used. To overcome this problem, blood samples from cancer patients containing 
CTCs may need to be considered, as these cells would have their membrane and its CAM molecules 
intact and possibly undamaged.  
Table  5.2 showed the PC3 cell retention numbers for the mixing experiment. The percentage of PC3 
cell retained was remarkable, especially for the most diluted sample, in which only 30 PC3 cells were 
spiked. 20 of the cells were identified to be ZO-1 TJ-positive; however, upon close examination of 
these cells, it became very apparent that many of them were simply damaged cells or large debris 
that were identified as PC3 cells due to their high staining intensity. This flaw, as well as the 
existence of false positive and negative cells when PC3 cells were mixed with PBL, meant that the 
use of ZO-1 TJ antibody might not be an ideal approach in detecting and isolating PC3 cells in 
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 Live Cell Analysis for the Identification of PC3 cells 6.
 
 
6.2 Introduction  
 
It has long been known that the number of cells is what makes an individual smaller or larger than 
another rather than the size of the cells within that individual (Wilson, 1925, Conlon and Raff, 1999). 
Cell size is relatively constant throughout the life cycle of the individual and they differ from one 
type of cells to another (Ginzberg et al., 2015). The mechanisms involved in determining a specific 
cell size remain ambiguous (Lloyd, 2013); however, the consistency at which types of cells fall within 
specific cell size ranges has made it a potential area to exploit differences between different cells for 
identification purposes.  
The focus in this research was revolved around prostate cancer epithelial cells and how they differ 
from lymphocytes and other blood cells. Peripheral blood consists of RBC, WBC and platelets 
(Mohammadi et al., 2014). Lymphocytes are the second most common WBC, making up around 20-
50% of the total number of WBC in humans (Peckham, 2003). In a normal adult, the average number 
of lymphocytes fluctuates between 5000 and 9000 cell per mm3 of blood. However, these numbers 
may be higher or lower than that range when influenced by diseases (Bergman et al., 2016). Most 
lymphocytes are small in size, and are only slightly larger than red blood cells with a diameter length 
of approximately 6-9µm. The rest (accounting for 10% of the total number of lymphocytes in the 
blood) are larger in size and range between 10-14µm in diameter (Bergman et al., 2016, Peckham, 
2003).   
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Figure  6.1: Variation in lymphocytes cell size 
 
 
Examples of two types of lymphocyte cells are shown in the figure above. The two cells shown in (A) represent small 
lymphocytes (6-9µm) and are the majority of lymphocytes in the body. The other two cells (B and C) are large 
lymphocytes (10-14µm) and form around 10% of the entire lymphocyte population. Both sets of cells possess the same 
morphological structure comprising of a nucleus and cytoplasm (Bergman et al., 2016).  
 
The other cells investigated in this research were prostate cancer cells and even though the origin of 
these cells was thought to be from prostate epithelial basal cells only (Goldstein et al., 2010), recent 
work by Park et al confirmed that prostate cancer can originate from both, the primary human basal 
and the luminal epithelial cells (Park et al., 2016). Prostate epithelial cells are classified as epithelial 
cells which are larger than lymphocytes and, once cancerous, the size of these cells is prone to 
change. The reason behind this change is attributed to a number of factors, such as various gene 
mutations. For example, mutations that occur in the PTEN gene, which is a tumour suppressor gene 
that negatively regulates cell survival and its mutation is associated with poor prognosis for prostate 
cancer patients (Deocampo et al., 2003), lead to variation in cell size based on the expression levels 
of this gene in cells (Backman et al., 2002).  
Cell size alterations were observed in vitro in my research and were mostly noticed in previous 
experiments when cells were prepared in varying approaches during method optimisation. There 
has also been in vivo evidence to suggest that external signals might have an effect on the size of 
cells. A perfect example of this was explained by Edgar et al when they examined the effects of low 
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nutrient levels during the development of flies and how it leads to 15% reduction in their size 
compared to normal flies (Edgar, 2006). Upon reaching maturation, cells were found to reach a state 
of growth balance, possibly resulting from having a defined growth pathway signalling. This balanced 
state results in a no net change in the cell volume or mass (Koivusalo et al., 2009). 
In line with what has been observed in my research about morphological changes in the cell-lines 
used, it is worth mentioning that in studies that have examined the use prostate cancer cells or cell-
lines, there have been reports of “dramatic” changes to the size and shape of these cells. Such 
changes might be brought about as a result of treating these cells with Trypsin or other sample 
processing reagents such as those used in CellSearch® system (Park et al., 2014). In fact, one major 
concern identified by Park et al was how the CellSearch® sample preparation protocol leads to cell 
shrinkage, resulting in smaller, elongated cells.  
Other approaches that observed morphological properties of cells relied on the use convenient 
microscopy. Cross-sectional microscopy images might be of higher clarity than flow cytometry but 
there are few challenges that present bias into the way cell sizes are estimated in this way. For 
example, larger cells examined with microscopy have a higher chance of being caught by the slice 
than those of smaller size. Additionally, it was found that the radius of a cross-sectional cell is 
smaller than that of the actual cell radius where the centre of the cell investigated is not at the 
centre of the slide (Lenz et al., 2016).  
In this research, another approach which was considered was to distinguish cell-lines based on their 
physical and morphological properties. Therefore, the morphology of live PC3, GMO0893 and PBL 
cells were examined using imaging flow cytometry. Morphological aspects such as cell area and 
aspect ratio were considered in the analysis of samples from both cell-lines. The accuracy of results 
obtained in this study was compared to that where immunological methods (such as EpCAM and 





• To establish a cell size range for PC3, GMO0893 and PBL cells 
• To identify PC3 cells and distinguish them from GMO0893 cells and PBL based on the 
morphological and physical properties of these cells 
• To determine the efficacy live cell analysis in identifying PC3 cells spiked in samples 
containing PBL cells  
• To compare the sensitivity of cell size analysis with the previously tested immunological 
approaches  
• To observe and compare the morphology and cell structure of PC3, GMO0893 and PBL cells 
and compare it with that of immunological methods 
• To determine the sensitivity of live cell analysis and compare it with previous methods used 
• To compare the cells retention between the live cell analysis method and the three 






6.4.1 PC3 cell size range 
 
PC3 cells were trypsinised with Trypsin-EDTA and washed with PBS. They were then resuspended in 
Accumax and stained with DRAQ5 antibody prior to examination with the ImageStreamX. The 
distribution of PC3 cells based on their cell size is demonstrated in Figure  6.2 below.   






The figure above shows the difference in size between PC3 cells captured using the ImageStreamX. Cell size is 
represented in arbitrary units (Arb) on the X-axis, while the Y-axis represents normalised frequency. Examples of small 
and large PC3 cells are shown through brightfield images of cells captured of cells at both ends of the graph, 
demonstrating that within the same PC3 sample, cells may considerably vary in size. Most PC3 cells, however, appear to 
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The figure above shows the average cell size scale and outlines the region of it where PC3 cells are located. The PC3 cell 
size range is coloured red and expands from 186.78Arb to 794.33Arb. Cell A is the smallest cell detected, whereas cell B 
is the largest PC3 cell observed in these samples. Detailed analysis and structure figures are given below each cell. Both 
brightfield images are highlighted with a blue mask as the software measured variable statistics for both cells and 
calculated their size. Images shown in this figure are captured at 60× plus EDF image acquisition.  
  
Careful analysis and observation of the captured PC3 cells outlined an accurate range for this cell-
line. Cells that had a relatively poor morphology as well as clusters of cells were rejected and not 
included in the final cell area measurement. Overall, the morphology of cells collected in this study 
was far superior to that of the immunostaining approaches previously used. The cell count and 
sample processing time were also faster than immunostaining methods.  
Cell size (Arb) 
PC3 cell size range 
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Figure  6.3: The average cell size range for PC3 cells 
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6.4.2 GMO0893 cell size range 
 
The GMO0893 cell-line has been associated with a dubious morphology that was more 
undistinguishable than the other two cell-lines, even before this study was conducted. Therefore, 
this the perfect test to verify whether the inadequate morphology of these cells was caused by the 
prolonged procedure of staining them or was due to the cell-line itself. Figure  6.4 below, shows the 
range of cells captured and examples of small and large GMO0893 cells.  




The figure above shows the difference in size between GMO0893 cells captured using the ImageStreamX. Cell size is 
represented in arbitrary units (Arb) on the X-axis, while the Y-axis represents normalised frequency. Examples of small 
and large GMO0893 cells are shown through brightfield images of cells captured of cells at both ends of the graph, 
demonstrating that within the same GMO0893 sample, cells vary significantly in size. Most GMO0893 cells, however, 














Cell size range for GMO0893 cells 






















The figure above shows the cell size scale and outlines the region of it where GMO0893 cells are located. The GMO0893 
cell size range is coloured red and expands from 109.25Arb to 527.5Arb. Cell A is the smallest cell detected in all samples 
containing GMO0893 cells that were tested. Whereas cell B is the largest GMO0893 cell observed. Detailed analysis and 
structure figures are given below both cells. Both brightfield images are highlighted with a blue mask as the software 
measured variable statistics for each cell and calculated their size. Images shown in this figure are captured at 60× plus 
EDF image acquisition. 
 
The range recorded for the GMO0893 cell-line varied greatly and exceeded what was originally 
hypothesised. Most cells seem to have enlarged and it is unclear whether this resulted from the 
centrifugation process or the cell resuspension steps. Moreover, the size range of GMO0893 cells 
overlaps greatly with that of PC3 cells, rendering the cell-line useless for size and morphology 
comparison. This observation of GMO0893 cells’ poor morphology was also evident in repeat 
experiments, indicating that previous immunostaining results obtained with this cell-line might not 
be credible.   
Cell size (Arb) 
GMO0893 cell size range 
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Figure  6.5: The average cell size range for GMO0893 cells 
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6.4.3 PBL cell size range 
 
As the GMO0893 cell-line maintained a size range that greatly overlapped with that of the PC3 cell-
line, the use of PBL for morphological comparison became essential. In previous experiments, PBL 
have maintained an optimal shape and structure throughout varying immunological tests. Samples 
containing millions of PBL cells were observed with the ImageStreamX and Figure  6.6 below shows 





The figure above shows the difference in size between PBL cells captured using the ImageStreamX. Cell size is 
represented in arbitrary units (Arb) on the X-axis, while the Y-axis represents normalised frequency. Examples of small 
and large PBL cells are shown through brightfield images of cells captured of cells at both ends of the graph, 
demonstrating that within the same PBL sample, cells may vary in size, but only slightly. Most PBL cells appeared to be 
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The figure above shows the cell size scale and outlines the region of it where PBL cells are located. The PBL cell size 
range is coloured red and expands from 61.78Arb to 146.78Arb. Cell A is the smallest cell detected in all samples 
containing PBL cells that were tested. Whereas cell B is the largest PBL cell observed. Detailed analysis and structure 
figures are given below both cells. Both brightfield images are highlighted with a blue mask as the software measured 
variable statistics for each cell and calculated their size. Images shown in this figure are captured at 60× plus EDF image 
acquisition. 
 
Unlike the GMO0893 cell-line, the size range of PBL cells was not overlapping with that of the PC3 
cells. In fact, the largest PBL captured was approximately 40Arb smaller than the smallest PC3 cell. 
The overall morphology and cell structure of PBL was exceptional, excluding few cells that were also 
larger than average PBL size, such as cell B in Figure  6.7 above. The consistency of PBL cells in 
maintaining a preserved structure meant that they were the ideal choice to be used in combination 
with PC3 cells to test the sensitivity of this approach.   
Cell size (Arb) 
PBL cell size range 
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Figure  6.7: The average cell size range for PBL cells 
172 
 
6.4.4 Mixing experiment using cell size comparison 
 
As mentioned in the previous cell size range tests, PC3 cells were used in combination with PBL cells 
to conduct the sensitivity test. Opting against using the GMO0893 cell-line in this experiment was 
due to the abnormally large cells obtained when it was previously used. The size range provided by 
the GMO0893 cell-line overlaps greatly with that of the PC3, making it difficult to distinguish 
between them.  Figure  6.8 below demonstrate the problem with using the GMO0893 cell-line in the 
identification of PC3 cells based on cellular size. The advantage of using PBL cells must also be noted 
in that their consistency in maintaining a relatively small size makes them a perfect tool to test the 







The figure above shows the cell size scale used in this study and demonstrates the difference between PC3, GMO0893 
and PBL cells in terms of cell size. The PC3 cell size range is in red and can be seen not to overlap with that of the PBL 
(green). At the same time,  a relatively large overlapping region occurs between the PC3 cell size range and the 
GMO0893 cell size range, expanding from 186.78Arb to 527.5Arb.  
 
This test is similar to the ones that used immunological markers such as EpCAM and CD45 in that 
PC3 cells were spiked in dilutions with a large number of PBLs. The difference, however, is the 
absence of staining comparison. Instead, distinguishing the two cell-lines will be achieved based on 
their size and morphological features.  
Cell size (Arb) 
0               100            200            300            400            500            600            700            800   
PC3 cell size range GMO0893 cell size range PBL cell size range 
Figure  6.8: Comparison between PC3, GMO0893 and PBL cell size ranges 
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When observed within the same sample, PC3 and PBL cells were positioned separately, with the 
exception of a very minute number of cells that were located in an overlapping region on the graph 
(Figure  6.9). The reason behind obtaining cells (from both cell-lines) within that region remains 
unclear; however, individual examination of each one of these cells proved useful in identifying PC3 
cells based on cellular morphology, such as nuclear localisation. Throughout numerous experiments, 
PC3 cells were characterised with having a clear, distinct cell structure and morphology. The DRAQ5 
nuclear staining of PC3 cell nuclei also helped in the identification of nuclear localisation within these 
cells. Whereas PBL cells were commonly observed stained with DRAQ5 covering most of the cell.  
Interestingly, the structure and morphology of both cell-lines remained as intact as when they were 
tested separately. Spiking PBL samples with PC3 cells did not seem to cause a major change in the 
physiological/structural appearance of either cell-line. This may be an indication that cells with a 
poor morphology captured in immunological experiments might have been obtained such properties 
as a result of the extensive sample preparation steps. Using the live cell analysis and the exclusion of 
cell fixation, blocking and the multiple staining and washing steps meant that both cell-lines were 









The figure above shows the distribution of PC3 and PBL cells from the same sample. The original number of cells within 
that test tube was 3×106 for each of the two cell-lines. The X axis represents the cell size (Arb), while the Y axis 
represents the normalised frequency for both cell-lines. Different cell size ranges are categorised on three different 
sections with the small overlapping region between the two cell-lines highlighted in a dark red colour. On the right side 
of the graph, brightfield images are shown as examples of cells that would be found within each region. The table below 
the graph shows exact percentages for cells, categorised based on their cell size. Images shown in this figure are 
captured at 60× plus EDF image acquisition. 
 
Region Population Percentage (%) 
 PBL cell size range 36.39 
 Overlapping region 5.31 
 PC3 cell size range 58.3 


















Figure  6.9: Distribution of PC3 and PBL cells based on their cell size 
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The retention percentages of PC3 cells were fluctuating between different samples; however, 
samples with very low numbers of PC3 cells were showing higher retention percentages than 
samples with high PC3 numbers. Generally, live PC3 retention numbers were noticeably higher than 
immunological methods.  
Table  6.1. Approximate retrieval numbers of live PC3 cells 
 
Total PC3 cells  
spiked into 1mL 
Approximate retrieval of  
Live PC3 cells 
(Cell size) 
3,000,000 7.46%  
(223,813) 
300,000 2.29%  
(6,864) 
30,000 6.48%  
(1,945) 
3000 53.43%  
(1,603) 
300 19.33%  
(58) 
30 60%  
(18) 
 
The left column of the table above shows the numbers of PC3 cells counted and spiked in each of the test tubes while 
the right column shows number of PC3 cells retrieved following examination with the ImageStreamX. The percentage of 
cells acquired varied from one tube to another, but the number of cells was in constant decline. Some of the numbers 
given in the right column, particularly for the last two samples, were different from the ones provided by the analysis 
software. The number of PC3 cells spiked in these two samples was very low, warranting a manual examination of each 
large object captured to confirm the identity of some of any PC3 cell that might be present.   
176 
 
6.4.5 Cellular morphology and structure comparison 
 
The morphology and structural integrity of cells has been a subject of a consistent comparison in this 
study. Different cell structures and morphologies are demonstrated in Table  6.2 below for each of 
the cell-lines used and for different CTC-identification approaches. The aim of this research was to 
achieve an accurate identification of CTCs (PC3 cells) and to successfully isolate them, including 
when very minute PC3 numbers are used. When relying on immunological methods, there was the 
challenge of obtaining false positive and false negative cells. 
Table  6.2: Comparison of cell morphology obtained from the four CTC identification methods used 
 
The table above provides a comparison of cell clarity and structural integrity through examples of cells obtained in 
various CTC identification approaches. The first column on the left mentions the type of experiment undertaken, while 
the three other columns give brightfield images as examples of the three cell-lines used in each of the four types of 
experiments.  















Non-specific staining was observed despite the use of a blocking buffer, which reduces the non-
specific binding between antibodies and cells. As a result, a hypothesis emerged that perhaps 
antibody non-specificity was occurring due to the rigorous sample-preparation process, which 
results in the exhaustion of cells and loss of structural integrity in which cells become very 
porous/permeabalised. This permeabalisiation might have in turn allowed for antibodies to be 
detected within cells that would otherwise not bind to cell antigens. This observation was noticeable 
for both PC3 and PBL cells when they were prepared for staining with EpCAM, CD45 and ZO-1 TJ 
antibodies. When live PC3 and PBL cells were used, the morphology of most cells was clear and the 
structure was intact (Table  6.2).  
On the other hand, the GMO0893 cell-line was not only observed to show high levels of nonspecific 
staining, but it was also presenting a consistently suboptimal morphology and a flawed structure. 
This meant that it was difficult to discriminate between GMO0893 cells and PC3 cells based on 
immunological methods and/or physical properties. As a result, the GMO0893 cell-line was deemed 
un-useful and was discontinued from future experiments, including the proof of principle 
experiment where samples were spiked with dilutions of PC3 cells.  
From the graphs that previously documented the existence of overlapping immunostaining 
intensities of PC3 and PBL cells (Figure  3.10, Figure  4.9 and Figure  5.10), the advantage of using the 
live cell analysis approach over immunological methods can be seen. Figure  6.9 clearly demonstrated 
that the cell size comparison approach provided a greater specificity in distinguishing between PC3 
and PBL cells and therefore potentially identifying CTCs in a blood sample. The existence of a minute 
overlap between the two cell-lines can be dealt with in a relatively short period of time upon manual 




6.4.6 Cell retrieval comparison 
 
As well as possessing a high specificity, the sensitivity of the test has to also be ideal in order to 
consider using the test in detecting CTCs in cancer patients’ samples. The sensitivity is measured by 
the retrieval numbers of PC3 cells from samples in which they were mixed with PBL cells. The higher 
the number of retrieved PC3 cells, the more sensitive and accurate the approach is.   
Table  6.3 below shows the approximate retrieval numbers and percentages for the approaches 
undertaken in this study to isolate PC3 cells. The immunological approaches previously conducted 
proved to have fluctuating rates of cell retrieval. The experiment which was based on the use of ZO-
1 TJ antibody to positively select PC3 cells in a mixed sample had the highest number of PC3 cells 
retrieved in the most diluted sample (20 out of 30 cells).  
Table  6.3: Approximate CTC retrieval number from the four methods examined 
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The number of PC3 obtained from staining with EpCAM, ZO-1 TJ or CD45 antibodies, however, might 
not be accurate, as these numbers are based on cells that were EpCAM- and ZO-1 TJ positive or 
CD45-negative and is not always representative of the true PC3 population. As demonstrated in 
previous chapters of this research, antibody staining was very often nonspecific; meaning that some 
of the cells that were identified as PC3 cells could be PBL cells. In fact, careful examination of EpCAM 
and ZO-1 TJ stained cells in diluted samples revealed that cells that were identified by the analysis 
software as PC3 cells were false positive PBLs.  
The same applies to CD45-negative cells, as images (Figure  4.2) provided in chapter 4 demonstrated 
how a portion of PC3 cells showed high intensity levels for the leukocyte-specific marker. Some of 
these cells were also excluded from the total PC3 cell count by the analysis software and replaced by 
PBL cells that showed little or no CD45 staining. With large overlapping regions such as the one 
shown in chapters 3, 4 and 5, it would take a relatively long period of time to manually examine all 
cells and distinguish PC3 cells from others. Hence why, the attainment of a relatively small 
overlapping region when PC3 and PBL sizes are compared may prove to be the ideal choice in 
identifying PC3 cells in imaging flow cytometry and ultimately for the identification and enumeration 




6.5 Discussion   
 
With immunological approaches lacking specificity in distinguishing between PC3 cells and PBL and 
GMO0893 cells, a different and more fundamental approach was considered. The analysis of cellular 
features such as the morphology and cell size did not only provide a new opportunity for a detailed 
comparison of the cell-lines in question, but it also presented an alternative to the method that has 
so far yielded cells with poor cell morphology as a result of immunological sample preparation 
steps/procedure.  
To begin with, the size range for each cell-line was established prior to comparing different cells and 
conducting the mixing experiment. This was done to eliminate the use of cell-lines that have similar 
size ranges as the method would become user-subjective and biased. The PC3 cells were found to 
have a cell size range that overlaps greatly with that of the GMO0893 cells. Having said that, the 
GMO0893 cells were repeatedly sighted in previous experiment to have poor morphology and 
unbalanced structure in which cells were seen to be expanded in size and have an irregular shape. 
On the other hand, PC3 cells and PBL cells did not overlap in size when examined separately, indeed 
there were approximately 40Arb separating the smallest PC3 cell from the largest PBL. As a result, 
the use of GMO0893 cells was discontinued; instead the reliance solely on PBL cells spiked with PC3 
cells became the standard of the proof of principle live cell analysis experiments.   
When the mixing experiment was constructed, the PC3 and PBL populations maintained separate 
size ranges with the exception of few cells. Approximately 5.31% of the cells in an evenly balanced 
sample (50% PC3 and 50% PBL) were found to be a mixture of PC3 and PBL cells that shared similar 
size. These cells kept a preserved shape and did not appear to have been enlarged due to the way 
the samples were prepared. Close examination of this region revealed that both types of cells indeed 
existed in that region; nonetheless, they were easily distinguishable as they morphology of these 
cells was optimal and clear, making for easy cell type categorisation.  
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The number of cells retrieved using this method far excelled what has been previously obtained with 
immunological approaches. In the presence of low PC3 numbers, such as in the most diluted tube 
where as little as 30 PC3 cells were spiked (Table  6.3), 60% of these cells were successfully retrieved 
and verified. The preservation of cellular features and structure meant that an easy and accurate 
examination of cells can take place. Furthermore, with much less cell processing steps than when 
staining methods were used, fewer cells were lost during the sample preparation steps. Careful 
examination of cells in each sample also revealed that the numbers of retrieved cells using the live 
cell analysis approach were a more accurate representation of the true numbers of each population 
than methods used in previous chapters.  
As the morphology of antibody staining experiments was compared to that of live cell analysis, it 
became clear that a simplified approach may perhaps provide more accurate results in clinical utility. 
It was also found that live cells retained more prototypical cell shape and structure, as well as 
preserving normal nuclear integrity as determined by DRAQ5 staining. The GMO0893 cells are 
excluded from these statements as they showed sustained characteristics of irregular shape and 
size, ultimately rendering the use of this cell-line unsuitable for the purposes of evaluating the live 
cell analysis as a method for CTC identification. 
The use of biomarkers such as EpCAM and ZO-1 TJ antibodies was originally deemed to be essential 
for marking PC3 cells and isolating them from other cells. As various experiments and tests were 
conducted, it became apparent, that exposing such a large number of cells in suspension to 
numerous sample preparation steps would lead to the acquisition of misleading data in the form of 
false positive and false negative cells. Obtaining similar data when dealing with real cancer patients 
would not be ideal; instead a concise and accurate approach is certainly essential. Hence why, the 









Chapter 7  
Identification of Circulating 





 Identification of Circulating Tumour Cells in 7.
Prostate Cancer Patients 
 
 
7.1 Introduction  
 
This research explored a number of methods to detect and enumerate CTCs in metastatic prostate 
cancer using cultured prostate cancer (PC3) cells. The methods used utilised the use of 
immunological detection of CTCs, either via the positive selection of stained cells (with EpCAM or 
ZO1 TJ staining) or the negative selection of cells (CD45-negative cells). The lack of specificity of 
antibody staining and the poor morphology in some of the cells obtained prompted an investigation 
into an alternative approach to provide a higher sensitivity of CTC detection with improved cellular 
morphology. As a result, the physical characteristics of PC3 cells were compared to other cell types 
such as GMO0893 and PBL cells. Not only were PC3 cells found to be bigger in size than the PBL cells 
but also the examination of physical cellular features did not require a prolonged sample 
preparation procedure. This live cell analysis method helped preserve both, the number of cells in a 
sample as well as cell morphology and structure. 
Clinical validation was then required In order to assess the efficacy of the live cell analysis in 
detecting CTCs and to evaluate its advantages over immunostaining techniques. Whole blood 
samples from advanced-stage CRPC patients were obtained from Mount Vernon Cancer Centre with 
informed consent and NHS ethical approval. The samples were processed to lyse RBCs (as described 
in the clinical samples preparation section in Chapter 2 on page 98 and the presence of CTCs was 
then observed using the live cell analysis technique as well as the positive selection of EpCAM-
stained cells. The use of clinical samples in this research is essential as the sole reliance on cultured 
prostate cancer cells may provide misleading data and subsequently inaccurate conclusions. With 
regards to the research I am conducting, differences in the morphology of cells has previously been 
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reported in cells captured from cultured prostate cancer cell-lines (including PC3) and cells from 
prostate cancer patients (Park et al., 2014).  
Differences such as the size of tumour cells, cell shape and nuclear cytoplasmic (N/C) ratio were 
examined in the study by Park et al and it was found that CRPC patient tumour cells were smaller in 
size than their cultured counterparts. The study relied on the use of the CellSearch® system which it 
claimed contributed to cell shrinkage (Approximately 6% cell diameter decrease) resulting from the 
prolonged storage of samples in CellSave® tubes, a factor that might have caused an alteration to in 
cell size. Additionally, patients’ CTCs were found to have a more elongated shape and a greater 
nuclear to cytoplasm ratio than cultured cancer cells.  
It is conceivable to assume that relying on the comparison of physical features between cultured 
cell-lines might lead to an inaccurate overestimation of the platform’s (in this case, the 
ImageStreamX) ability to capture and identify CTCs. The reason for this hypothesis is that in spite of 
the established knowledge of epithelial cancer cells being relatively larger in size than leukocytes 
(Fehm et al., 2005), the heterogeneity of CTCs may cause a significant overlap in the physical 
properties of some CTCs with that of other cell types, such as WBCs (Peeters et al., 2011, Hyun et al., 
2013, Jin et al., 2014). Crucially, the combination of leukocyte-like physical characteristics in some 
CTCs and the general rarity of circulating cancer cells in patients suggest that the detection of these 
cells may not be a simple task. Hence why the sole reliance on cultured CTCs (such as PC3 cells) as 
models for patients’ CTCs may be misleading as these cultured cancer cells are far more different 
(physically) to leukocytes than patient CTCs are.  
In order to avoid false estimations of the ImageStreamX capability in identifying and enumerating 
CTCs, as well as to validate the advantages of the live cell analysis method over immunostaining 
techniques with regards to detection accuracy and sensitivity, the use of CRPC patient samples was 





• To identify and enumerate Circulating Tumour Cells (CTCs) from two CRPC patients using the 
live cell analysis approach 
• To identify and enumerate CTCs from the same patients using EpCAM staining  
• To evaluate the specificity of EpCAM antibody in staining CTCs in CRPC patients 
• To compare the sensitivity of the live cell analysis approach with that of EpCAM staining for 






7.3.1 Identification of circulating tumour cells using EpCAM staining 
 
Both patients’ samples were depleted of RBCs and stained with the EpCAM antibody as previously 
explained. EpCAM is an epithelial-specific marker and was used to target potential CTCs present in 
these samples. The figure below gives account to images of CTCs and WBCs captured from patient 1 
(Pt1) and patient 2 (Pt2).  
Figure  7.1: EpCAM staining of CTCs and WBCs in prostate cancer patients  
 
Samples shown in the figure above demonstrate different patterns of staining of CTCs with the EpCAM antibody. The 
first column, titled brightfield shows brightfield images of cells on Ch01. The second column shows EpCAM antibody 
staining in green on Ch02. DRAQ5 nuclear staining is displayed in red in the third column and captured on Ch05. At the 
far right, the fourth column shows a composite of EpCAM and DRAQ5, underlining the morphology within these cells. 
Panels A, B and C represent images of CTCs captured from both patients, while Panels D, E and F are examples of WBCs 
from the same samples. Images shown in this figure are captured at 60× plus EDF image acquisition. 
 
Other than the cells shown in the figure above, many cells (CTCs and WBCs) were found to exhibit an 
irregular staining outline of the EpCAM antibody. EpCAM was found in high intensity in the 
Brightfield EpCAM DRAQ5 Composite
Panel - A 
 
Panel - B 
 
Panel - C 
 
Panel - D 
 
Panel - E 
 
Panel - F 
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cytoplasmic region of cells and without confinement to the membrane. More importantly, several 
WBCs were found to be EpCAM-positive with a complete peripheral staining. Additionally, there 
were also several large CTCs that showed little or no EpCAM staining. This lack of specificity of 
EpCAM staining was evident in cultured CTCs (PC3 cells) and remains evident in patient clinical 
samples as demonstrated in the figure below.  
Figure  7.2: Lack of EpCAM staining specificity in WBCs and CTCs 
 
Samples shown in the figure above demonstrate different patterns of staining of CTCs with the EpCAM antibody. The 
first column, titled brightfield shows brightfield images of cells on Ch01. The second column shows EpCAM antibody 
staining in green on Ch02. DRAQ5 nuclear staining is displayed in red in the third column and captured on Ch05. Finally, 
the fourth column shows a composite of EpCAM and DRAQ5, underlining the morphology within these cells. Panels-A 
and B represent images of WBCs captured from both patients showing an EpCAM staining similar to that of EpCAM 
positive CTCs (False positives). Panels-C and D on the other hand are examples of CTCs where there was an absence of 
EpCAM staining (False negatives). Images shown in this figure are captured at 60× plus EDF image acquisition. 
 
The intensity of EpCAM staining for CTCs and WBCs is represented in Figure  7.3 for Pt1 and 
Figure  7.4 for Pt2. The two figures highlight the weakness of EpCAM as a specific marker for CTCs, an 
observation that is backed by evidence of lower EpCAM expression in CTCs when compared to 
cultured prostate cancer cell-lines (Lazar et al., 2012). Upon careful examination of the CTC 
populations in these samples, cells that were observed to retain a complete periphery staining with 
the EpCAM antibody (Figure  7.1, panel A) were counted and the percentage of CTCs in the sample 
was given in the table below each graph.   
Brightfield EpCAM DRAQ5 Composite
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The figure above shows the distribution of CTC and WBC populations based on their EpCAM staining intensity in Pt1. The 
X axis represents the intensity of EpCAM antibody staining, while the Y axis represents the normalised frequency of 
cells. The population of CTCs (highlighted in red) represents a large group of cells where CTCs might be present. While 
the blue region of the graph represents where most of the WBCs in the sample are located. Some cells from both 
populations overlap in their staining intensity, and these cells fall within the purple region on the graph. The table below 
the graph represents a count of CTCs within the sample, where only cells with a complete EpCAM staining in their 
periphery (e.g. Figure  7.1, panels A, B and C) were counted as CTCs.    
Examined volume (µl) 1.9657 
Confirmed CTCs (size/staining) 48 
Total sample volume (µl) 50.4 
Approx. CTCs (in 7.5mL) 2461 
Percentage of CTCs in sample 0.58% 

























The figure above shows the distribution of CTC and WBC populations based on their EpCAM staining intensity in Pt2. The 
X axis represents the intensity of EpCAM antibody staining, while the Y axis represents the normalised frequency of 
cells. The population of CTCs (highlighted in red) represents a large group of cells where CTCs might be present. While 
the blue region of the graph represents where most of the WBCs in the sample are located. Some cells from both 
populations overlap in their staining intensity, and these cells fall within the purple region on the graph. The table below 
the graph represents a count of CTCs within the sample, where only cells with a complete EpCAM staining in their 
periphery (e.g. Figure  7.1, panels-A, B and C) were counted as CTCs.   
  
Examined volume (µl) 2.6209 
Confirmed CTCs (size/staining) 6 
Total sample volume (µl) 45.3 
Approx. CTCs (in 7.5mL) 207 
Percentage of CTCs in sample 0.07% 













EpCAM staining in CTCs and WBCs 
Figure  7.4: Distribution of CTCs and WBCs from Pt2 based on their EpCAM staining intensity  
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7.3.2 Identification of circulating tumour cells using live cell analysis 
 
Samples from the same two patients were also examined using the live cell analysis approach. 
Whole blood samples were prepared in an identical way to the EpCAM-labelled samples but were 
not fixed, blocked or stained with any biomarker. The preparation of these samples for analysis took 
approximately 40-60 minutes from the moment they were collected from the patients and until they 
were examined with the ImageStreamX. The results of the live cell analysis are as follows:  
Figure  7.5: Live cell images of CTCs and WBCs in prostate cancer samples 
 
The figure above shows a gallery of images taken of live cells from CRPC patients’ samples. The first column on the left, 
titled Brightfield, shows brightfield images of CTCs and WBCs. The middle column shows DRAQ5 nuclear stain in red, an 
indication that the captured object is a cell. The column on the right shows a composite of the brightfield images and the 
localisation of DRAQ5 nuclear stain, giving an account to the morphology in these cells. Panels-A, B and C represent CTCs 
in the two prostate cancer patients, while panels-D, E and F are images of WBCs from the same patients. Images shown 
in this figure are captured at 60× plus EDF image acquisition.  
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The figure above shows the distribution of CTCs and WBCs based on their cell size as obtained from Pt1. The X axis 
represents the cell size (Arb), while the Y axis represents the normalised frequency of cells. The population of CTCs 
(highlighted in red) represents a large group of cells where CTCs might be present. While the blue region of the graph 
represents where most of the WBCs in the sample are located on the graph. The CTC population (red) was explored 
carefully and an accurate count of CTCs (e.g. Figure  7.5, panels A, B and C) in that sample was given in the table below 
the graph along with the percentage of CTCs in that sample.   
 
Examined volume (µl) 7.7873 
Confirmed CTCs (size/staining) 123 
Total sample volume (µl) 98.8 
Approx. CTCs (in 7.5mL) 3121 
Percentage of CTCs in sample 1.47% 













Cell size comparison between CTCs and WBCs 













The figure above shows the distribution of CTCs and WBCs based on their cell size as obtained from Pt2. The X axis 
represents the cell size (Arb), while the Y axis represents the normalised frequency of cells. The population of CTCs 
(highlighted in red) represents a large group of cells where CTCs might be present. While the blue region of the graph 
represents where most of the WBCs in the sample are located on the graph. The CTC population (red) was explored 
carefully and an accurate count of CTCs (e.g. Figure  7.5, panels-A, B and C) in that sample was given in the table below 
the graph along with the percentage of CTCs in that sample.   
  
Examined volume (µl) 3.7567 
Confirmed CTCs (size/staining) 144 
Total sample volume (µl) 32.3 
Approx. CTCs (in 7.5mL) 2476 
Percentage of CTCs in sample 1.9% 













Cell size comparison between CTCs and WBCs 
Figure  7.7: Distribution of CTCs and WBCs from Pt2 based on cell size 
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7.3.3 Cellular morphology and structure comparison  
 
Differences in the morphology between cells captured using the live cell analysis approach and those 
that are EpCAM positive was clear. Images of CTCs and WBCs captured using both methods are 
shown in the figure below.  
 




















The figure above shows brightfield images of CTCs and WBCs captured at 60× with EDF image acquisition. The middle 
column shows images of cells captured using the live cell analysis method, while the column on the right contains 
images of cells captured using the EpCAM staining method.  
 

















The previous table provides similar observations to the ones obtained in Table  6.2 when the 
morphology and structure of cultured cell lines were examined and compared. There appears to be a 
clear advantage in using live cell analysis approach over the use of immunological techniques 
indicated by the preservation of cellular morphology and structure. CTCs captured using the live cell 
analysis method retained a clearer membrane, perhaps due to not undergoing the permeabalisiation 
procedure that the EpCAM stained cells had undergone. Moreover, the outline of the nucleus in live 
cells is far clearer than the EpCAM stained cells, allowing for a more accurate identification through 
the morphological and structural features within these cells.  
Live WBCs on the other hand showed an optimal cellular integrity and appeared visibly clearer than 
the EpCAM stained WBCs. With a clear morphology as demonstrated in Table  7.1, discriminating 
leukocytes from CTCs was an easier task. The clear morphology of live CTCs and WBCs allowed for an 
accurate localisation of nuclear staining within these cells, which further helped in categorising each 
cell type.   
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7.3.4 Cell retrieval comparison  
 
The high sensitivity of a CTC detection method is essential for its success and the sensitivity of the 
live cell analysis approach was compared to that of EpCAM staining in both patients. The table below 
contains the calculated average number of confirmed CTCs in both patients. This number is then 
multiplied to give an approximate account for the number of CTCs in the whole sample (7.5mL). The 
percentage of the average number of confirmed CTCs is also presented, showing a clear advantage 
in using live cell analysis method over the EpCAM immunostaining approach.  











The table above shows a comparison in CTCs numbers and percentages in Pt1 and Pt2 between the live cell analysis 
approach and the EpCAM staining method.   
 
Several factors must be accounted for in the calculations above, such as the stage of cancer in these 
two patients, the treatment that they have undergone – which may cause a decline in CTC numbers 
– the age and more. However, there is a clear indication of higher cell retention using the live cell 
analysis, which is likely to be attributed to the simplicity of this sample preparation procedure.  
 Live cell analysis EpCAM staining 
Average number of 
confirmed CTCs  
133 27 
Average approximate 
number of CTCs in whole 
sample (7.5mL) 
2798 1334 





7.4 Discussion   
 
In this chapter, earlier observations of CTC targeting using EpCAM as well as the utilisation of CTC 
kinetical characteristics were validated using metastatic CRPC patient samples. 7.5mL whole blood 
samples were collected from two patients, with informed consent and full NHS ethical approval. 
Both sets of samples were processed to lyse RBCs in an identical procedure prior to analysing one set 
of the samples using the live cell analysis method (without fixing, blocking or staining) and analysing 
the other using EpCAM antibody staining.  
Careful examination of approximately 17,000 images from both patients captured using the EpCAM 
staining method revealed the presence of 48 and 6 EpCAM-positive CTCs in Pt1 and Pt2 respectively. 
On the other hand, live cell analysis demonstrated the presence of 123 CTCs in Pt1 sample and 144 
CTCs in Pt2 sample. The higher number of detected CTCs in the live cell analysis may have resulted 
from the simplicity of the sample preparation procedure prior to ImageStreamX examination. The 
EpCAM staining method was conducted over a time period of three consecutive days in which the 
primary EpCAM antibody was used to label CTCs in these samples. The EpCAM staining observed in 
patient samples showed small number of CTCs with a full and clear EpCAM staining on their 
membrane – a crucial requirement by pathologists to confirm the identity of a cell as a CTC.  
Examining a large number of cells from each sample revealed the presence of many CTCs which 
lacked EpCAM staining as demonstrated in Figure  7.2. Likewise, EpCAM was found to be non-specific 
in targeting leukocytes as shown in the same figure. The lack of EpCAM specificity was a key 
weakness that undermined the use of this marker as a reliable identification tool for CTC detection 
in cultured cancer cells (PC3) and remains a challenging aspect in the identification of CTCs obtained 
from metastatic CRPC patients. It is also important to consider that most of the cells categorised by 
the analysis software (IDEAS®) as EpCAM-positive had expressed high staining intensity within the 
cells rather than on their periphery, providing a false estimation of the CTCs and WBCs populations 
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within these samples. This was best demonstrated by Figure  7.3Figure  7.4 which highlighted the 
significant overlap (purple region) in the staining properties of CTCs and WBCs. 
Not only did the live cell analysis provide a higher count of CTCs from the same patient samples, but 
it also presented images of CTCs and WBCs that were significantly clearer than those obtained using 
EpCAM staining. The reduced number of sample preparation steps in the live cell analysis method 
meant that these cells were exposed to less morphologically altering factors such as fixation and 
permeabalising reagents which could have contributed to an improved cellular integrity and 
structure. This argument was backed by images of CTCs and WBCs obtained from both techniques in 
Table  7.1, outlining the clear superiority of the live cell analysis in the preservation of cellular 
morphology and structure.  
The clear morphology of CTCs captured using the live cell analysis method allowed for a clear 
localisation of DRAQ5 nuclear staining. CTCs were characterised by a clearly defined nuclear 
membrane that was confined in a restricted region within cells as demonstrated in Figure  7.5. WBCs 
on the other hand displayed DRAQ5 nuclear staining covering a large area within these cells, 
outlining the difference in the nuclear cytoplasmic (N/C) ratio between CTCs and WBCs. This proved 
useful in providing an accurate discrimination of CTCs from leukocyte-rich samples based on the N/C 
ratio observation of cells.  
Overall, the evidence provided in this chapter of improved cellular morphology and the increased 
CTCs detection when using the live cell analysis approach over immunological techniques (such as 
EpCAM staining), provided stronger evidence to back earlier notions about the advantages of this 
simple approach. Further testing in the clinical utility of this method, perhaps on a larger cohort, is 











 General discussion  8.
 
 
8.1 Inclusive analysis of results  
 
8.1.1 Identification of PC3 cells using Immunostaining methods  
 
The aim of this project was to develop a specific and sensitive detection method that is reliable in 
identifying CTCs in blood samples using Amnis ImageStreamX Mark II. To reconstruct the scenario 
where CTCs are found in the blood of metastatic prostate cancer patients, the PC3 human prostatic 
carcinoma cell-line were spiked in samples containing PBL cells. A number of approaches were 
undertaken and compared to determine the most effective and accurate means of detecting and 
enumerating CTCs (PC3 cells). Some of these approaches were immunological methods that relied 
on the use of biomarkers such as:  
• Anti-EpCAM antibody 
• Anti-CD45 antibody 
• Anti-ZO-1 TJ antibody.  
The EpCAM and ZO-1 TJ antibodies were epithelial biomarkers that were used to target PC3 cells and 
immunologically label them to help distinguish them from non-epithelial cells (PBLs) via positive-
selection. The CD45 antibody was used to target non-epithelial cells such as PBL and GMO0893 cells, 
subsequently identifying PC3 cells via negative selection. For each of the three immunostaining 
methods used, different cell-lines were stained separately with the antibodies before the proof of 
principal experiment was conducted to determine the antibody specificity and binding efficiency.  
A different approach, which filters different types of cells based on their physical and morphological 
properties, was also examined. Cellular properties such as the size of cells and the aspect ratio were 
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considered in order to distinguish different types of cells that may be found in the blood of a 
metastatic prostate cancer patient.  
The EpCAM antibody displayed promiscuity in staining PC3 cells when initially used to test its 
specificity in a sample containing PC3 cells. More than 86% of the cells were found to be EpCAM-
positive (Figure  3.4). Crucially, however, 2.21% of the PC3 cells were found to be EpCAM negative. 
The major limitation of using EpCAM was the lack of specificity of the antibody. When EpCAM was 
used in samples containing GMO0893 (B-lymphocytes) or PBL cells, it was found that 30.3% of the 
GMO0893 cells and 17.3% of the PBLs were EpCAM positive. The identification of these false-
positive non-epithelial cells that were targeted by EpCAM, an epithelial-specific marker, raised early 
doubts about its usefulness as an accurate cancer biomarker.  
The ambiguity over EpCAM staining specificity increased when the PC3 cells were spiked in PBL 
samples to mimic the presence of CTCs in prostate cancer patients. Although more than 94% of PC3 
cells were fully stained with the antibody, there were some PC3 cells that showed weak or no 
EpCAM staining and therefore were not categorised as cancer cells by the analysis software. 
Additionally, the EpCAM staining patterns in PC3 cells varied; some cells showed expected peripheral 
(membrane) staining, while in some PC3 cells EpCAM was located in the cytoplasm (Panel-B in 
Figure  3.9). On the other hand, 95.1% of PBL cells showed little or no EpCAM staining, leaving 
approximately 4.9% of the PBL population positively staining for EpCAM and located in the 
overlapping region of EpCAM-positive PC3 cells (Figure  3.10). The presence of this overlapping 
region in which both PC3s and PBLs had a similar EpCAM staining intensity, presented a difficulty in 
identifying some PC3 cells with the EpCAM approach.  
The promiscuity of EpCAM staining led to the investigation of another biomarker, the CD45 
antibody, which targeted blood cells such as PBLs. It was hypothesised that as PC3 cells are epithelial 
in nature, they were not expected to stain with the CD45 antibody, enabling the negative-selection 
of these cells to help enumerate them within a sample. The CD45 antibody was initially tested on 
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PC3 cells alone to confirm staining specificity of this biomarker in epithelial cells. Despite most 
(69.9%) PC3 cells showing no CD45 staining, there was a percentage (6.8%) of these cells that were 
CD45-positive. Some PC3 cells showed weak, yet visible CD45 staining; and while some of the 
staining patterns observed in PC3 cells were weak and confined to small regions within cells, there 
were cells with full peripheral staining, similar to that expected of a PBL (Panel-E, Figure  4.2). 
When the specificity and sensitivity of the CD45 antibody was examined by mixing PBL and PC3 cells, 
elevated levels of CD45-positive PC3 cells were obtained (up to 10% increase). Moreover, the 
number of CD45-positive PBL cells was reduced from 75.5% of the total population (when stained 
separately) to 62.27%, creating a large overlap of cells with similar CD45 staining intensity between 
the PC3 and PBL cells. Therefore, relying solely on the CD45 antibody as an exclusive marker for 
haematopoietic cells to isolate CD45-negative cells (CTCs) was not accurate nor reliable in this 
investigation. The presence of non-haematopoietic cells stained with the CD45 antibody has been 
previously reported in literature and will be discussed in the next section of this chapter (Stott et al., 
2010a).  
The ZO-1 TJ antibody is similar to the EpCAM antibody, being an epithelial cell-surface marker. This 
antibody targets the tight junctions molecules located on the membrane of epithelial PC3 cells. 
When tested on PC3 cells, 95.76% of the cells were found to be ZO-1 TJ positive. On the other hand, 
the ZO-1 TJ antibody was detected at variable levels in more than 95% of the GMO0893 (B-
lymphoblastoid) cells (Figure  5.6), rendering the use of these cells as unsuitable when testing the 
sensitivity of this antibody. PBL cells, however, proved to be a far more successful option to use as 
just over 4% of these cells showed any level of ZO-1 TJ staining (Figure  5.8). When PBL samples were 
spiked with PC3 cells to recreate the CTCs presence in prostate cancer patients, the PC3 cells 
maintained a high level of ZO-1 TJ staining but many PBL cells also expressed variable levels of ZO-1 
TJ staining. With more than 46% of the PBL population identified as ZO-1 TJ positive, it was difficult 
to distinguish PC3 from PBL cells using this approach (Figure  5.10). 
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Various repeat experiments showing images collected of PC3, GMO0893 and PBL cells stained with 
the three biomarkers investigated in this research persistently highlighted the major weakness that 
arises from using immunological approaches, that is the lack of staining specificity. The graphs 
created with the analysis software, IDEAS®, provided evidence for the presence of epithelial PC3 
cells that exhibit immunostaining properties similar to that of haematopoietic (PBL) cells. 
 
8.1.2  Identification of PC3 cells using live cell analysis  
 
The lack of staining specificity and the reduced structural integrity of cells in immunological methods 
made it difficult to discriminate between PC3 and PBL cells. Therefore, I decided to compare cells 
based on physical parameters such as cell size and aspect ratio in a short, simplified test. After 
establishing a separate cell size range for each cell-line (PC3, GMO0893 and PBL cells) I was then able 
to compare the size parameters of each type of cells to confirm whether PC3 and PBL cells were the 
optimal choice for testing the sensitivity of this approach.  
The results provided by this approach were robust in distinguishing PC3 cells from PBLs on the basis 
of cell size. The procedure in which the samples were prepared was relatively short and simple, 
meaning that the numerous sample preparation steps that were undertaken in immunological 
approaches were no longer required. This also preserved the structure and morphology of both PC3 
and PBL cells and increased cell retention of diluted PC3 cells spiked in PBL samples. For the most 
diluted sample, 18 out of the 30 PC3 spiked into a PBL sample were identified based on their size. 
Providing a rapid and accurate enumeration of PC3 cells that otherwise would not be possible using 
immunostaining methods such as EpCAM, ZO-1 TJ and CD45 staining. There was, however, a 
relatively small overlap in the cell size of PC3 and PBL cells. The small margins of this overlap meant 
that the examination of cells within this region could be carried out in minutes to confirm the 
identity of cells in that region.  
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8.1.3 Clinical validation of CTC identification methods 
 
Identification of CTCs using EpCAM and cell morphology parameters (such as cell size and aspect 
ratio) was compared using clinical blood sample obtained from two metastatic CRPC patients. In Pt1, 
the number of confirmed CTCs using the live cell analysis was found to be 123 cells – a 256.25% 
increase on the number of enumerated EpCAM-positive CTCs (48). This significant increase in the 
detection of CTCs was even higher in Pt2 with 144 CTCs observed using the live cell analysis, 
compared to merely 6 EpCAM-positive CTCs (2400% increase).  
Few factors may contribute the difference in CTC detection between the two patients such as the 
stage of cancer, age and treatment undertaken, but the enhancement of CTC detection and cellular 
morphology of captured cells is unquestionable. Furthermore, histograms (such as Figure  7.3 and 
Figure  7.6) comparing the immunostaining and physical properties of CTCs and WBCs, clearly 
demonstrated the benefit of using the live cell analysis instead of immunostaining in the 





8.2 Non-specific staining 
 
The ability of some cells to be identified with both, epithelial (e.g. EpCAM, ZO-1 TJ) and 
hematopoietic (e.g. CD45) markers, has been previously outlined as a critical challenge in CTC 
isolation techniques (Stott et al., 2010a). Cells with similar immunostaining nature were referred to 
as “double positive” cells (Figure  8.1) and while many CTC isolation methods often disregard these 
cells when enumerating CTCs from metastatic cancer patients, the origin and nature of these cells 
remains unclear. Some groups claimed that overlooking these cells when isolating CTCs is justified by 
the fact that most of them possess similar morphology to that of leukocytes (Stott et al., 2010a). 
Others argue that the existence of these cells is due to a fusion of hematopoietic cells and CTCs and 
that CD45 staining in these cells might be caused by the non-specific binding of antibodies to these 
cells (Lustberg et al., 2012). Empirical evidence is required, however, to support these assertions. 
Figure  8.1: Micrographs of isolated “double positive” cells from prostate cancer patients using the 
HB-Chip 
 
A and B display micrographs of cells isolated from metastatic prostate cancer patients using the herringbone-chip device 
(HB-Chip). These cells were stained with PSA (epithelial marker, in green) and CD45 (hematopoietic marker, red) and 
were found to be more predominantly present than CTCs in these cancer patients. Additionally, their numbers were 
found to be significantly lower in healthy individuals than metastatic patients (Stott et al., 2010a).  
 
In addition to obtaining false-positive staining in all three cell-lines used, the cell structure and 
morphology of the cells captured often appeared suboptimal. The troubleshooting of this issue led 
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to an investigation into whether the sample preparation steps, which were undertaken when cells 
were stained, were responsible for poor cell morphology and the non-specific staining observed. 
Therefore, a series of experiments were conducted in which the various steps of sample preparation 
such as fixing, blocking and staining cells, as well as the numerous washes with PBS between these 
steps, were removed. The result was a quick, more efficient method of imaging cells using the 
ImageStreamX with an enhanced cell morphology and structure.  
Thorough analysis of results obtained using the live cell analysis method provided accurate 
morphological features of the PC3 and PBL cells, where different populations of these cells rarely 
shared similar properties (e.g. cell size, aspect ratio of cells). As a result, a simplified approach 
capable of preserving cellular integrity began to gather momentum in these investigations. The 
analysis software, IDEAS®, was now capable of producing histograms that separated PC3 cells from 
PBLs with less error than before. Such graphs relied solely on the comparison of the cell size and 
aspect ratio of these cells and omitted the use any staining other than nuclear staining using the 
DRAQ5 antibody. The reason for continuing to use DRAQ5 in the live cell analysis experiments was to 
confirm the capture of single cells and exclude debris and other objects that may be captured. This 
simplified approach not only surpassed its predecessors in accuracy and cell retrieval, but also meant 
that CTC isolation may now be carried out in few hours rather than three days. 
PC3 cells retrieval numbers were one of the key comparison criteria when the four methods were 
discussed. The ability to retrieve the highest possible number of PC3 cells with great accuracy would 
mean the method used could be a sensitive tool in the detection of CTCs in the blood of prostate 
cancer patients. Table  6.3, which compared the number of positively- or negatively-stained cells 
retrieved and the number of confirmed live PC3 cells, showed that the highest numbers of stained 
cells retrieved were achieved using the ZO-1 TJ antibody. The numbers in the ZO-1 TJ staining 
experiments were closely matched by the cell size experiment numbers, especially in the most 
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diluted samples. However, the accuracy of the three immunostaining techniques in identifying clear 
PC3 cells was much lower than that of the alternative physical analysis of cells.  
For example, in the most diluted sample where 30 PC3 cells were spiked in PBL samples, the ZO-1 TJ 
staining experiment identified 20 cells as ZO-1 TJ-positive, categorising them as PC3 cells. These cells 
cannot, however, be certainly confirmed as PC3 cells as they appeared to exhibit a poor morphology, 
accompanied with a loss of membrane integrity, possibly allowing for the expansion of these cells 
into a larger size and permitting antibody presence and detection within them. This analysis was 
supported by images on Ch02 where ZO-1 TJ antibody staining was seen to be distributed 
throughout the cell rather than confining to cell periphery. In contrast, the cell size experiment 
provided images of cells with improved morphology and retention. The identity of the 18 cells that 
were identified as PC3 cells (when 30 PC3 cells were used) was confirmed upon manual examination 
of images of these cells, demonstrating that the numbers of confirmed PC3 cells obtained using this 
method (live cell analysis) could be a far more accurate representation of the actual number of PC3 
cells than the immunological methods. 
The CTC detection accuracy of live cell analysis and EpCAM immunostaining in clinical utility was also 
validated using the samples obtained from the CRPC patients. The number of CTCs detected using 
positive selection of EpCAM stained cells was relatively low in Pt1 and significantly inferior in Pt2 
when compared to the numbers of CTCs captured using the live cell analysis approach. These CTC 
numbers provide strong evidence that the enumeration of EpCAM-positive CTCs may indeed present 




8.3 Weaknesses and future work 
 
This study explored the use of the live cell analysis approach using the ImageStreamX. The isolation 
of CTCs by size is a method that has been previously utilised through an ISET assay which allows for 
the isolation of tumour cells through size filtration (Vona et al., 2000). Nevertheless, little has been 
published using novel imaging flow cytometry in identifying circulating tumour cells based on their 
physical properties. The method provides a clear advantage over using immunological approaches by 
offering an enhanced cellular integrity and preserved cell structure and morphology. However, 
besides the accurate sorting of cells based on their physical properties (e.g. size, aspect ratio) and 
the examination of high quality brightfield images, this method provides little verification of the 
identity of cells captured. The exclusion of biomarkers use may lead to a user-bias judgement when 
confirming the presence of CTCs in a sample. For frequent ImageStreamX users, regular examination 
of the samples containing PC3 or PBL cells makes for an accurate classification of cells based on their 
type (cancerous or haematopoietic), but the same cannot be said for end users who are not used to 
observing CTCs images regularly.  
EpCAM, ZO-1 TJ and CD45 antibodies are the three biomarkers that were examined in this study to 
verify the identity of PC3 cells using imaging flow cytometry. Other studies have used other 
techniques such as enrichment of CTCs via the expression of CKs along with the absence of CD45 
staining. CKs that are expressed by CTCs include CK 4,5,6,8, 10, 13, 18, and 19 (Allard et al., 2004). 
Exploiting the expression of CK as a biomarker for CTCs identification could have been investigated 
using imaging flow cytometry as other studies have confirmed success in using it for CTC 
identification (Weissenstein et al., 2012, Dent et al., 2016).  
The reason I deemed investigating CK expression in PC3 cells using the ImageStreamX as unurgent is 
the same reason why I chose to rely on live cell size analysis over immunological techniques. Lack of 
CTC targeting specificity is a common weakness for many biomarkers and cytokeratins are no 
exception. This was supported by other groups reporting susceptibility to error in CTC detection 
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when using a CK- (and EpCAM-) dependant methods compared to ISET (Mikolajczyk et al., 2011, 
Chinen et al., 2013). The study by Chinen et al particularly presented important findings as it 
examined CTC detection in clinical follow up (after treatment). The lack of EpCAM and CK staining in 
CTCs from lung cancer patients is attributed to the heterogeneous nature of CTCs. The presence of 
circulating tumour cells with epithelial, mesenchymal or even with both markers present (CTCs 
undergoing EMT) proved too difficult to target with immunocytochemical techniques only. It was 
concluded that relying on biomarker-dependant methods such as CK positive selection may prove 
misleading in evaluating patient’s response to treatment.    
To address the low EpCAM presence as well as the absence of other epithelial markers in some CTCs, 
it was suggested that a range of different antibodies to be used simultaneously to enhance the 
enrichment of CTCs and capture them more accurately (Schneck et al., 2015). My stance on using 
prolonged sample preparation protocols to detect CTCs remains firm in that it would cause a higher 
loss of CTCs during the various sample preparation steps than it would increase CTCs capture 
(detection sensitivity). Nonetheless, CK staining in PC3 cells (and CTCs) using imaging flow cytometry 
remains a future goal, chiefly to confirm early conclusions about the non-specificity of 
immunostaining techniques in identifying CTCs.    
In addition to testing other biomarkers, further protocol optimisation to improve cell retention 
would have been useful. As seen in Table  6.3, cell retention numbers for the four methods examined 
varied and many cells were lost in the process of sample preparation. Some CTC detection studies 
utilised the use of immunomagnetic cell separation technologies to isolate CTCs with CK expression 
and the lack of CD45 expression (Wit et al., 2015, Dent et al., 2016). An example of such technology 
involves the use of EasySep™, a magnetic-particle based method which can help in the positive or 
negative selection of a desired type of cells (STEMCELL, 2016). The use of EasySep™ could have 
proved efficient in depleting samples of PBLs/WBCs prior to examination with the ImageStreamX, 
having previously been exploited for the depletion and isolation of blood cells (Le Dieu et al., 2009, 
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McQueen et al., 2016). In turn, this could have helped in reducing the sample running time as well as 
restricting the cell capture to the desired type of cells (PC3/CTCs).  
The validation of the live cell analysis method utility in CTC capture and its advantages over the use 
of immunological techniques was essential in this study. Samples obtained from two CRPC patients 
provided data that supported early findings in cultured cancer cells about the benefits of relying on a 
rapid, simple technique for CTC detection and identification. If more resources were available, then 
perhaps the clinical utility of the live cell analysis could be further investigated. The use of more 
clinical samples from a variety of patients with different stages of the disease would provide an 
excellent verification of the method’s capabilities and weaknesses. Samples from cancer patients 
before and after treatment would have provided the much-needed evaluation of the possibility of 
using live cell analysis in imaging flow cytometry as a point-of-care system in prostate cancer. Future 
studies could perhaps test the possibility of using a similar method in imaging flow cytometry for the 
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